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A B S T R A C T
Evidence from lesion and cortical-slice studies implicate the neocortical cholinergic system in the
modulation of sensory, attentional and memory processing. In this review we consider ﬁndings from
sixty-three healthy human cholinergic functional neuroimaging studies that probe interactions of
cholinergic drugs with brain activation proﬁles, and relate these to contemporary neurobiological
models. Consistent patterns that emerge are: (1) the direction of cholinergic modulation of sensory
cortex activations depends upon top-down inﬂuences; (2) cholinergic hyperstimulation reduces top-
down selective modulation of sensory cortices; (3) cholinergic hyperstimulation interacts with task-
speciﬁc frontoparietal activations according to one of several patterns, including: suppression of
parietal-mediated reorienting; decreasing ‘effort’-associated activations in prefrontal regions; and
deactivation of a ‘resting-state network’ in medial cortex, with reciprocal recruitment of dorsolateral
frontoparietal regions during performance-challenging conditions; (4) encoding-related activations
in both neocortical and hippocampal regions are disrupted by cholinergic blockade, or enhanced with
cholinergic stimulation, while the opposite proﬁle is observed during retrieval; (5) many examples
exist of an ‘inverted-U shaped’ pattern of cholinergic inﬂuences by which the direction of functional
neural activation (and performance) depends upon both task (e.g. relative difﬁculty) and subject (e.g.
age) factors. Overall, human cholinergic functional neuroimaging studies both corroborate and
extend physiological accounts of cholinergic function arising from other experimental contexts,
while providing mechanistic insights into cholinergic-acting drugs and their potential clinical
applications.
 2011 Elsevier Ltd. 
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Disruption to cholinergic neurotransmission – whether by
targeted lesions, toxins, drugs, aging or disease –induces
impairments in a range of functions, including perception
(Erskine et al., 2004), attention (Robbins et al., 1989), memory
and learning (Kopelman, 1986), emotion (Kamboj and Curran,
2006), and sleep (Kim and Jeong, 1999). This broad cognitive-
behavioural proﬁle reﬂects in part the pan-cortical and subcorti-
cal reach of cholinergic neurons (Mesulam and Geula, 1991).
These facts, together with evidence for en masse activation of
corticopetal cholinergic ﬁbres (Phillis and Chong, 1965); a non-
synaptic, ‘volume transmission’ mode of acetylcholine release
(Descarries et al., 1997); generalised postsynaptic excitation
(Krnjevic´ et al., 1971); plus cholinergic correlations with EEG
desynchronisation (Buzsa`ki and Gage, 1989) and gamma rhythms
(Bo¨rgers et al., 2005), have led to one conceptualisation of
acetylcholine (ACh) as part of an ascending arousal system
(Lewandowski et al., 1993; Berntson et al., 2003) that potentiates
consciousness (Frohlich and Franco, 2010).
In contrast to the role of ACh as a diffuse neural activator, a
growing body of evidence demonstrates that cholinergic trans-
mission can also act on more precise spatial and temporal scales
(Sarter et al., 2009). Cholinergic inﬂuences in non-human
primates are often synaptically localised (Smiley et al., 1997),
regionally segregated (Lidow et al., 1989), and modulated over
narrow spatial ranges by virtue of fractional basal forebrain
activation (Golmayo et al., 2003); local glutamatergic control of
cholinergic terminals (Parikh et al., 2008); or cortical cholinergic
interneurons (von Engelhardt et al., 2007). Phasic, as opposed to
tonic, cholinergic signalling may engender predominantly inhib-
itory, rather than excitatory, postsynaptic effects (Gulledge et al.,
2007), thereby altering spatial patterns of cortical activity (Xiang
et al., 1998; Roberts et al., 2005). These emerging properties of the
cholinergic system suggest that ACh sculpts information-ﬂow in
ways that favour speciﬁc rather than diffuse processing. For
example, by favouring stronger, at the expense of weaker, inputs
(Krnjevic´ et al., 1971; McCormick and Prince, 1986), or by
selective strengthening of input-driven synapses (Huerta and
Lisman, 1993), the cholinergic system may bias particular modes
of attentional or memory processing, respectively (Hasselmo and
McGaughy, 2004).
To reconcile these two roles – as a general modulator of cortical
activity, and as a mediator of highly speciﬁc regional processing
effects – several models have emerged that embrace both
perspectives (e.g. Hasselmo and Sarter, 2011; Sarter et al., 2005;Yu and Dayan, 2005). Such models typically characterise the
cholinergic system as an orchestrator of neural activity across
widespread cortical ﬁelds, with separable cholinergic inﬂuences on
sensory processing, attention and memory, all acting in synergy.
Furthermore, characteristic patterns of cholinergic neural modu-
lation on columnar circuitry (Hasselmo and Cekic, 1996) and
cortical oscillations (Rodriguez et al., 2004), appear to be replicated
in diverse parts of the cortex, with differing functional effects
depending upon each region’s connectivity.
Since acetylcholine acts over broad populations of neurons,
causing fundamental shifts in processing modes or cortical
patterning (e.g. Kilgard and Merzenich, 1998; Kimura et al.,
1999), we might expect that functional neuroimaging – by virtue of
its ability to map cortical activations associated with sensory,
attentional and memory processes – should be sensitive to
cholinergic manipulations. Over the last eighteen years, in the
order of one hundred functional neuroimaging studies have been
published, in healthy humans and patients, that describe brain
activation patterns associated with administration of drugs acting
on cholinergic pathways, in different cognitive contexts.
The purpose of the current review is to evaluate how human
functional neuroimaging contributes to an understanding of
cholinergic interactions with cognitive function. The review
focuses on fMRI or PET studies in healthy subjects who received
either cholinergic antagonists or stimulants, and who were
scanned during active task states (as opposed to solely resting).
A comprehensive list of all sixty-three human cholinergic
functional imaging studies is tabulated, with results divided
according to whether modulations are primarily within sensory,
frontoparietal or medial temporal cortices, and according to the
cognitive function tested. We subsequently attempt a synthesis of
general patterns of cholinergic neuromodulation, and suggest
neural bases for these given contemporary integrative models. In
order to facilitate interpretation, we ﬁrstly provide an overview of
existing cholinergic neurophysiology (i.e. derived primarily from
non-human or human behavioural pharmacology studies), before
considering pharmacological functional neuroimaging methodo-
logical issues of relevance.
2. Cholinergic modulation of cognitive processing – non-
human and psychopharmacological studies
2.1. Sensory
Sensory cortices are richly innervated by cholinergic ﬁbres from
nucleus basalis (Zilles and Wree, 1990), and show some of the
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(Zilles et al., 2002). The importance of this input is demonstrated
by a profound impairment in stimulus sensitivity that follows
cholinergic denervation (Sato et al., 1987a). Moreover, cholinergic
release within sensory areas is triggered by stimulus presentation
in a modality-speciﬁc manner (Laplante et al., 2005; Fournier et al.,
2004), and is enhanced by directing attention to particular
stimulus properties in awake animals (Sarter et al., 2005). More
complex sensory functions, such as feature binding and selective
attention, also involve neocortical cholinergic afferents, but appear
more dependent upon cholinergic inﬂuences in frontoparietal
regions (Botly and De Rosa, 2009).
Sensory cortices are highly responsive to acetylcholine (ACh),
for example with 90% of visual cortical neurons showing
responses to ACh, of which approximately two-thirds show
facilitation (Sato et al., 1987b; Zinke et al., 2006). However,
response patterns appear segregated, with cholinergic facilitation
of cortical activity occurring in cells that: (1) are conﬁned to layer
IV, i.e. receive input from lower stages of sensory processing,
including sensory afferents via the thalamus (e.g. in somatosenso-
ry cortex: Gil et al., 1997; or visual cortex: Kimura et al., 1999; or
auditory cortex: Hsieh et al., 2000); and (2) are already strongly
driven by input activity (Krnjevic´ and Phillis, 1963). Sensory
neurons that reside in other layers – receiving intracortical inputs –
plus layer IV cells that are not co-stimulated by sensory inputs, are
suppressed rather than facilitated by ACh (Sato et al., 1987b;
Kimura et al., 1999).
As a consequence of such selective facilitation/suppression, ACh
can increase signal-to-noise ratio, as well as reduce top-down and
lateral inﬂuences on sensory responses. These effects in turn are
manifest as enhanced stimulus detectability (Sato et al., 1987b),
while reducing inﬂuences of spatial context (Roberts et al., 2005) or
expectation (Yu and Dayan, 2005). Furthermore, by reducing
intracortical lateral inhibition, and favouring anatomically non-
dominant over dominant sensory inputs (Kuo et al., 2009), ACh can
broaden sensory tuning curves and thereby reduce stimulus
selectivity (Sato et al., 1987b; Zinke et al., 2006). Although this
might be expected to impair certain sensory functions, e.g.
stimulus discrimination, other studies have observed that raised
ACh levels can sharpen sensory tuning curves (Sillito and Kemp,
1983; Murphy and Sillito, 1991), the discrepancy possibly arising
from differences in the type of neurons sampled (Zinke et al., 2006),
ACh stimulation pattern or animal species.
Acetylcholine also prolongs stimulus-evoked responses by
reducing adaptation (McCormick and Prince, 1986; Zinke et al.,
2006); potentiates subsequent responses for up to 30 min or so
(Golmayo et al., 2003), and promotes gamma-range synchronisa-
tion of sensory units (Rodriguez et al., 2004). In turn, these effects
can increase the likelihood that a stimulus will be detected and
correctly discriminated (Sato et al., 1987b; Womelsdorf et al.,
2006), and facilitate encoding into memory through mechanisms
such as long-term potentiation (in sensory cortices: Bro¨cher et al.,
1992; Dringenberg et al., 2007; and medial temporal cortices:
Huerta and Lisman, 1993), and plastic reshaping of sensory cortex
maps (Weinberger, 2007). Thus, many of the described cholinergic
inﬂuences on sensory cortices are conducive to both attentional
enhancement of sensory processing, as well as memory encoding
(Golmayo et al., 2003; Sarter et al., 2005), thereby favouring
processing of stimuli recently encountered (Greuel et al., 1988; Gu,
2003; Hasselmo and Sarter, 2011), and/or those accorded
emotional signiﬁcance (Weinberger, 2007).
2.2. Attention
Neocortical cholinergic lesions impair the ability to detect,
identify, or localise brief stimuli, especially in the presence ofattention-demanding challenges such as distractors, while not
affecting overall motivational state, response rate, rule memory,
or directional bias (Robbins et al., 1989; Moore et al., 1995; Muir
et al., 1994). The fact that such lesions result in performance
impairments that are proportionate to the degree to which
sensory/attentional processing is taxed (Himmelheber et al.,
2001), suggests that the cortical cholinergic system plays a role
in shaping interactions of attention with sensory processing,
rather than inﬂuencing either in isolation (McGaughy et al.,
2002). One inﬂuential model relates neocortical cholinergic
release with the degree of mismatch between motivation-driven
goals and actual performance, i.e. ‘attentional effort’ (Sarter et al.,
2006). By this means, cortical ACh levels increase following
challenges that degrade reward-driven performance, which itself
is instrumental in reversing the initiating behavioural im-
pairment (Himmelheber et al., 2000; Kozak et al., 2006). This
may account for correlations between ACh release and either
sensory demands or motor response (Richardson and DeLong,
1990; Passetti et al., 2000).
The functional anatomy (and effective connectivity) by which
the cortical cholinergic system supports attention involves
interactions between prefrontal, parietal and sensory regions
(Golmayo et al., 2003; Nelson et al., 2005). Performance
monitoring information from prefrontal regions, combined with
arousal and motivational information from reticular and limbic
regions, provides input to basal forebrain, and determines cortical
acetylcholine release (Sarter et al., 2006; Gozzi et al., 2010). The
amygdala may also directly activate basal forebrain, in conveying
contingency-violation or fear-conditioned signals (Holland and
Gallagher, 2006). In turn, cholinergic inputs to prefrontal and
parietal regions modulate processes such as distractor suppres-
sion (Gill et al., 2000), attentional shifting (Davidson and
Marrocco, 2000) and disengagement (Bushnell et al., 1998)
between spatial locations or features (Bucci et al., 1998).
Following repeated training with an attention-taxing task,
cellular mediators of cholinergic neurotransmission are upregu-
lated in prefrontal regions, and correlate with enhanced signal
detection (Apparsundaram et al., 2005). Cholinergic inputs to
prefrontal cortex may also serve to inhibit impulsive responses via
subcortical structures (Bushnell et al., 1998; McGaughy et al.,
2002).
Cholinergic inﬂuences on bottom-up sensory processing –
including selectively potentiating stimulus-evoked inputs and
suppressing adaptation (Section 2.1) – complement effects of ACh
on top-down attentional shifting and focusing (Sarter et al., 2001).
This is supported by evidence that ACh is released in a pan-cortical
fashion (Phillis and Chong, 1965), and that selective attention is
dependent upon cholinergic stimulation of both frontoparietal
(Gill et al., 2000; Broussard et al., 2009) and sensory cortices
(Herrero et al., 2008).
A computational account of cortical acetylcholine release
relates it to processing ‘uncertainty’ (Yu and Dayan, 2005)
regarding stimulus–stimulus or stimulus–response contingen-
cies (Bucci et al., 1998; Dalley et al., 2001). On this view, high
acetylcholine levels favour bottom-up over top-down processes,
so as to reduce cortical inference in times of uncertainty (see also
Hasselmo, 1995). Importantly, this model accords with ACh efﬂux
being related both to ‘attentional effort’ in the face of performance
challenges (Arnold et al., 2002) and to novelty (Acquas et al., 1996;
Wilson and Rolls, 1990). It also ﬁts cortical slice data demonstrat-
ing that ACh promotes feedforward over feedback signalling
(Hasselmo and McGaughy, 2004). The model successfully predicts
that cholinergic levels are inversely correlated with cue validity in
a Posner spatial-attention paradigm, and that as ACh levels
increase, the degree to which a cue focuses attention – i.e. the cue
validity effect – decreases (Phillips et al., 2000). Furthermore,
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serial contingency reversals, but not initial acquisition of
contingency (Cabrera et al., 2006), consistent with ACh commu-
nicating expected, rather than unexpected, uncertainty – the
latter of which may be represented by norepinephrine instead (Yu
and Dayan, 2005).
2.3. Memory
Memory impairment is strongly associated with cholinergic
receptor antagonism, or cholinergic neuropathology, as for
example seen early in Alzheimer’s disease (Kopelman, 1986).
The hippocampus contains one of the highest cerebral densities of
cholinergic ﬁbres (Mesulam et al., 1986), and receives dedicated
cholinergic input from the septal basal forebrain, distinct from the
nucleus basalis–neocortical projection. While this anatomical split
of the cholinergic system into neocortical and hippocampal
divisions may roughly underlie cholinergic mediation of attention
and memory, respectively (Everitt and Robbins, 1997), accumu-
lating evidence suggests that the neocortical cholinergic innerva-
tion is also important for normal memory (Hasselmo and
McGaughy, 2004; Parent and Baxter, 2004).
A key behavioural ﬁnding is that acetylcholine is more critical
for memory encoding than consolidation (Hasselmo, 1999), with
cholinergic stimulation being counterproductive if occurring after
encoding (Bunce et al., 2004; Gais and Born, 2004). A characteristic
of cholinergic modulation on columnar circuitry (Gil et al., 1997) –
described above in the context of sensory processing – may
account for this directionality in time, arising not only in sensory,
but also entorhinal and hippocampal cortices (Hasselmo and
McGaughy, 2004). Speciﬁcally, ACh-induced favouring of feedfor-
ward connections encourages self associations between novel
patterns of input, while suppression of feedback by ACh minimizes
the risk of pro-active interference from previously established
associations (Hasselmo, 1995; De Rosa et al., 2001; Atri et al.,
2004). Conversely, consolidation of existing traces, and retrieval,
are supported by a feedback-predominant state that occurs under
low ambient ACh levels, e.g. slow-wave sleep. Differential impacts
of ACh on encoding and retrieval components of memory may also
be related to modulation of the hippocampal theta rhythm
(Hasselmo et al., 2002).
As well as inﬂuencing feedforward-versus-feedback dynamics,
ACh impacts upon several other cortical memory mechanisms.
Two of these – long-term potentiation (LTP) and persistent-spiking
– are expressed in higher sensory, entorhinal, perirhinal and
hippocampal, as well as prefrontal, regions (Klink and Alonso,
1997; Anagnostaras et al., 2003; McGaughy et al., 2005; Hasselmo
and Stern, 2006). Cholinergic potentiation of these may underlie
observations that nucleus basalis activation acts as a driver for
sensorimotor cortex remapping, e.g. as seen with changes in the
representation of a conditioned auditory stimulus in tonotopic
auditory cortex (Weinberger, 2007). This in turn may account for
cholinergic inﬂuences on behaviours such as conditioning and
motor learning (Conner et al., 2003). Cholinergic inﬂuences on LTP
and persistent-spiking may also underlie the dependency of
sensory discrimination learning and recognition memory on
cholinergic inputs to extrastriate temporal and perirhinal cortices,
respectively (Ridley et al., 2005; Tang et al., 1997). By contrast,
repetition suppression (i.e. a reduced neural response for repeated
relative to novel stimuli) has not been found to be dependent on
cholinergic integrity in monkey inferior temporal cortex (Miller
and Desimone, 1993), despite evidence that behavioural priming
(i.e. an improvement in performance to repeated stimuli) is
sensitive to cholinergic manipulation (Thiel et al., 2002c).
Numerous other examples exist of cholinergic memory effects
that suggest additional mechanisms. These include ACh-inducedprolongation of evoked responses and enhancement of signal-to-
noise ratio in hippocampus (Everitt and Robbins, 1997); and
cholinergic inﬂuences on prefrontal cortex for working memory
(Chudasama et al., 2004); cingulate cortex for sensory-response
contingency learning (Dunnett et al., 1989) and amygdala for
consolidation (rather than acquisition) of contextual conditioning
(Power, 2004).
3. Cholinergic-functional neuroimaging – methodological
considerations
3.1. Cholinergic functional neuroimaging in humans
Functional neuroimaging has increasingly established itself as a
valid and informative tool for studying activation patterns across
the whole brain in different cognitive and/or pharmacological
contexts, complementing invasive methodologies such as single-
unit or lesion-based techniques. Such convergence has arisen even
though most functional neuroimaging measures primarily reﬂect
regional metabolic or vascular responses, as indirect indices of
neural activity (Logothetis, 2002); and despite the restricted
(millimetre) spatial resolution of existing functional neuroimaging
approaches.
Numerous examples of functional neuroimaging paradigms
exist that show robust, reproducible and interpretable regional
activations, consistent with more invasive measures in animals.
These include retinotopic (e.g. DeYoe et al., 1996) and category-
speciﬁc (e.g. Kanwisher et al., 1997) mappings of visual cortex;
attentional inﬂuences on sensory cortices (e.g. Martinez et al.,
2001); attentional control signals in frontoparietal regions (e.g.
Hopﬁnger et al., 2000); learning-related plasticity of sensory cortex
(e.g. Morris et al., 1998); repetition suppression (e.g. Henson and
Rugg, 2003; van Turennout et al., 2003); working memory-delay
activity (e.g. Courtney et al., 1997); and subsequent-memory
effects in medial temporal cortex (e.g. Wagner et al., 1999). From
the standpoint of the current review, it is notable that many such
functional imaging paradigms probe neural mechanisms that non-
human studies have shown to be under cholinergic control.
Consequently, it becomes meaningful to ask whether or not
cholinergic manipulations alter activation patterns in directions
consistent with existing accounts; and furthermore whether
human neuroimaging can provide new data to help reﬁne existing
models of cholinergic function.
3.2. Possible confounding factors in pharmacological functional
neuroimaging
With pharmacological functional neuroimaging, the gap be-
tween that which we wish to infer (i.e. neural activity) and that
which is actually measured (typically regional cerebral blood ﬂow
(rCBF) or blood-oxygen level dependent (BOLD) magnetic reso-
nance signal) becomes more complicated, due to potential
pharmacological inﬂuences on the neurovascular relationship.
Many types of drug inﬂuence both rCBF (Edvinsson et al., 1987) and
coupling between blood ﬂow and metabolism (Leithner et al.,
2009) – both with the potential to confound fMRI and PET (Burke
and Bu¨hrle, 2006). Furthermore, drug inﬂuences on baseline (i.e.
resting-state) neural activity or blood ﬂow may modulate the
apparent strength and spatial spread of active functional responses
(van Eijsden et al., 2009).
Of particular relevance here is that acetylcholine can act both to
increase regional cerebral blood ﬂow, and to uncouple neurovas-
cular responses (Table 1); moreover, these effects may vary by
brain region and age. For example, cholinergic antagonism with
scopolamine suppresses the rCBF response to somatosensory
stimulation, but does not affect glucose uptake (Ogawa et al.,
Table 1
Evidence for cholinergic interactions with neurovascular variables relevant to functional imaging.
Anatomical
Cholinergic terminals apposed to cerebral cortex capillaries; arterioles
and perivascular glia
Parnavelas et al. (1985), Arneric´ et al. (1988), Che´dotal et al. (1994)
Cerebral blood ﬂow (CBF)
ACh causes vasodilatation Furchgott and Zawadzki (1980)
ACh increases CBF Scremin et al. (1973), Matsuda et al. (1976)
Nicotine or cholinesterase inhibition causes cerebral vasodilation and increased CBF Linville et al. (1993), Uchida et al. (1997), Aoyagi et al. (1975),
Nakahata et al. (2008)
CBF increase can occur through stimulation of cortical cholinergic
interneurons or nucleus basalis
Scremin et al. (1991), Fukuyama et al. (1996), Biesold et al. (1989)
CBF variability
ACh effects on CBF are region-dependent Sato et al. (2004), Lacombe et al. (1989)
ACh effects on CBF are age-dependent Uchida and Hotta (2009)
Neurovascular coupling
Scopolamine impairs functional hyperemia but not cerebral glucose metabolism Ogawa et al. (1994)
Cholinergic lesions impair cerebral glucose metabolism without affecting rCBF response Ouchi et al. (1996), Ogawa et al. (1996)
Physostigmine increases CBF without altering cerebral oxygen consumption Scremin et al. (1982), Tsukada et al. (1997, 2000)
Physostigmine increases global CBF while decreasing regional glucose metabolism Blin et al. (1997)a
Nucleus basalis stimulation increases cortical ACh release and CBF
but not cerebral metabolism or EEG changes
Kimura et al. (1990), Hallstrom et al. (1990),
Lacombe et al. (1989), Vaucher et al. (1997)
Baseline activity
Cholinergic drugs affect baseline pattern of activity McNamara et al. (1990), Gustafson et al. (1987)a, Gitelman and
Prohovnik (1992)a, Blin et al. (1994)a, Stein et al. (1998)a
a Human studies.
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mine) increases global CBF, apparently at the same time as not
altering cerebral metabolism (Scremin et al., 1982; Hallstrom et al.,
1990; Tsukada et al., 1997), or electrophysiological responses
(Lacombe et al., 1989), or even while decreasing regional
metabolism (Blin et al., 1997). It should be noted, however, that
the doses of cholinergic drugs required to induce direct effects on
vasomotor reactivity appear to be signiﬁcantly greater than those
typically used in functional neuroimaging studies, even when in
the latter cases behavioural effects due to relatively low drug doses
can be reliably observed (e.g. Thiel et al., 2001).
The extent to which cholinergic inﬂuences on cerebral blood
ﬂow confound cholinergic-functional imaging ﬁndings is unclear.
Acetylcholine-induced increases of event-related rCBF responses
would be expected to increase BOLD responses measured by fMRI
(Davis et al., 1998), independent of any neural effects. Alterna-
tively, if ACh increases baseline (i.e. resting) rCBF, then we might
expect reduced BOLD responses, as can occur with acetazolamide
administration or hypercapnia (Cohen et al., 2002; Brown et al.,
2003). However, several studies report no changes in stimulus-
induced BOLD or rCBF responses in early visual cortex secondary to
nicotine (Jacobsen et al., 2002; Hahn et al., 2007); scopolamine
(Thiel et al., 2001; Sperling et al., 2002), or physostigmine (Mentis
et al., 2001; Furey et al., 2000a,b,c). Furthermore, perfusion-
sensitive MRI shows no effect of nicotine on rCBF changes elicited
by stimulus or movement in early sensory and motor areas,
respectively (Hahn et al., 2009). These facts suggest a degree of
immunity of typical functional neuroimaging measures, when
combined with typical, relatively low drug doses, to cholinergic-
vascular interactions – even in cortical regions where such
interactions might be most prominent (Sato et al., 2004). For
greater certainty, co-measurement of BOLD or rCBF with electrical
activity is ideally needed. In this regard, it is reassuring to note that
BOLD responses remain tightly coupled to local electrical activity
following challenges with vasoactive drugs such as general
anesthetics, serotonergic agonists and cocaine (Goense and
Logothetis, 2008; Rauch et al., 2008; Gollub et al., 1998).
Furthermore, the direction of cholinergic inﬂuences on task-
related PET and fMRI activations in thalamus (typically enhanced
by pro-cholinergic drugs: Cohen et al., 1994; Mentis et al., 2001)
and visual cortex (typically suppressed by pro-cholinergic drugs:Bentley et al., 2004; Silver et al., 2008) appear congruent with
cholinergic inﬂuences on electrophysiological responses in these
same regions (McCormick, 1992; Lo¨rincz et al., 2008; Kimura et al.,
1999).
3.3. Strategies to circumvent possible confounds in pharmacological
neuroimaging
Given concerns over pharmacological inﬂuences on the
neurovascular coupling relationship, pharmacological functional
imaging experiments are designed in ways that: (1) assess any
changes in global and/or session parameters, independent of the
cognitive paradigm, and (2) reduce the impact of any such
potential confound. Table 2 outlines the range of methodological
strategies employed in this regard, with examples given from the
cholinergic functional imaging literature (see also Iannetti and
Wise (2007) for methodological issues pertaining to pharmaco-
logical fMRI more generally).
Unlike resting-state activation studies (e.g. Honer et al., 1988;
Geaney et al., 1990), task-related studies as focused on here probe
for interactions between a drug challenge and two or more
functional conditions. For example, if a given brain region shows
approximately similar levels of activation across two or more
behavioural conditions (relative to baseline), then ﬁnding that a
drug modulates activity speciﬁcally during a subset of conditions,
but not during others, strongly suggests an interaction with a
neurocognitive process (e.g. Hahn et al., 2009). However, where
activation strengths differ between conditions, before drug is
given, then task  drug interactions may actually reﬂect effects on
a neurovascular scaling relationship, or appear due to metabolic-
vascular ceiling (or ﬂoor) effects. In these cases, it is useful to
observe whether other neocortical regions showing a similar
condition-speciﬁc pattern of activity, in the absence of drug, also
demonstrate the same type of condition  drug interaction –
suggesting perhaps a non-speciﬁc, vascular drug effect, or whether
the interaction is region-speciﬁc (e.g. Thiel et al., 2001). However
region-speciﬁc modulations provide only a partial guarantee for
inferring neural modulations, not least because cholinergic drug
effects on cerebral vasculature may vary between regions, with
cholinergic stimulation increasing rCBF by progressively smaller
amounts between prefrontal, parietal, hippocampal and subcorti-
Table 2
Methodological strategies to check for neurovascular confounding in pharmacological-functional imaging studies.
Example references
Global physiological–psychological indices
Systemic physiological measurements – pulse, blood pressure: compare between sessions;
or include as regressors of no interest
Kukolja et al. (2009)
Subjective scores (e.g. Bond and Lader, 1974) – as for physiological parameters Thiel et al. (2001)
Co-administration of drug that counteracts extracerebral cardiovascular side-effects,
e.g. glycopyrrolate with centrally acting cholinesterase inhibitor
Furey et al. (2000a)
Mean rCBF/BOLD values
Grand mean rCBF or BOLD values – over whole brain per session; compare between sessions
and/or correct (scaling)
Grasby et al. (1995); most fMRI studies
Global mean BOLD values – over whole brain per scan; include as regressor of no interest or
correct (scaling)
Thiel et al. (2001)
High-pass ﬁltering – removes gradual changes in response, e.g. due to declining drug levels Most fMRI studies
Voxel-level session effect; compare across conditions Bentley et al. (2004)
Drug  condition interactions
Dissociations: identify interactions with similar activation levels between conditions
under placebo (e.g. placebo: A – low; B – low; drug: A – low; B – high)
Bentley et al. (2004)
Cross-over: identify interactions in which drug causes an opposite pattern of responses
across conditions (i.e. placebo: A – high; B – low; drug: A – low; B – high)
Hahn et al. (2007), Kukolja et al. (2009)
Cross-over re-mapping: e.g. where drug modulates differential responses to two arbitrary
stimuli whose cognitive signiﬁcance reverses in half of subjects
Thiel et al. (2002a)
Region-speciﬁc interactions, e.g. task-speciﬁc drug interaction in parietal but not occipital cortex
despite similar activation levels under placebo
Thiel et al. (2001), Sperling et al. (2002)
Behavioral correlations
Correlation of drug-induced activation change and behavioural measure of interest suggests
drug effect on neural activity, especially if scan and behavioural measure separated in time
Furey et al. (2000b), Bentley et al. (2009)
Alternative analytic methods
Modelling multiple basis functions for BOLD response Rombouts et al. (2005)
Measurement of BOLD phase relationship only with respect to alternating visual stimulus Silver et al. (2008)
Fractal complexity (Hurst exponent, H) and inter-regional correlations of resting-state fMRI time-series Wink et al. (2006), Suckling et al. (2008)
Inter-regional correlations of event-related fMRI (functional connectivity) Jacobsen et al. (2004), Kobiella et al. (2011)
Measurement of BOLD and rCBF
Use of arterial-spin labelling in addition to T2* MRI sequences Hahn et al. (2009)
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If it is assumed (or demonstrated) that drug-induced changes in
our neuroimaging signal (e.g. rCBF or BOLD) reﬂect a speciﬁc neural
effect, rather than a nuisance vascular effect, the question then
arises as to what this modulated activity signiﬁes. If a drug-
induced modulation of regional activation is accompanied by a
behavioural change, it is tempting to interpret the functional
imaging change causally, in terms of enhanced or impaired
functionality of the modulated region. However, one must also
consider the possibility that the activation change might reﬂect
compensation (e.g. for a remote drug-induced impairment in some
other areas), or are a consequence of the observed behavioural
change rather than vice versa. In certain situations, it is possible to
make a reasonable interpretation of what drug-induced modula-
tion of cerebral activity means even without concomitant
behavioural changes, e.g. when increasing or decreasing top-down
attentional-modulation of sensory activations (Bentley et al.,
2004), or when biasing the relative sizes of sensory stimulus
representations (Thiel et al., 2002a).
A further set of methodological considerations arises from the
timeline for the pharmacological action of particular cholinergic
drugs. Ideally, scanning should take place during a timewindow
when pharmacokinetic and pharmacodynamic variables are
relatively stable – the latter as established either chemically or
behaviourally (Furey et al., 2000c). Animal microiontophoretic and
human radioligand studies contribute in this regard by demon-
strating, for example, the time-course of effects from cholinergic
drugs on brain neurotransmitter levels (Tsukada et al., 2004) and
receptor occupancy (Brody et al., 2006). In other cases, drug-
induced functional activation changes may be assessed many days
after the drug has been withdrawn, presumably due to drug
inﬂuences on plasticity (Rosier et al., 1999). It also needs to beappreciated that the response to a set dose of a drug, or the dose at
which an optimal behavioural effect is achieved, can vary widely
between subjects for drugs such as cholinesterase inhibitors
(Bartus, 2000). This may be related to age, baseline performance,
and genetic variability (Kukolja et al., 2009; Bizzarro et al., 2005),
which if known, can be included as covariates within the
regression model. Finally, we note that the localisation of
pharmacological functional neuroimaging effects will not neces-
sarily reﬂect the only sites where the drug is acting. For example,
enhancements of neocortical activation secondary to cholinergic
stimulation may reﬂect modulatory effects within the thalamus,
mediated via a tegmental-thalamic reticular system, rather than
due to interactions with the nucleus basalis–neocortical system
(McNamara et al., 1990). Furthermore, cholinergic drugs are likely
to inﬂuence other neuromodulatory systems such as dopamine
(Dewey et al., 1993), while muscarinic receptor blockers may
paradoxically enhance cholinergic neurotransmission, e.g. within
hippocampus (Mishima et al., 2000), due to autoregulatory effects
(Hoss et al., 1990), or by enhancing nicotinic receptor transmission
(Mentis et al., 2001).
4. Systematic review
We performed an exhaustive search for human cholinergic
functional imaging studies using the PubMed database with
combinations of the search terms [cholinergic OR acetylcholine OR
nicotine OR scopolamine OR cholinesterase OR smoking OR
varenicline] AND [functional imaging OR fMRI OR PET] up to May
2011. PubMed-suggested ‘Related Articles’, references and cita-
tions of relevant articles were also interrogated. Selected studies
were those in which: (1) functional neuroimaging measures were
obtained in healthy humans during a stimulus-driven and/or
behavioural activation paradigm; and (2) the effects of a systemic
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examined. The majority of such studies actually scanned subjects
over at least two behavioural conditions, sometimes including a
resting state. Hence, the results of such studies often take the form
of interactions between drug and task- (or stimulus-) determined
conditions in determining regional brain activations.
Cholinergic functional neuroimaging studies in patient groups
(mostly in Alzheimer’s disease or mild cognitive impairment) are
not listed here because of differences in the general methodology
of such studies. The vast majority of such clinical studies observe
changes in neural activation over a long course of treatment
(typically many months), rather than using placebo-controlled,
single drug challenges, unlike most healthy studies. Moreover,
many measure resting-state metabolic proﬁles alone, rather than
task and/or stimulation-related activations. Clinically focused
cholinergic functional neuroimaging reviews can be found
elsewhere (see Dickerson, 2006; Nordberg, 2004).
A summary of all relevant human cholinergic functional
imaging studies is presented in Tables 3–5. To assist exposition,
and in line with the various functional conceptualisations of
acetylcholine summarised in Section 2 (viz. sensory, attention and
memory functions), studies are categorised according to whether
the critical effects primarily arose in sensory, frontoparietal or
medial temporal cortical regions. Activations in other brain regions
(e.g. lateral temporal cortex and subcortical structures) are listed
alongside frontoparietal effects for convenience. Furthermore,
within each anatomical division, effects are secondarily classiﬁed
according to the broad cognitive construct putatively tested (e.g.
passive viewing, attention-demanding or memory task). Then for
each study and anatomical region we tabulate: a more accurate
description of the behavioural paradigm; the drug administered;Table 3
Cholinergic functional imaging studies – sensory cortices.
Scanning task Drug Effect o
A. No task/irrelevant task/task-independent
Cohen et al. (1994)
PET-FDG
Auditory discrimination Scopolamine # prim
irreleva
Grasby et al. (1995)
PET-rCBF
Auditory word:
5- and 15-spans
Scopolamine " bilate
sensory
Bahro et al. (1999)
PET-rCBF
Auditory – eyeblink
conditioning
Scopolamine " latera
sensory
placebo
Thiel et al. (2001) Word-stem completion Scopolamine No effe
conditi
Sperling et al. (2002) Face–name pairs Scopolamine No effe
conditi
Jacobsen et al. (2002)a Chequerboard Nicotine No effe
Hahn et al. (2007)a Chequerboard Nicotine No effe
Hahn et al. (2009)a Chequerboard Nicotine No effe
Mentis et al. (2001)
PET-rCBF
Alternating eye
light ﬂash
Physostigmine 
scopolamine
Physos
Physo. 
No effe
Physo +
Furey et al. (2000a) Face WM Physostigmine No effe
Silver et al. (2008) Chequerboard Donepezil # prim
Bentley et al. (2004) Chequerboard Physostigmine # prim
Bentley et al. (2008)
(Elderly)
Face versus houses Physostigmine # fusifo
conditi
B. Demanding perceptual task
Thienel et al. (2009a) Attention network
task
Mecamylamine # super
orienti
Thienel et al. (2009b) ANT Scopolamine " midd
tempor
Ghatan et al. (1998)
PET-rCBFa
Visual maze Nicotine " occip
difﬁcul
Thiel et al. (2005) Alerting/spatial cues Nicotine # latera
post. oc
anteriothe imaging modality; plus the critical functional neuroimaging
and behavioural results. Studies are duplicated across tables
where, for example, both sensory and frontoparietal regions were
studied.
The general format of all studies is that of a randomised-
controlled trial in which subjects receive a single challenge or short
course of drug or placebo. Most studies adopt a within-subject,
cross-over design. Cholinergic drugs used were scopolamine
(muscarinic receptor antagonist); nicotine (nicotinic receptor
agonist); physostigmine or donepezil (cholinesterase inhibitors;
the former of which is given intravenously and has a well-
documented pharmacokinetic time-course); mecamylamine (nic-
otinic receptor antagonist), or varenicline (a nicotinic a4b2
receptor partial agonist and a7 receptor full agonist, typically
used in the context of ameliorating smoking withdrawal symp-
toms; and in functional imaging paradigms often administered for
2–3 weeks before scanning). Studies in which smoking a cigarette
are used as a nicotine source are also included, although such
studies typically do not control for the behavioural or chemical
properties of smoking, and so must be interpreted accordingly.
5. Functional neuroimaging: sensory modulations
5.1. Sensory cortex modulations depend upon task demands
5.1.1. Functional neuroimaging results
Forty-one functional imaging studies in healthy adults have
probed interactions of cholinergic modulation with stimulus-
evoked sensory cortex activity (Table 3). Results are categorised
according to the nature of the task that applied. One striking
pattern is that the direction of modulation of cholinergic drugs onf drug on functional activations Effect of drug on performance
ary visual, parieto-occipital cx (i.e.
nt sensory cx); N.B. no control task
Poorer target discrimination.
Performance inversely correlated
with parieto-occipital cx activity
ral lateral occipital cx (i.e. irrelevant
 cx), in sub- and suprascan tasks
Memory impairment on supraspan
task only
l occipital–temporal cx (i.e. irrelevant
 cx); N.B. no direct comparison with
 group
Not measured
ct in primary visual cortex across task
ons
No effect on performance
independent of repetition
ct in primary visual cortex across task
ons
Memory impaired
ct in sensory cortices Not measured
ct in sensory cortices Not measured
ct in sensory cortices Not measured
tigmine: # middle occipital
+ scopolamine: " middle occipital
ct of physo. in primary visual cx
 scopolamine: # primary visual cx
Not measured
ct on control stimuli in extrastriate cx Not measured
ary visual cortex extent and magnitude Not measured
ary visual cortex across task conditions Faster RT over all tasks independent
of task
rm, parahippocampal cx, across task
ons
No task-independent effect
ior occipital cx; " anterior fusiform cx –
ng; # calcarine cx – conﬂict
Slowing across all trial types; no
interactions
le occipital cx – alerting; # lingual gyrus, inf
al cx – conﬂict
Slowing of responses
ital–temporal–parietal cx more during
t than control task
No effect
l occip.–temp., medial occip. – alerting; #
cip, post. fusiform cx, but " anterior occip.,
r fusiform cx – orienting
Speeding of invalidly cued trials;
alerting numerically but
insigniﬁcantly speeded
Table 3 (Continued )
Scanning task Drug Effect of drug on functional activations Effect of drug on performance
Hahn et al. (2007)a Spatial cues Nicotine (smokers) " cuneus (valid precise-cues), # cuneus (valid
imprecise-cues); " lingual gyrus (invalid low-
intensity targets); # lingual gyrus (invalid high-
intensity targets)
Speeding in precise-cueing trials
Thiel and Fink (2008) Spatial cues Nicotine No effect in occipital cx Less slowing in invalidly cued trials
Vossel et al. (2008) Spatial cues Nicotine # anterior lingual gyrus to invalid versus valid
cues in high versus low-predictability blocks
Reduced invalidity effect
Hahn et al. (2009) Visual angle; colour;
signal-detection
Nicotine (smokers) # occipital–temporal cx across all tasks
(i.e. high- and low-attention)
Speeding in selective-attention and
signal-detection tasks, but not
divided attention
Loughead et al. (2011)a Emotion detection Varenicline for 13 days # middle occipital cx Speeded responses
Bentley et al. (2003a) Spatial cues Physostigmine " fusiform cx; # lateral occipital cx Trend for speeded responses
Bentley et al. (2004) Spatial cues Physostigmine " superior, lateral occipital cx; #cue-driven,
differential retinotopic activity
Speeded responses. # cue-driven
occipital selectivity correlates with #
invalidity effect
Bentley et al. (2008)
(Elderly)
Visual depth
of processing
Physostigmine # task-differential activity in posterior STS, lateral
occipital cx, due to " activity in low-attention task
No effect
C. Memory (encoding)
Rosier et al. (1999)
PET-rCBF
Shape recognition Scopolamine
(at encoding);
scan 3 days later
# bilateral fusiform cx, esp. L (both tasks), and
middle occipital cx (during sensory-challenge
rather than standard conditions)
Impaired recognition accuracy.
Fusiform activity correlates with
memory accuracy
Sperling et al., 2002 Face–name pairs Scopolamine # fusiform cx Activity correlates with subsequent
memory
Bullmore et al. (2003) Object–location Scopolamine # lateral occipital; inferior temporal; cuneus
during task independent of memory load
No effect
Schon et al., 2005 Delayed
match-to-sample
Scopolamine # bilat. mid-fusiform, parahippocampus (delay-
period of WM); # R fusiform (delay-period of
subsequently remembered trials)
Impairs performance on control
task, WM task and subsequent
memory
Dumas et al. (2010) Word recognition Scopolamine/
mecamylamine
# cuneus, lat. occip. (scopolamine), middle occip.
(mecamylamine): new versus old words
Worse recognition with
scopolamine (trend)
Antonova et al. (2010) Allocentric spatial WM Scopolamine # fusiform cx at encoding No effect
Lawrence et al. (2002)a Visual number
WM (RVIP)
Nicotine " middle occipital, fusiform cx in RVIP and
visuomotor control task
Improved accuracy on RVIP task
(dependent on treatment order)
Hong et al. (2009)a RVIP Nicotine " cuneus, fusiform, parahippocampal cx Improved accuracy on RVIP task
Jacobsen et al. (2004)a Auditory n-back;
dichotic versus
binaural
Nicotine " posterior sup. temporal cx during 2-back, not 1-
back; # medial occipital (i.e. irrelevant sensory cx)
during dichotic presentation
Accuracy worsened in hardest
condition (2-back, dichotic)
Jacobsen et al. (2006)a Auditory n-back Nicotine # sup. temporal cx during 2-back, dichotic; #
occip., fusiform (i.e. irrelevant sensory cx)
Accuracy worsened in hardest
condition (2-back, dichotic)
Furey et al. (1997)
PET-rCBF
Face WM Physostigmine # lateral temporo-occipital cx in WM versus
control tasks
Speeded responses
Furey et al. (2000b)
PET-rCBF
Face WM Physostigmine " medial occipital correlates with RT decreases Speeded responses, and correlation
with activation increases
Furey et al. (2000a) Face WM Physostigmine " amplitude in fusiform, occipital, parietal cx
(encoding phase); " activation volume in occipital,
inf temporal cx (encoding and delay)
Trend to speeded responses
Bentley et al. (2004) Spatial WM Physostigmine " middle, superior occipital cx during encoding
phase only
Speeding over all tasks. No effect on
accuracy
Freo et al. (2005)
PET-rCBF
Face WM Physostigmine " medial occipital (in elderly); # es lateral
occipital, ventral temporal cx (esp in young)
Speeded responses
Furey et al. (2008a,b)
PET-rCBF
Face WM Physostigmine # lateral occipital cx (1, 6, 16 s delays); " medial
occipital cx (6–16 s delays)
Speeded responses independent of
delay
Chuah and Chee (2008)
(sleep-deprived)
Visual color WM Donepezil " visual extrastriate cx in sleep-deprived,
independent of item number
Improved performance; correlated
with activation enhancements
Ricciardi et al. (2009)
PET-rCBF
(Young, elderly)
Face WM Physostigmine # lateral occip., ventral temporal (young); " lateral
occip. (elderly): for long delays; " medial occipital
cx (all): for long delays
Speeded responses independent of
delay
Bentley et al. (2009)
(Elderly)
Face recognition Physostigmine " fusiform cx correlating with memory of deep
versus superﬁcial encoded faces
Correlates with memory
improvement
D. Memory (conditioning)
Thiel et al. (2002a) Auditory fear
conditioning
Scopolamine # auditory cx plasticity due to # response to CS+ or
" response to CS
Reduced speeding of responses to
CS+ (paired) relative to CS
(unpaired tone)
Thiel et al. (2002b) Auditory fear
conditioning
Physostigmine # auditory cx plasticity due to " CS response
(unpaired tone)
No effect
E. Memory (priming)
Thiel et al. (2001) Word stem-cell
completion
Scopolamine # L lateral occipital repetition decrease due to "
response to repeated stimulus. No effect in
primary visual cortex.
Reduced priming (accuracy) for
previously presented words
Thiel et al. (2002c) Faces – judging
famousness
Scopolamine # fusiform cx (all faces); # fusiform repetition
decrease (famous faces), due to higher signal with
repeated face
Reduced priming (RT) for repeated
famous faces; no effect if drug given
after study phase
Bentley et al. (2003b) Spatial attention
using faces, houses
Physostigmine " repetition decreases only to attended faces, due
to larger # during repeated face
" priming effect for attended versus
unattended faces
N.B.: All studies use BOLD-fMRI except where indicated under study ﬁrst author. Abbreviations: WM, working memory; ANT, attention network task; RVIP, rapid visual
information processing task; cx, cortex; PFC, prefrontal cortex; RT, reaction time; sup., superior; post., posterior; occip., occipital; temp., temporal.
a Subjects included smokers.
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Table 4
Cholinergic functional imaging studies – task-related activations in frontal, parietal, lateral temporal cortices, and subcortical regions.
Scanning task Drug Effect of drug on functional activations Effect of drug on performance
A. Sensory – passive/task
Cohen et al. (1994)
PET-FDG
Auditory
discrimination
Scopolamine # thalamus, R PFC, cingulate, inf parietal cx; " L
anterior prefrontal, superior parietal cx
Poorer discrimination of targets.
Correlation between R PFC and score
Thienel et al. (2009a) Attention network
task
Mecamylamine " OFC (alerting); # sup. PFC (orientation); " sup.
PFC (no-orientation trials); # precuneus, sup.
parietal (conﬂict); " L inf. parietal (conﬂict)
Slowing across all trial types; no
interactions
Thienel et al. (2009b) Attention network
task
Scopolamine " R middle temporal; " L sup. PFC (alerting); # L
sup. PFC (orientation); # ant. cing., OFC, R PFC,
precuneus (conﬂict); " L inf. parietal (conﬂict)
Slowing across all trial types; greater
slowing for incongruent (conﬂict)
trials; also reduced interaction of
alerting with conﬂict
Ghatan et al. (1998)
PET-rCBFa
Visual maze Nicotine # ant. cing., basal ganglia, thalamus, cbllm No effect
Mentis et al. (2001)
PET-rCBF
Alternating eye
light ﬂash
Physostigmine 
scopolamine
Physostigmine: # inf. parietal; " thalamus;
scopolamine: no effect in these regions
Not measured
Thiel et al. (2005) Alerting/spatial cues Nicotine " R angular gyrus, R PFC (alerting); # L lateral
occipito-temporal during alerting; # L parietal,
precuneus during invalid-cue
Speeding of invalidly cued trials, esp
in subjects with large validity effect
at baseline
Giessing et al. (2006) Visual spatial cues Nicotine # R post. parietal (invalid cues, highly reliable); " R
post. parietal (valid cues; poorly reliable)
No effect
Thiel and Fink (2007) Auditory/visual alerting Nicotine # R parieto-occipital, frontal, sup temporal, ant.
cingulate (cued trials); " R angular gyrus (cued
visual trials); # R angular gyrus (uncued trials)
Trend to speeding for cued visual
trials and uncued auditory trials
Xu et al. (2007)a Stroop color test Nicotine
(smoking)
# R precentral sulcus during incongruent
condition (i.e. reverses abnormal hyperactivation
not seen in non-smokers)
No effect
Kobiella et al. (2011) Passive viewing of
emotional stimuli
Nicotine " anterior cingulate, OFC, striatum for unpleasant
(versus pleasant) stimuli; " es coupling between
ant. cingulate and amygdala
No effect on subsequent memory
Thiel and Fink (2008) Spatial cues Nicotine # R parietal, L inf. PFC, temporal (invalid trials) Speeding of invalidly cued trials
Vossel et al. (2008) Spatial cues Nicotine # R parietal, temporal, ant. cing. (invalid trials,
90%-reliable); " R parietal (invalid trials, 60%-
reliable)
Speeding of invalidly cued trials in
90%-valid block, but slight slowing
in 60%-valid block
Hahn et al. (2007)a Spatial cues Nicotine Enhances deactivations in ant. and post. cingulate,
L angular gyrus, L PFC. " R PFC; # thalamus (valid
targets); # precuneus (invalid targets); # R PFC, L
parietal (invalid; high-intensity)
Speeding for precise-cue, high-
intensity targets, and invalid trials.
Improved accuracy with high-
intensity targets. Correlation of RT #
and nicotine-induced BOLD
deactivations
Hahn et al. (2009)a Visual angle; colour
sequence; signal-
detection
Nicotine # dorsal prefrontal during low-attention, but "
during high-attention; also main-effect #
(enhances deactivation) in ant. cing., medial PFC,
parahippocampal cx
Speeding of high and low-attention
tasks. Correlations of RT # with
thalamus, PFC deactivations in
signal-detection task
Ettinger et al. (2009)a Pro- and anti-saccades Nicotine # dorsal prefrontal during anti-saccades; #
posterior cingulate, precuneus, R superior
temporal gyrus during pro-saccades
Speeding of anti-saccades
Azizian et al. (2010)a Color-word Stroop task Nicotine
(smoking)
# anterior cingulate during incongruent trials; "
middle frontal
Speeding independent of
congruency
Rose et al. (2010)a Intention versus
Attention Cues
Nicotine " L parietal, R superior temporal gyrus, to
intentional, but # for attentional, cues
Improved accuracy for both cue
types
Franklin et al. (2011)
MRI-perfusiona
Passive viewing
smoking cues
Varenicline for
3 weeks
# medial OFC, ventral striatum to smoking cues,
but " lateral OFC
Reduced withdrawal symptoms
while viewing smoking cues
Loughead et al. (2011)a Emotion detection Varenicline for
13 days
# medial prefrontal, cingulate cx, thalamus; "
middle temporal gyrus
Speeding responses
Bentley et al. (2004) Spatial cues Physostigmine " superior prefrontal cx; # medial parietal cx Speeding and improved accuracy
Bentley et al. (2008)
(Elderly)
Visual depth
of processing
Physostigmine # R parietal cx No effect
B. Working memory
Grasby et al. (1995)
PET-rCBF
Auditory word lists:
5- and 15-words
Scopolamine # bilat. PFC, ant. cing. (supraspan task); #
premotor, R thalamus, precuneus; " OFC in supra-
and subspan tasks
Memory impairment on supraspan
task only
Dumas et al. (2008)
(Elderly)
Visual verbal
n-back WM
Scopolamine/
mecamylamine
# R prefrontal (either drug); # precuneus
(scopolamine)
No effect
Craig et al. (2010)
(Menopause)
Delayed
match-to-sample WM
Scopolamine
(GnRH)
# bilat. PFC, anterior cingulate, R parietal,
especially in GnRH group
Poorer accuracy and slower,
especially in GnRH group
Antonova et al. (2010) Allocentric
spatial WM
Scopolamine # L lateral temporal cx; " PFC, cingulate, parietal,
striatum, thalamus (mostly at recall)
No effect
Ernst et al. (2001a)
PET-rCBFa
Visual letter
2-back WM
Nicotine " L lateral PFC; bilat. parietal cx; # ant. cingulate
(in ex-smokers);
# frontoparietal, ant. cingulate (smokers)
Improves accuracy in smokers;
accuracy correlates positively with
PFC, cingulate activity under
nicotine
Lawrence et al. (2002)a RVIP and target
detection
Nicotine " bilat. parietal, post. cingulate, caudate, thalamus
(RVIP); enhances insula deactivations
Improved accuracy on RVIP task
(dependent on treatment order)
Hong et al. (2009)a RVIP Nicotine " bilat. prefrontal, cingulate, parietal cx; insula,
thalamus; striatum; midbrain, cbllm.
Improved accuracy on RVIP task;
correlated with " BOLD activity
Kumari et al. (2003) n-Back WM Nicotine " dorsofronto-parietal, ant. cingulate, esp at 1-
back; # R dorsal parietal for 3-back
Increased accuracy, and correlation
with BOLD effects. RT # in 3-back
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Table 4 (Continued )
Scanning task Drug Effect of drug on functional activations Effect of drug on performance
Jacobsen et al. (2004)a Auditory
1- or 2-back
Nicotine # R frontal, pallidum and thalamus during dichotic
(high-attention) or 2-back conditions
Impaired accuracy during dichotic,
2-back condition
Jacobsen et al. (2006)a Auditory
1- or 2-back
Nicotine # L prefrontal, posterior cingulate during dichotic
2-back condition
Impaired accuracy during dichotic,
2-back (more so in 957T carriers)
Xu et al. (2005)a n-Back WM Nicotine
(smoking)
# L dorsolateral PFC during 1-back (but not 2-back
or 3-back)
Slower and less accurate with
abstinence (trends)
Xu et al. (2006)a n-Back WM Nicotine
(smoking)
# L dorsolateral PFC during 1-back (during
abstinence day) but " PFC during 1-back (during
ad libitum smoking day)
Improved accuracy (trend)
Sweet et al. (2010)a 2-Back verbal WM Nicotine " inferior, middle temporal; parietal (correlations
with craving during placebo); # deactivations in
medial PFC, temporal poles
No effect
Sutherland et al. (2011)a Attention-
switching WM
Nicotine
(smoking)
No effects with acute challenge (but higher PFC
activity in smokers than non-smokers)
Speeded responses and more
accurate in smokers
Loughead et al. (2010)a Visual pattern
n-back WM
Varenicline
(in abstinent
smokers)
" prefrontal cx during 3-back Speeded responses with drug in
highly dependent smokers across all
conditions
Furey et al. (1997)
PET-rCBF
Face WM Physostigmine # R prefrontal cx Speeded responses and correlation
with prefrontal reductions
Furey et al. (2000b)
PET-rCBF
Face WM Physostigmine # R prefrontal cx ant. cingulate, L lateral temporal
cx correlates with RT decreases
Speeded responses and correlations
with activation decreases
Furey et al. (2000c)
PET-rCBF
Face WM Physostigmine # R prefrontal cx Speeded responses
Furey et al. (2000a) Face WM Physostigmine # anterior dorsal prefrontal cx,; " inferior PFC, to
all phases of task
Speeded responses
Freo et al. (2005)
PET-rCBF
(Young, elderly)
Face WM Physostigmine # dorsal (young) and anterior, inferior (elderly)
PFC; trend to " in ant. cingulate cx; greater
deactivations in insula, medial frontal
Speeded responses in both young
and elderly
Furey et al. (2008a,b)
PET-rCBF
Face WM Physostigmine # anterior, inferior prefrontal cx, esp. at longer
WM delays; # sup. PFC at all delays
Speeded responses independent of
delay
Ricciardi et al. (2009)
PET-rCBF
Face WM Physostigmine # anterior prefrontal cx Speeded responses independent of
delay
Chuah and Chee (2008)
(sleep-deprived)
Visual color WM Donepezil " R intraparietal sulcus. L prefrontal in sleep-
deprived
Improved performance; correlated
with activation enhancements
Bentley et al. (2004) Spatial WM Physostigmine # L inferior prefrontal cx Speeding. No effect on accuracy.
C. Short-term memory
Rosier et al. (1999)
PET-rCBF
Shape recognition Scopolamine: – at
encoding; scan
3 days later
" posterior thalamus, bilateral parietal Impaired recognition accuracy. No
effect on stimulus discrimination or
detection (at time drug given)
Thiel et al. (2001) Word stem-cell
completion
Scopolamine # inferior and middle PFC repetition decrease due
to # response to new items
Reduced priming for previously
presented words
Sperling et al. (2002) Face–name pairs Scopolamine # inferior, dorsolateral, orbital PFC; deactivations
in lateral parietal, precuneus, lateral temporal cx
Slowed responses to gender
judgement. Impaired subsequent
memory.
Bullmore et al. (2003) Object–location
learning
Scopolamine # bilateral dorsolateral PFC, ant. cingulate,
striatum for high memory loads; # parietal for
high and low memory loads
No effect
Bozzali et al. (2006) Word retrieval Scopolamine # bilateral PFC in exclusion condition (i.e. source
not familiarity memory) for New but not old items
No overall effect. Correlation of # in
left PFC activity with score on New
items
Craig et al. (2009)
(Menopause)
Subsequent memory
for written words
Scopolamine
(GnRH)
# L inferior frontal cx subsequent memory effect in
subgroup treated with GnRH
Impaired recognition
Dumas et al. (2010) Word recognition
memory
Scopolamine/
mecamylamine
# parietal cx (either drug); " frontal cx (either
drugs; trends), for new versus old words
Worse recognition with
scopolamine (trend)
Abbreviations: RT, reaction time; WM, working memory; ANT, attention network task; RVIP, rapid visual information processing task; cx, cortex; PFC, prefrontal cortex; OFC,
orbitofrontal cortex; cing., cingulate; bilat., bilateral; ant., anterior; post., posterior; sup., superior; inf., inferior; cbllm, cerebellum; GnRH, gonadotrophin releasing hormone
(decreases estrogen secretion and so mimics menopause).
a Subjects included smokers.
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attend to the stimulus. Thus Table 3A documents that when the
stimulus was observed passively, or was irrelevant to task-set,
cholinergic stimulation (with nicotine or cholinesterase inhibition)
generally either elicited no effect (e.g. Jacobsen et al., 2002), or else
suppressed sensory cortex – both in terms of overall activation
strength and lateral spread – especially in early processing areas
such as striate cortex (Silver et al., 2008). Cholinesterase inhibition
also decreases visual cortex activations independent of task,
suggesting a modulation of stimulus-driven processing alone
(Bentley et al., 2004, 2008). Consistent with these results, the
muscarinic receptor antagonist scopolamine results in enhanced
visual cortex activations during paradigms involving passive
exposure to visual stimulation (Mentis et al., 2001), or tasksinvolving auditory processing – i.e. when visual cortex is not
stimulated via afferent pathways (Grasby et al., 1995; Bahro et al.,
1999). Resting-state studies further support this general pattern
with scopolamine tending to increase, but physostigmine decreas-
ing, sensory cortex glucose consumption (Blin et al., 1994; Blin
et al., 1997). Such ﬁndings suggest that stimulation of cholinergic
receptors, especially muscarinic-type, can lead to net suppression
of activity within early sensory cortical regions, for stimuli that are
task-irrelevant.
In contrast, when the stimulus becomes task-relevant – either
because of instructions for a sensory judgement (Table 3B) or to
remember (Table 3C) – the opposite pattern is typically found.
Thus, stimulus-evoked visual cortex activity is enhanced by
cholinergic stimulation (e.g. Furey et al., 2000a), but suppressed
Table 5
Cholinergic functional imaging studies – medial temporal areas.
Scanning task Drug Effect of drug on functional activations Effect of drug on performance
A. Memory
Sperling et al. (2002) Face–name pairs Scopolamine #es fusiform cx, anterior hippocampus Correlates with memory
impairment
Bullmore et al. (2003) Object–locations Scopolamine # hippocampal, parahippocampal cx. For higher
memory load
No effect
Schon et al. (2005) Scenes: delayed
match-to-sample
WM; subsequent
memory test
Scopolamine # fusiform, parahippocampal (WM delay). #
fusiform, parahippocampal, hippocampus (WM
delay, for subsequently remembered items
presented once); " hippocampus (subsequent
memory effect for stimuli previously presented
twice)
Impairs accuracy and speed on
visual control task and WM task.
Impairs subsequent conﬁdent
memory
Bozzali et al. (2006) Word retrieval Scopolamine # L perirhinal cx in exclusion condition (i.e. source
not familiarity memory) for new but not old items
No overall effect. Correlation of # in
left perirhinal cx activity with score
on new items
Dumas et al. (2008)
(Elderly)
Visual verbal n-back
WM
Scopolamine/
mecamylamine
" R parahippocampal cx (mecamylamine) No effect
Dumas et al. (2010)
(Elderly)
Word recognition
memory
Scopolamine/
mecamylamine
# R uncus (scopolamine); L parahippocampal cx
(mecamylamine, trend); " R hippocampus (either
drug, trend)
Worse recognition with
scopolamine (trend)
Craig et al. (2010)
(Menopause)
Delayed match-to-
sample WM
Scopolamine # L parahippocampal cx, during encoding,
especially in GnRH group
Poorer accuracy and slower,
especially in GnRH group
Antonova et al. (2010) Allocentric spatial
memory
Scopolamine # hippocampal, parahippocampal cx (at
encoding); reduces deactivations in amygdala (at
encoding and recall)
No effect
Postma et al. (2006) Tactile pre-pulse
inhibition
Nicotine " hippocampus in prepulse + pulse verus pulse
only
Increases pre-pulse inhibition
Furey et al. (2000a) Face WM Physostigmine # L hippocampus correlates with RT # Speeding of responses
Bentley et al. (2009)
(Elderly)
Depth of processing
face memory
Physostigmine No effect on subsequent-memory comparison;
enhanced correlation between hippocampal
successful encoding and fusiform cx
Increased depth of processing
Kukolja et al. (2009) Item and spatial
source memory
Physostigmine " R hippocampal (successful encoding); # R
amygdala (encoding); # R amygdala (successful
retrieval)
# in source memory accuracy
(trend); Baseline memory negatively
correlated with physostigmine
effect on memory
B. Other tasks
Thienel et al. (2009a) ANT Mecamylamine " L parahippocampal cx during orienting Slowing of responses
Thienel et al. (2009b) ANT Scopolamine # L hippocampus during alerting Slowing of responses
Lawrence et al. (2002)a RVIP Nicotine Enhances L parahippocampal, amygdala
deactivations
Improved performance
Hong et al. (2009)a RVIP Nicotine " parahippocampal cx Improved accuracy
Vossel et al. (2008) Spatial cues Nicotine # R hippocampus to invalid versus valid cues Reduced invalidity effect
Hahn et al. (2009)a Several attention
tasks
Nicotine Enhances L parahippocampal deactivations Speeding of responses
Kobiella et al. (2011) Viewing emotional
stimuli
Nicotine " amygdala, hippocampus for unpleasant (rather
than pleasant) stimuli; " coupling between ant.
cingulate and amygdala
No effect on subsequent memory
Abbreviations: WM, working memory; ANT, attention network task; RVIP, rapid visual information processing task; cx, cortex; PFC, prefrontal cortex; GnRH, gonadotrophin
releasing hormone (decreases estrogen secretion).
a Subjects included smokers.
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stimulus processing. In many cases, opposite types of sensory
cortex modulation by the same cholinergic challenge, dependent
upon task-related attention, can arise within the same experiment.
For instance, physostigmine enhances the strength and spatial
extent of activity in visual extrastriate cortex speciﬁcally during
face-encoding (Furey et al., 2000b), and spatial attention (Bentley
et al., 2004). By contrast, the same studies show that physostig-
mine induces negative modulation, or none, within the same
sensory regions, during periods with similar stimulus properties
but little or no stimulus-processing demands, or when the same
stimulus property must now be ignored instead of attended
(Bentley et al., 2003a).
A concordant pattern of effects is seen with nicotine. Nicotine
induces higher visual cortex activity during a demanding visual
maze task, rather than a visuomotor control task (Ghatan et al.,
1998); while increasing auditory cortex activations more during an
attention-demanding 2-back, rather than a 1-back, auditory
working-memory paradigm (Jacobsen et al., 2004). In one study,
where nicotine appeared to enhance visual extrastriate activity
during both a working memory and a control task, it is noteworthythat even the control task required active attention to a series of
rapidly presented visual digits (Lawrence et al., 2002). Nicotine
also enhances occipital activity during visual target-detection
tasks, particularly in trials preceded by spatially precise cues or
using difﬁcult, low-contrast targets (Hahn et al., 2007), or for
invalidly cued targets (Thiel et al., 2005) – i.e. when attentional
demands are relatively high in all cases. By contrast, nicotine
decreases occipital activity on trials with spatially imprecise cues
or high-contrast targets (Hahn et al., 2007), or with alerting but
non-orienting cues (Thiel et al., 2005), in which cases there is
relatively less demand for top-down processing. Consistently,
cholinergic antagonism decreases occipital cortex activation
selectively during trials requiring spatial orientation or with
distractors (Thienel et al., 2009a,b).
A related observation is that subjects who show attentional
impairments – e.g. through sleep-deprivation (Chuah and Chee,
2008), age (Freo et al., 2005; Ricciardi et al., 2009) or disease
(Kumari et al., 2006; Goekoop et al., 2006; Bentley et al., 2008) –
tend to exhibit a greater enhancement of (task-dependent) sensory
cortex activity with cholinergic stimulation than seen in unim-
paired subjects. This dependency upon state/trait is reﬂected in a
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poorly performing subjects (Kukolja et al., 2009; Bentley et al.,
2009). Since less-able subjects are likely to experience greater
difﬁculty than healthy subjects for a given task, and therefore
require more attentional effort to achieve similar performance,
these results parallel observations made above in healthy subjects
(e.g. Jacobsen et al., 2004), that cholinergic stimulation increases
sensory cortex activations selectively during attentional-demand-
ing conditions.
5.1.2. Interpretation
From the perspective of existing accounts of cholinergic
impacts on sensory processing that recognise separable inﬂuences
for bottom-up and top-down processes (Sarter et al., 2001)
(Fig. 1A), the results of cholinergic functional imaging can be
summarised as: (1) cholinergic stimulation typically suppresses (or
cholinergic blockade enhances) net sensory activations under
conditions in which bottom-up processing predominates – e.g. with
passive or task-irrelevant, or task-independent, sensory stimula-
tion; or alerting but non-orienting cues; while (2) cholinergic
stimulation instead typically enhances (or cholinergic blockade
decreases) net sensory cortical activations under conditions where
top-down inﬂuences are strong, e.g. demanding perceptualFrontoParietal  
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2007), thereby heightening signal-to-noise ratio speciﬁcally for
sensory, i.e. thalamocortical inputs (Sato et al., 1987b), while
reducing lateral or feedback inﬂuences (Gil et al., 1997; Roberts
et al., 2005). By comparison with functional imaging data, it is
apparent that pro-cholinergic drugs are also often associated with
reduced sensory activation magnitude (Bentley et al., 2004) or
spread (Silver et al., 2008) (or vice versa for anti-cholinergics, e.g.
Bahro et al., 1999), speciﬁcally during low-attention or passive
stimulation paradigms.
Following the schema of Sarter et al. (2001), and bearing in
mind that most electrophysiological studies measure stimulus-
evoked responses divorced from top-down inputs, the functional
neuroimaging ﬁndings that pro-cholinergic drugs decrease stimu-
lus-evoked sensory cortex activations under low-attention condi-
tions correspond to electrophysiological ﬁndings of ACh-induced
suppression of overall activity in sensory cortex – i.e. when
spatially summing over all layers of a cortical column. (Note, how
this is distinct from the earlier point that the majority of sensory
neurons show facilitation in response to ACh.) However, although
the net signal is less than normal, we know that in this situation
(e.g. Kimura et al., 1999) cholinergic stimulation actually increases
afferent activity within layer IV while reducing interference from
lateral or top-down inputs, and so, this functional imaging
signature of sensory cortex hypoactivation may be considered to
be a marker of enhanced bottom-up processing. Behaviourally this
is supported by human fMRI studies showing that cholinesterase
inhibition speeds reaction times in a visual-stimulus detection
task, while suppressing striate cortex activations, independently of
task requirements in both cases (Bentley et al., 2004). Conversely,
anti-cholinergics are associated with slower target detection, and
increased occipital cortex activations, speciﬁcally in trials without
spatial cues or target-conﬂict – i.e. when top-down requirements
are less (Thienel et al., 2009b).
If decreases in sensory cortex activation induced by cholinergic
stimulatory drugs reﬂect neural suppression of lateral or feedback
inﬂuences as seen following ACh application to cortical slices, then
what neurophysiological events do pro-cholinergic drug-induced
increases in sensory activation relate to, as are generally found in
high-attention conditions within neuroimaging paradigms? To
recap, a critical role for the cholinergic system is to maintain
sensory processing in the face of performance challenges such as
distractors (Sarter et al., 2006). Thus we would expect ACh to
potentiate neural correlates of selective attention, in which
sensory processing is biased towards task-relevant stimulus
features, and away from task-irrelevant ones. In keeping with
this, two recent studies in awake monkeys and rats respectively,
indicate that cholinergic input to sensory (Herrero et al., 2008) and
parietal (Broussard et al., 2009) cortices can potentiate neural
correlates of selective attention by disproportionately increasing
weighting of task-relevant versus task-irrelevant inputs (Fig. 1C).
However, of relevance here, is that ACh application also increased
the overall level of visual neural activity, both in cells coding for
task-relevant and task-irrelevant locations, speciﬁcally during
target detection. Accordingly, with attention-demanding, relative
to baseline, conditions, as listed in Table 3B and C, we might expect
pro-cholinergic treatments to enhance stimulus-evoked responses
at the spatial scale of fMRI or PET, that integrate activity over
thousands of such units (potentially including both task-relevant
and task-irrelevant). The potential implications for the differential
activation of task-relevant versus task-irrelevant sensory units are
discussed in Section 5.3.
Combining neurophysiological accounts of cholinergic modu-
lation on bottom-up (e.g. Hasselmo and McGaughy, 2004) and top-
down (e.g. Herrero et al., 2008) processes within sensory cortices,
we propose an account that accommodates the attention-dependent proﬁle of cholinergic impact on sensory activations
studied with neuroimaging (see Fig. 1B–D). Whenever a stimulus is
presented, regardless of task, we expect cholinergic stimulation to
facilitate bottom-up circuitry, while reducing feedback and
horizontal inﬂuences – the net metabolic signature of which
may be decreased sensory cortex activation (e.g. Kimura et al.,
1999) (Fig. 1B). Conversely, in a subset of sensory paradigms, in
which attention is focused towards the stimulus, top-down
glutamatergic-mediated signals will enhance activity in selected,
task-relevant sensory regions. Knowing that ACh potentiates
neural activation of task-relevant, relative to task-irrelevant,
sensory cortical regions (Herrero et al., 2008), we might expect
human functional imaging studies to reveal a reduction in task-
driven sensory cortex activity following cholinergic antagonism, as
is seen (Fig. 1C). Furthermore, the electrophysiological ﬁnding that
both task-relevant and task-irrelevant sensory units increase in
ﬁring frequency with cholinergic stimulation (Herrero et al., 2008)
provides a potential explanation as to why further increases in
both magnitude and spatial extent of task-driven sensory cortex
activations can be observed in healthy subjects administered a
cholinesterase inhibitor or nicotine (Fig. 1D). The hypothesis that
in these human paradigms, pro-cholinergic drugs exaggerate top-
down ampliﬁcation of sensory signalling is supported by ﬁndings
that such sensory modulations are more apparent in subjects with
poorer baseline performance (e.g. Chuah and Chee, 2008; Bentley
et al., 2008) – for whom it is plausible that a greater top-down
‘attentional effort’ is operative in order to sustain error-free
performance (Sarter et al., 2006). Alternatively, impaired subjects
may start off having lower tonic acetylcholine, and task-related
activation, levels than normal, allowing for a greater dynamic
range of responses secondary to pro-cholinergic therapies than
seen in healthy subjects (see also Section 8).
5.2. Anatomical variations of sensory cortex modulations
Several neuroimaging experiments probing visual cortex reveal
an anterior – posterior gradient of cholinergic modulation,
suggesting differential inﬂuences between early versus higher
visual processing. For example, physostigmine decreases stimulus-
induced visual striate cortex activations (Silver et al., 2008), and
can do so regardless of task (Bentley et al., 2004); but increases
them in higher extrastriate visual regions in a task-speciﬁc manner
(Furey et al., 2000a; Bentley et al., 2004). Similarly, during visual
tasks, nicotine decreases posterior visual cortical activations while
increasing those in more anterior visual regions (Thiel et al., 2005;
Hahn et al., 2009). Furthermore, scopolamine decreases activations
in extrastriate visual cortex speciﬁcally during face–name
learning, whereas no modulation is observed in striate cortex
(Sperling et al., 2002; Thiel et al., 2001). These ﬁndings suggest that
primary visual cortex may be less susceptible to cholinergic
modulation, especially in its interaction with top-down factors.
One way by which such anatomical-speciﬁcity of ACh effects may
occur is through receptor segregation – for example, a preferential
expression of muscarinic receptors in V2 relative to V1 cortex
parallels a spatial gradient in attentional modulation (Disney et al.,
2006).
A further consistent anatomical division by which visual
regions differ according to cholinergic response arises between
ventromedial and posterolateral visual regions, with the former
showing increases, and the latter decreases, in activity following
cholinergic stimulation. Across three separate paradigms, involv-
ing either active or passive viewing, physostigmine increases
stimulus-induced, ventromedial extrastriate activations (including
fusiform gyrus), at the same time as decreasing activations in
posterolateral occipital regions (Furey et al., 2000b, 2008a;
Ricciardi et al., 2009; Bentley et al., 2003a; Mentis et al., 2001).
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2007) or varenicline (Loughead et al., 2011) as the cholinergic
stimulant concord with this pattern. Conversely, muscarinic
blockade results in activation decreases in fusiform cortex (Thiel
et al., 2002c; Sperling et al., 2002; Schon et al., 2005; Rosier et al.,
1999) or medial occipital cortex (Dumas et al., 2010), but activation
increases in lateral occipital cortices (Grasby et al., 1995; Bahro
et al., 1999; Mentis et al., 2001; Thienel et al., 2009b; Dumas et al.,
2010).
Cholinergic-induced enhancement of inferior-medial temporal
cortex might relate to this region’s critical role in stimulus
encoding for later memory. Since activation in inferior temporal
cortex can index subsequent memory (Grady et al., 1998),
cholinergic-induced enhancements here may reﬂect facilitation
of encoding (Bentley et al., 2009), possibly due to processes such as
persistent-spiking (Klink and Alonso, 1997; Hasselmo and Stern,
2006). This might explain why cholinergic modulation of medial,
but not lateral, occipital regions increases with temporal delay
between encoding and subsequent memory testing (Furey et al.,
2008a). Conversely, lateral occipital cortex, that is heavily
inﬂuenced by top-down and lateral connections (Vinberg and
Grill-Spector, 2008), might be expected to show depressed activity
following cholinergic stimulation, given that ACh generally
inhibits intracortical transmission (Kimura et al., 1999; Roberts
et al., 2005). An anatomical basis for a medial–lateral occipital
dissociation of cholinergic responsivity is hinted at by ﬁndings that
cholinergic ﬁbres to human occipital cortex segregate into medial
and lateral tracts (Selden et al., 1998).
5.3. Modulations of attentional effects within sensory cortex
Neocortical cholinergic afferents play a key role in selective
attention (Sarter et al., 2006), with evidence from single-unit rat
and monkey studies of ACh potentiating attentional modulation of
visual (Herrero et al., 2008) and parietal (Broussard et al., 2009)
responses. One might therefore expect pro-cholinergic drugs to
enhance neural correlates of selective attention in sensory cortices
as measured by functional neuroimaging, e.g. differential activa-
tion of retinotopic visual cortex as a function of spatial cueing
(Martinez et al., 2001). It was therefore unexpected when several
functional imaging paradigms reported that cholinesterase inhibi-
tion appeared to reduce top-down, selective effects in sensory
cortices. This was seen for both spatial attention (Bentley et al.,
2003a, 2004) and depth-of-processing (Bentley et al., 2008) visual
tasks, in which physostigmine actually reduced task-driven (as
opposed to stimulus-driven) modulation of extrastriate visual
cortices. Similarly, in a fear-conditioning paradigm, physostigmine
reduced the differential activation of auditory cortex to a
conditioned stimulus (i.e. previously paired with a shock) relative
to a non-conditioned stimulus (i.e. no shock association) (Thiel
et al., 2002b). Physostigmine has also been shown to increase the
spatial extent of visual cortex activations during a face working
memory task, implying a reduction in task-driven visual-selectivi-
ty (Furey et al., 2000a).
To reconcile this set of ﬁndings with those described earlier
(Section 5.1) – that pro-cholinergic drugs generally elevate
functional activations during attention-demanding tasks – these
experiments also showed that a main reason for such decreases in
attentional selectivity is because of a disproportionate increase in
sensory activity for task-irrelevant (or non-conditioned), rather
than a decrease for task-relevant (or conditioned) stimuli (Bentley
et al., 2004, 2008; Thiel et al., 2002b). Moreover, behavioural data
acquired during scanning show that enhancement of unattended
stimulus processing associated with a hypercholinergic state has
functional consequences. For example, enhanced activation of
visual cortex contralateral to invalidly cued (in this sense,unattended) targets, due to physostigmine, correlates with
behavioural speeding of performance for them (Bentley et al.,
2004). Furthermore, high-ACh states can enhance behavioural
(Holley et al., 1995) and autonomic (Quigley et al., 1994) responses
to irrelevant or low salience (Furey et al., 2008b) stimuli. Thus, by
heightening activity in sensory regions away from those favoured
by top-down commands, a hypercholinergic state can increase
detectability of unexpected or invalidly cued signals. This ﬁts a
computational model outlined in Section 2.2, in which heightened
cortical ACh levels serve to reduce endogenous weighting of inputs
under conditions of high uncertainty (Yu and Dayan, 2005).
Nicotine may induce similar inﬂuences on selective attention as
cholinesterase inhibition. One consistently observed behavioural
effect is that nicotine reduces the penalty incurred by invalid
attentional cueing (Witte et al., 1997; Thiel et al., 2005), suggesting
that it can reduce endogenous weighting, paralleling effects of
physostigmine described above. Furthermore, nicotine reduces
correlation between occipital deactivations and increasing spatial
precision of a cue in a target-detection task, suggesting that it
enhances activity in task-irrelevant retinotopic areas (Hahn et al.,
2007). However, nicotine does not consistently modulate cue-
driven selectivity in visual cortex (Thiel and Fink, 2008), suggesting
that more regionally abundant muscarinic receptors (Paterson and
Nordberg, 2000; Zilles et al., 2002) may account for the full proﬁle
seen with physostigmine (Bentley et al., 2004).
Does evidence from other techniques, including invasive
cellular recordings, also indicate a hypercholinergic state
decreases attention-related selectivity in sensory cortex? As
mentioned, local ACh application in visual cortex can increase
the difference in ﬁring rates between cells coding for task-relevant
versus task-irrelevant locations (Herrero et al., 2008). However,
the same study also found that ACh increased the overall ﬁring
rate; and, moreover, in some neurons ACh increased it dispropor-
tionately more for stimulus-attribute values (e.g. bar length) that
were non-optimal for the neuron’s usual tuning preferences. Other
studies have noted ACh-induced reductions in selectivity to
stimulus features (Zinke et al., 2006) or spatial coding (Kuo
et al., 2009), at the same time as enhancing overall activity. This
concords with functional imaging ﬁndings of enhanced sensory
cortex activation levels following cholinergic stimulation, con-
comitantly with reduced selectivity (Fig. 1).
Conceivably, under hypercholinergic conditions – i.e. those
achievable pharmacologically, but not encountered under ‘normal’
physiological states – weak top down signals are boosted more
than strong ones, because the latter have already reached a ceiling.
This might explain why some cholinergic-functional imaging
results seem maladaptive in the sense that they apparently favour
task-irrelevant (e.g. invalidly cued) over task-relevant (e.g. validly
cued) stimulus processing. Apparent support for this interpreta-
tion comes from an animal model of anxiety and psychosis
(Berntson et al., 1998), showing that excessive ACh neurotrans-
mission produces a hypervigilant state – including heightened
sensitivity to distractor, irrelevant stimuli. Additionally, acute
nicotine challenges in non-smokers can result in hyperarousal and
anxiety (Kobiella et al., 2011).
6. Functional neuroimaging: attentional modulations in
frontoparietal regions
The next four subsections (Sections 6.1–6.4) interpret cholin-
ergic neuromodulations of frontoparietal activity as revealed by
human functional imaging studies (Table 4) according to one of
four general schemes. In the ﬁrst three, the discussion focuses on
those results where pro-cholinergic drugs suppress task-speciﬁc
frontoparietal activity (or, consistent with this, where anti-
cholinergics increase activity), while the fourth attempts to
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i.e. frontoparietal hyper-activation secondary to pro-cholinergic
therapies (or suppression by cholinergic blockade). These accounts
(see also Fig. 2A–D) can be summarised as follows: (1) pro-
cholinergic reductions in parietal activity are associated with
reduced attentional orienting; (2) pro-cholinergic reductions in
frontal activity may occur due to enhanced sensory processing, or
via other efﬁciency-enhancing mechanisms, thereby requiring less
‘attentional effort’; (3) pro-cholinergic reductions in activity of a
predominantly medially located, resting-state network suggest a
shift from internal to external (i.e. stimulus) processing; and (4)
pro-cholinergic increases in activity, especially of a dorsolateral
frontoparietal network, may reﬂect increased recruitment of
attentional-executive processes. To extend comments made under
Sections 3.2–3.3, we emphasise here the fact that the same
frontoparietal regions show either increases or decreases in
activity secondary to the same drugs, in the same subjects, albeit
under different cognitive conditions, strongly argues against
general modulation of vascular responses, but rather invites an
interpretation in terms of neuropsychological interactions. The
interpretations that follow are intended to draw together the most
consistent ﬁndings within Table 2, and are not intended to be
exhaustive.Fig. 2. Explanations for modulations of frontoparietal activations in cholinergic-functio
secondary to pro-cholinergic drugs (especially nicotine) may occur indirectly becau
frontoparietal activation secondary to pro-cholinergic drugs may also be secondary to 
heightened efﬁciency, and thus less ongoing need for executive control. (C) Decreases in m
recognised resting-state network, which together with drug-induced reciprocal increase
feedback-predominant mode to externally directed feedforward mode. (D) Increases in
demanding task conditions, and sometimes with performance improvement, suggest re
intended to show possible order by which processes are modulated, and not anatomic6.1. Effects on top-down control of attentional orienting
If cholinergic stimulation reduces top-down modulation of
sensory cortices (see Section 5.3), then we might expect the same
drugs to modulate those frontoparietal regions – notably including
right parietal cortex – believed to exert top-down control of
attention (e.g. Yantis et al., 2002). Consistent with this, both
physostigmine (Bentley et al., 2008) and nicotine (Rose et al.,
2010), reduce parietal activity during selective attention para-
digms, while also causing a reduction in task-driven, differential
sensory cortex activation (Bentley et al., 2004).
A related observation originates from studies employing a
version of the Posner spatial cueing task. In those studies, nicotine
consistently decreases inferior parietal cortex activations speciﬁcal-
ly during invalidly cued trials, when there is a need for reorienting
away from a cued location (Thiel et al., 2005; Thiel and Fink, 2007,
2008) (Fig. 2A). Since nicotine also decreases the performance-cost
of invalid cues (Phillips et al., 2000; Thiel et al., 2005), this decreased
parietal activation during invalid trials seems not to reﬂect impaired
reorienting, but rather a processing beneﬁt for the invalidly cued
trials. Further variations of this paradigm reveal that nicotine-
induced decreases in parietal responses to invalid cues are
diminished when cue-derived expectation is reduced, i.e. bynal imaging studies. (A) Decreases in parietal activation during re-orienting trials
se of a hypercholinergic-induced reduction in spatial biasing. (B) Decreases in
direct effects of cholinergic stimulation in sensory cortical regions, which result in
edial frontal–parietal activations secondary to pro-cholinergic drugs overlap with a
s in activity in dorsolateral regions, suggests a state change from internally focused
 frontoparietal activations secondary to pro-cholinergic drugs, speciﬁcally during
cruitment of additional executive-attentional processes. Note that thick arrows are
al connectivity.
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appear at the cued location (Vossel et al., 2006, 2008; Giessing et al.,
2006). Taken together, these data suggest that nicotine decreases
cue-elicited spatial biasing – thereby secondarily reducing parietal-
mediated reorientation to targets at uncued location, because
participants are already less committed to the cued location when
the uncued target appears. The fact that performance may be
enhanced by nicotine on invalid trials is consistent with cholinergic
stimulation favouring bottom-up over top-down processing. This
squares with the point made earlier (Section 5.3) that physostigmine
reduces top-down driven selective activation of sensory cortices,
while increasing sensory responses in general. Moreover, choliner-
gic effects on parietal-mediated reorienting for invalidly cued
targets satisﬁes for invalidly cued targets satisﬁes a key prediction of
a model proposing that ACh reduces inference-driven biasing of
sensory cortex, to the beneﬁt of stimulus-driven signalling during
periods of ‘expected’ uncertainty (Yu and Dayan, 2005). However,
nicotine itself has not been found to reduce attentional modulation
of sensory cortex, perhaps suggesting that muscarinic receptors are
essential for the latter effects (see Thiel and Fink, 2008).
Other patterns of frontoparietal modulation by cholinergic drugs
support such an account of acetylcholine reducing top-down
attention. First, nicotine reduces anterior cingulate, as well as
parietal cortex, activity during invalid trials, coincident with
speeding and reduced response variability (Vossel et al., 2008).
Given that anterior cingulate acts as a source of attentional control
(Sarter et al., 2006), a nicotinic-induced reduction in its activity
might reﬂect reduced ‘attentional effort’ and/or error detection, on
invalidly cued trials, due to less of a top-down bias towards the cued
location. Second, nicotine decreases right angular gyrus activations
during uncued relative to cued (i.e. ‘alerting’) trials (Thiel et al., 2005;
Thiel and Fink, 2007). Since this region appears to mediate
reorienting to unattended stimuli (Yantis et al., 2002), this suggests
that nicotine reduces the ‘surprise’ element of uncued stimuli,
possibly by heightening vigilance (Wesnes and Warburton, 1984),
and thus reducing the subsequent need to reorient. Finally, and
mirroring pro-cholinergic reductions in parietal activity, anti-
muscarinic or anti-nicotinic drugs (i.e. scopolamine or mecamyl-
amine) increase parietal activity during a visual attention task, with
associated impaired performance (Thienel et al., 2009a,b). Since
these drug-induced hyperactivations occurred selectively with
target–distractor conﬂict, when parietal activity might reﬂect
attentional refocusing (Corbetta et al., 2000), and given that
performance was most impaired by these drugs during conﬂict
trials, the parietal hyperactivations here may be because anticho-
linergics decreased selective attention to the cued target location
prior to target appearance. Thus both hypocholinergic and
hypercholinergic states can be associated with parietal and
performance modulations that suggest impairment in top-down
processing (see also Section 8).
In the absence of reliable cues, target-associated activations
within inferior parietal or adjacent supramodal superior temporal
gyrus may reﬂect processing within a stimulus-driven, bottom-up
‘interrupt’ system (Corbetta et al., 2000), rather than top-down
orienting. If cholinergic stimulation favours bottom-up over top-
down processing, then we might expect pro-cholinergic therapies
to increase such activations – which is indeed what is found.
Hence, superior temporal gyrus activity increases with nicotine in
uncued trials, but decreases in cued trials, resulting in a ‘levelling
out’ of responses (Thiel and Fink, 2007). Furthermore, with poorly
predictive cues, nicotine increases target-induced parietal activa-
tions (Vossel et al., 2008; Giessing et al., 2006), that may reﬂect
nicotine potentiating bottom-up processing of unexpected stimuli,
or registering of uncertainty (Yu and Dayan, 2005). This is
compatible with nicotine speeding responses to highly salient
stimuli selectively (Rycroft et al., 2005); and parietal modulationby nicotine correlating with performance improvements selec-
tively for high-, rather than low-, intensity targets (Hahn et al.,
2007). Taken together with the observations made at the start of
this subsection, these results indicate that cholinergic stimulation
may suppress top-down enhancement of subtle inputs (i.e.
orienting), by favouring a state in which bottom-up inputs
compete for attention by virtue of their salience. Note also how
this molds with conceptualisations of cholinergic modulations of
sensory processing (see Section 2.1) – by which acetylcholine
enhances sensory unit ﬁring proportionately to the degree of
afferent input (Krnjevic´ and Phillis, 1963), and favours feedforward
over feedback processing (Hasselmo and McGaughy, 2004).
6.2. Efﬁciency of cortical processing
When a drug reduces task-related activity, and at the same
time, improves performance, one parsimonious account is to
suggest that the drug enhances cortical processing efﬁciency. This
is analogous to non-pharmacological functional imaging para-
digms, where correlations between enhanced performance and
reductions in prefrontal activations have been interpreted in terms
of efﬁciency (Rypma et al., 2006), presumably because of reduced
processing times; smaller volumes of active cortex, fewer numbers
of locally recruited neurons, reduced ﬁring rates, etc., which
together result in less metabolic demands. Regional hypoactiva-
tion may reﬂect improved processing efﬁciency within the region
itself; in remote region(s) that provide input to the modulated
area; or in the interconnections between them.
Numerous examples exist whereby pro-cholinergic drugs
improve performance while decreasing frontoparietal activation
(Table 4). For example, physostigmine-induced reductions in dorsal
prefrontal cortex activity, during encoding and maintenance-phases
of a working memory task (Furey et al., 2000a), have been
interpreted in terms of reduced task effort, on account of a
correlation between these imaging effects and drug-induced
speeding of responses (Furey et al., 1997). One explanation
(Fig. 2B) is that physostigmine produces a more robust neural
representation of studied stimuli – indexed by enhanced responses
in visual extrastriate regions during encoding (Furey et al., 2000a) –
thereby necessitating less prefrontal, executive-related activity
during a subsequent working memory delay period. Since such drug
effects on BOLD responses and performance are more marked at
longer memory delays (Furey et al., 2008a; Ricciardi et al., 2009), the
beneﬁt appears to be speciﬁc for memory processes, e.g. by
enhancing stimulus-speciﬁc persistent-spiking in higher sensory-
perirhinal cortices (Klink and Alonso, 1997; Hasselmo and Stern,
2006), rather than being directly related to stimulus processing,
retrieval or motor response.
The idea that drug-induced facilitation of sensory processing, or
encoding, secondarily decreases prefrontal activations is comple-
mentary to ﬁndings from non-pharmacological functional imaging
studies that prefrontal activation scales with sensory processing
demands (Grady et al., 1996). Moreover, the general observation
that pro-cholinergic manipulations lead to reciprocal modulations
between frontoparietal and sensory regions is supported by
studies showing the opposite proﬁle with cholinergic antagonists.
Hence scopolamine decreases fusiform cortex activations, at the
same time as increasing parietal (and thalamic) activations, during
the recollection stage of a visual memory task (Rosier et al., 1999).
Similarly, either scopolamine or mecamylamine decrease visual
cortex activation, while increasing frontal activations (Dumas
et al., 2010), suggesting greater executive processing for the same
performance, and paralleling a recognised ‘Posterior-to-Anterior
Shift in Aging’ activation proﬁle (Davis et al., 2008).
Diminutions in prefrontal activity, in association with improved
performance, are also found with nicotine (Hahn et al., 2009;
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in prefrontal activity during a perceptual task are associated with
increased posterior cortical activations (Ghatan et al., 1998),
suggesting that nicotine may primarily enhance sensory proces-
sing efﬁciency. In the case of nicotine, these ﬁndings may also
reﬂect direct effects within prefrontal cortex itself, by, for example,
nicotine-induced facilitation of presynaptic neurotransmitter
release, without an increase in presynaptic electrical activity
(Vidal and Changeux, 1993; Lambe et al., 2003; Wonnacott et al.,
2006). Furthermore in some subject groups, e.g. as characterised by
dopamine receptor genetic polymorphisms, nicotine may actually
worsen performance while being associated with hyperactivations
in relevant processing regions, e.g. in left anterior insula – a critical
node within an ‘articulatory-loop’ during an auditory working
memory task (Jacobsen et al., 2006), suggesting a worsening of
efﬁciency.
An additional explanation for nicotine-associated modulations in
frontal activity, and improved performance, is that it induces a
positive emotional state, or arousal, which may be indirect drivers of
efﬁciency (Eysenck et al., 2007; Foster et al., 2008). This is especially
relevant in the context of studies scanning smokers, in whom
nicotine serves to relieve withdrawal symptoms. Typically, the
comparator of these experiments is placebo, which in this set of
subjects may actually signify the development of negative
symptoms such as craving. Thus, in these situations, nicotine-
induced reductions in prefrontal activity, associated with improved
performance (Ernst et al., 2001a; Xu et al., 2007; Azizian et al., 2010),
may actually signify the removal of distracting physical and
emotional symptoms, thereby necessitating less attentional control.
Do reduced activations in frontoparietal cortex secondary to
cholinergic stimulation reﬂect enhanced processing efﬁciency in
general, or are they functionally speciﬁc? On the one hand, nicotine-
induced deactivations of frontoparietal cortices (and thalamus)
correlate with response speeding, yet do not interact with cue
predictivity in a spatial attention task (Hahn et al., 2007, 2009). This
suggests that nicotine may exert a general preparatory or alerting
effect in frontoparietal regions, rather than interacting with spatial
orienting per se. However, in other cases, pro-cholinergic treatments
induce modulations that are context-speciﬁc, e.g. hypoactivation of
frontoparietal cortex during spatial attention, but not spatial
working memory (Bentley et al., 2004); with invalidly, rather than
validly, cued targets (Vossel et al., 2008) or with incongruent, rather
than congruent, Stroop targets (Xu et al., 2007). Moreover, the proﬁle
of these pharmacological interactions suggests that they do not
merely arise from differences in the degree of task-induced cortical
activation in the absence of drug (e.g. due to proportionate scaling),
but possibly reﬂect differences in local processing or inputs between
differing cognitive contexts.
One difﬁculty in interpreting drug-induced reductions in
frontoparietal activations, in association with performance
improvements, relates to the issue of reaction time confounding.
By this argument, a shortening of reaction times implies that the
total amount of task-speciﬁc processing between stimulus and
response is less, which in itself would give rise to smaller
hemodynamic responses. Hence drug-induced cortical hypoacti-
vations may be a result of enhanced efﬁciency – possibly due to
effects in other brain regions – rather than being the cause of it. For
this reason, it is useful to test whether pharmacological
neuromodulations are still observed after partialling out reaction
time effects (e.g. Bentley et al., 2008), in which case such confounds
are less signiﬁcant (although, in such cases, the neural modulations
observed are arguably less relevant as explanations for the
performance change).
A further caveat to an efﬁciency account of cholinergic
frontoparietal modulations is that it clearly cannot account for
all results, as seen by the number of contradictory examples inTable 4. For example, cholinergic antagonists, like pro-cholinergic
drugs, also reduce task-associated frontoparietal activations, but
are associated with performance impairments, e.g. with visual
discrimination (Thienel et al., 2009a,b), or memory tasks (Sperling
et al., 2002; Bullmore et al., 2003; Craig et al., 2009). Alternatively,
pro-cholinergic drugs can improve performance while increasing
(e.g. Chuah and Chee, 2008), or while having no detectable effect
(Ettinger et al., 2009; Sutherland et al., 2011), on frontoparietal
activity. In some cases even, nicotine may reduce prefrontal
activity, while being accompanied by performance impairment
(Jacobsen et al., 2004, 2006). Such ﬁndings necessarily demand
additional interpretations, such as supposing that some fronto-
parietal activations are critical for task performance (and hence
positively correlate with performance), rather than reﬂecting
extraneous ‘effort’ (which negatively correlate with perfor-
mance); or in the case of bi-directional nicotine effects by
supposing that whether efﬁciency is increased or decreased
depends upon baseline cholinergic tone, or performance – i.e. that
responses follow an inverted-U shaped proﬁle (discussed further
in Section 8).
6.3. Default network
Many fronto-parietal–temporal regions whose activity is
suppressed by pro-cholinergic treatments (notably including
nicotine) are either medially located (e.g. cingulate, precuneus,
and parahippocampal gyri), or involve superior–middle temporal,
and angular gyri (Ghatan et al., 1998; Bentley et al., 2004; Hahn
et al., 2007, 2009; Ettinger et al., 2009; Azizian et al., 2010;
Loughead et al., 2011). These regions overlap with the so-called
‘default’ or ‘resting-state’ network (Raichle and Snyder, 2007), and
as such suggest another mechanism by which the cholinergic
system and cholinergic drugs may act. Cholinergic stimulation
typically exaggerates deactivations within these regions, seen
without drug during attention-demanding tasks, while not
affecting activity at rest. At the same time, many of these studies
also show that cholinergic stimulation increases task-related
activity in dorsolateral frontoparietal or posterior regions,
suggesting a reciprocal shift in the balance of processing or
activation between ‘resting-state’ and ‘attentional-sensory’ corti-
ces (Fig. 2C). Conversely, hyperactivations are seen in medial
frontoparietal regions with nicotine in the resting state, or with
low-attention tasks (Stein et al., 1998; Lawrence et al., 2002;
Kumari et al., 2003); or with anti-cholinergics during taxing tasks
(Dumas et al., 2010; Antonova et al., 2010).
Given the similarity between nicotinic-mediated, task-related
hypoactivations and the ‘resting-state’ network, it has been
suggested that this pattern of pharmacological neuromodulation
may represent a switch in processing from an internally focused
state to one where sensory processing is required (Hahn et al.,
2007) (see Fig. 2C). The fact that such drug-induced hypoactiva-
tions occur independently of the level or type of attention (Hahn
et al., 2009) implies that cholinergic modulation may act to focus
attention towards any externally speciﬁed task. Furthermore,
positive correlations of nicotine-induced deactivations with
performance appear in keeping with the idea that trial-to-trial
performance depends upon the efﬁciency with which the resting-
state network can be deactivated, possibly because of a reciprocal
enhancement of task-relevant processing (Polli et al., 2005).
A cholinergic-mediated transition from a resting-state, inter-
nally focused network to one favouring processing of external
stimuli would ﬁt with the recognised capacity for acetylcholine to
switch cortical dynamics from a cortico-cortical, or feedback state,
to one that favours thalamocortical, or input-driven, signalling (Gil
et al., 1997; Hasselmo and McGaughy, 2004). Hence to extend our
earlier discussion of sensory cortex effects (Section 5.1), the
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processing may include both sensory cortex suppression (e.g.
Bentley et al., 2004; Silver et al., 2008), and enhanced deactivations
of a resting-state default network.
As a caveat, it should be considered whether nicotine-induced
response speeding may itself have led to some of the relevant
deactivations (e.g. Herath et al., 2002), although BOLD-behavioural
correlations were found only under certain conditions, or
restricted to the thalamus (Hahn et al., 2007, 2009). Furthermore,
nicotine-induced hyperactivations of anterior cingulate can be
associated with positive performance effects (Ernst et al., 2001a;
Kumari et al., 2003), while cholinergic blockade is associated both
with hypoactivations in similar regions and with performance
impairment (Grasby et al., 1995; Thienel et al., 2009a,b), indicating
that not all medial cortical regions respond homogeneously.
Furthermore, nicotine-induced hypoactivations of medial prefron-
tal regions may occur speciﬁcally in conﬂict scenarios (Hahn et al.,
2007; Vossel et al., 2008), while speeding responses (Hasenfratz
and Ba¨ttig, 1992), suggesting a more selective interpretation.
6.4. Recruitment of cortical processes
Certain studies show that pro-cholinergic drugs increase
activation in frontoparietal regions (e.g. Ernst et al., 2001a;
Lawrence et al., 2002; Bentley et al., 2004; Thiel et al., 2005), in
contrast to the proﬁle of nicotinic or physostigmine-induced
deactivations discussed in Sections 6.1–6.3. Many of these drug-
induced increases correlate positively with performance improve-
ments. Consistently, multiple studies demonstrate that cholinergic
blockade engenders task-related, frontoparietal hypoactivations,
concomitant with performance decrements (e.g. Cohen et al.,
1994; Bullmore et al., 2003; Thienel et al., 2009a,b). One factor that
can account for the discrepancy of these ﬁndings with the pro-
cholinergic associated hypoactivations described earlier (or anti-
cholinergic associated hyperactivations) is anatomical. Pro-cho-
linergic deactivations tend to occur predominantly in medial
prefrontal–parietal locations; whereas increased activations in-
duced by cholinergic stimulants are often in dorsolateral fronto-
parietal cortices (Fig. 2C; as discussed in Section 6.3). This supports
the suggestion that ACh biases processing away from an internally
directed resting-state, and towards active processing of the
environment, or task-engagement (Hahn et al., 2007).
A different sort of explanation is required to account for
situations in which the same (usually dorsolateral) frontoparietal
regions show either increases or decreases in neural activation, in
response to a given cholinergic drug, depending upon condition.
One pattern is that increases in frontoparietal activity secondary to
pro-cholinergic drugs often occur speciﬁcally during the most
challenging stimulus or task conditions (e.g. Lawrence et al., 2002;
Bentley et al., 2004; Hahn et al., 2007, 2009; Hong et al., 2009;
Loughead et al., 2010), often with associated performance
improvements. Conversely, anti-cholinergics reduce activations
in these same regions and impair performance during the most
attention-taxing conditions (Bullmore et al., 2003; Bozzali et al.,
2006; Thienel et al., 2009a). Furthermore, it should be noted that in
most studies testing nicotine or varenicline, the comparator
(placebo) is likely to reﬂect a period of abstinence, when subjects
may experience adverse symptoms; and so this context may
accentuate any interaction of drug with difﬁculty or attentional
effort, relative to non-smokers. This may account for the fact that
nicotinic stimulation increases frontoparietal activations selec-
tively during the most difﬁcult (3-back) working memory
condition in smokers (Loughead et al., 2010), but not non-smokers
(Kumari et al., 2003).
One interpretation of these ﬁndings is that ACh mediates
recruitment of performance-dependent frontoparietal activityselectively when resources are pushed to near-maximum use,
with the effect of enhancing rate-limiting step processing (Fig. 2D).
In support of this, prefrontal cholinergic inputs are essential for
increases in prefrontal activity that occur with distraction during a
stimulus-detection task (Gill et al., 2000), while lesions to this
input impair performance speciﬁcally in this demanding context.
Furthermore, a principal set of triggers for cholinergic release is
performance challenges – i.e. when ‘attentional effort’ is required,
with prefrontal cortex then both triggering and receiving
cholinergic stimulation (Sarter et al., 2006). It is possible that
pro-cholinergic enhancements of prefrontal activity, seen in
human functional imaging studies speciﬁcally during attention-
demanding conditions, reﬂect accentuated persistent spiking
secondary to cholinergic transients, that facilitate cue detection
and subsequent behavioural priming (Parikh et al., 2008; Hasselmo
and Sarter, 2011). Moreover, evidence from non-human studies
that a prefrontal–cholinergic basal forebrain loop becomes co-
activated, at the same as potentiation of sensory cortex (Golmayo
et al., 2003), is supported by human neuroimaging studies
demonstrating positive three-way correlations between choliner-
gic drug modulation of frontoparietal cortices, visual cortices and
accuracy (Chuah and Chee, 2008; Bentley et al., 2009; Thienel et al.,
2009a,b; Sweet et al., 2010).
Other examples of pro-cholinergic frontoparietal hyperactiva-
tions can also be interpreted in terms of processing recruitment.
For example, activation of prefrontal cortex processing by nicotine
is seen selectively with emotionally negative, rather than positive,
stimuli, possibly due to the former evoking greater ‘bottom up’
attention (Kobiella et al., 2011). Additionally, frontoparietal
hyperactivations due to nicotine, seen during periods of low cue
predictivity (Thiel et al., 2005; Giessing et al., 2006; Vossel et al.,
2008), and interpreted earlier as reduced attentional reorienting
(Section 6.1), could alternatively be interpreted as cholinergic-
recruitment of vigilance-related processing during periods of poor
target predictability, or heightened task difﬁculty. Similarly, in an
attentional paradigm showing predominantly nicotine-induced
pan-cortical deactivations, it was noted that the few examples of
drug-associated frontoparietal hyperactivations occurred in the
most taxing task condition, viz. invalidly cued low-intensity
targets (Hahn et al., 2007). However, there was no behavioural
correlation with these neural modulations, and the same study also
showed that nicotine-induced prefrontal hyperactivations corre-
lated with nicotine-induced performance impairments, during a
relatively easy task condition, viz. highly predictive, validly cued
high-intensity targets. In these cases, presumably nicotine-
induced recruitment of prefrontal regions was either insufﬁcient
to compensate for poor performance, or these hyperactivations
reﬂected maladaptive responses that contributed to response
slowing. Similar to points made in Section 6.2, of pro-cholinergic
hypoactivations being associated with either performance im-
provement or deterioration (Jacobsen et al., 2004, 2006), the
ﬁnding here of pro-cholinergic frontoparietal hyperactivations
being associated with either positive or negative performance
effects may also be attributed to task or subject differences, that
entail different starting points on an inverted-U shaped proﬁle of
responses (see also Section 8).
In smokers, nicotinic stimulation appears to re-instate the
normal prefrontal functional activation pattern whereby greater
task demands (e.g. 3 > 2 > 1-back working memory) result in
proportionate increases in activation (Loughead et al., 2010).
However, this may occur either via drug-induced increases during
the hardest condition (Loughead et al., 2009, 2010), or because of
selective decreases during the easiest condition (Xu et al., 2005); in
the latter case, the interpretation possibly being one of ‘enhanced
efﬁciency’ (in line with Section 6.2). In non-smokers, nicotine may
push subjects away from this normal recruitment pattern (Kumari
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conditions, and inappropriately diminished processing (or possibly
exhaustion) during hard conditions (here again, reﬂecting an
inverted-U shaped pattern of response).
Finally, the fact that cholinergic stimulants induce frontopar-
ietal hyperactivations during a highly circumscribed set of task
parameters, e.g. with spatial orienting rather than spatial working
memory (Bentley et al., 2004); or intentional rather than
attentional cues (Rose et al., 2010) argues against explanations
in terms of the cholinergic system’s proposed role in general
arousal (see Section 1). This assertion is supported by data showing
that frontoparietal hyperactivations secondary to cholinesterase
inhibitors do not correlate with arousal or alertness (Bentley et al.,
2004; Chuah and Chee, 2008), in contrast to activations induced by
nicotine within the midbrain (Kumari et al., 2003).
7. Functional neuroimaging: memory modulations
7.1. Medial temporal regions
Given inﬂuences of cholinergic drugs, neuropathology and
genes on memory performance (Kopelman, 1986; Anagnostaras
et al., 2003), and the anatomical facts of an abundance of
cholinergic terminals and receptors within rhinal–perirhinal
cortex (Mesulam et al., 1986), it is reassuring that numerousFig. 3. Overview of memory-related processes modulated by cholinergic drugs as reve
models in which high ACh levels facilitate encoding while suppressing retrieval (Hasselm
(Sarter et al., 2006). (A) Sensory regions, especially fusiform cortex, show enhanced act
attention-demanding periods, including during encoding phases of working memory ta
cholinergic sensitivity in several memory-related processes elicitable by functional ima
remapping. (B) Medial temporal regions show enhanced activation with pro-cholinergic
cholinergic therapies) – this proﬁle corresponding to the discussed computational mode
medial temporal regions: anti-cholinergic therapies decreasing activations during enco
during retrieval (and vice versa for pro-cholinergic therapies except in the case of one woneuroimaging studies demonstrate direct associations between
cholinergic modulation of medial temporal structures and memory
encoding (Fig. 3B and Table 5). Hence scopolamine reduces
activation of hippocampal and parahippocampal cortices during
encoding and maintenance phases of spatial (Antonova et al., 2010)
and item (Sperling et al., 2002; Schon et al., 2005; Bozzali et al.,
2006; Craig et al., 2010) paradigms, while often decreasing
subsequent memory success. Conversely, cholinesterase inhibitors
increase hippocampal responses to stimuli subsequently remem-
bered compared to forgotten stimuli (Kukolja et al., 2009), and
enhance associations between sensory cortex and hippocampal
activations on trials subsequently remembered (Bentley et al.,
2009), suggesting facilitation of neuronal encoding mechanisms
that could account for these drugs’ pro-mnemonic actions. Indeed,
in Alzheimer’s disease or mild cognitive impairment, pro-
cholinergic enhancements of memory-related hippocampal activ-
ity are even more apparent (Potkin et al., 2001; Goekoop et al.,
2004; Gro¨n et al., 2006; Teipel et al., 2006), and behavioural
beneﬁts are more manifest.
Attempts have been made to interpret cholinergic neuromo-
dulations within medial temporal regions seen with functional
imaging. Effects of scopolamine on working memory maintenance-
period BOLD activity (Schon et al., 2005) have been interpreted in
terms of persistent-spiking multi-unit activity, observed in
perirhinal and entorhinal cortex neurons during, and after,aled by cholinergic-functional imaging studies, and relationship with theoretical
o and McGaughy, 2004) as well as potentiate top-down control of sensory processing
ivations with pro-cholinergic drugs (and vice versa with anti-cholinergics) during
sks, which correlates with subsequent memory. Sensory regions also demonstrate
ging – sustained-activity, repetition decreases, and conditioning-induced sensory
 therapies during encoding, but suppression during retrieval (or vice versa for anti-
l of memory function. (C) Prefrontal regions show a similar pattern of responses as
ding or working memory paradigms, but increasing or not modulating activations
rking memory paradigm* that was interpreted as increased efﬁciency – see Fig. 2B).
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task (Young et al., 1997). Cortical slice studies have shown that this
ﬁring pattern is stimulus-speciﬁc and cholinergic-dependent
(Egorov et al., 2002; Fransen et al., 2002). Furthermore, choliner-
gic-dependent, delay-period BOLD activity predicts not only
working memory success, but also subsequent conﬁdent memory
on a later surprise recognition test (Schon et al., 2005). This is
consistent with models invoking persistent-spiking activity within
hippocampus as being instrumental to encoding of long-term,
recollection-based memory (Hasselmo and Wyble, 1997; Koene
et al., 2003).
A further neurophysiological interpretation addresses the
ﬁnding that responses in hippocampus to cholinergic challenge
depend upon memory subcomponents. Thus, as well as increasing
hippocampal responses to stimuli at encoding, physostigmine
decreases activity in amygdala at retrieval (Kukolja et al., 2009),
and, moreover, tends to worsen memory accuracy relative to
placebo. Donepezil also selectively enhances hippocampal activity
during stimulus presentation, while decreasing it at rest (Teipel
et al., 2006). Scopolamine, on the other hand, decreases
hippocampal activity at encoding (Craig et al., 2010), but increases
amygdalar activity at retrieval (Antonova et al., 2010). It may also
be relevant here that physostigmine increases hippocampal
activations to successfully encoded locations, but decreases them
to unsuccessfully encoded locations (Kukolja et al., 2009).
Similarly, the direction that scopolamine inﬂuences hippocampal
activations associated with subsequent memory depends upon
whether the items are presented for a second time (Schon et al.,
2005), with a decrease following single presentation (during which
hippocampal activity is likely to be critical to recall), but increases
when items are presented on a second time (so that on some trials,
hippocampal activity during the initial presentation – that was
measured – may in fact reﬂect encoding failure).
This proﬁle of neuroimaging data mirrors behavioural ﬁndings:
namely, scopolamine impairs memory when administered prior to,
but not after, encoding (Ghoneim and Mewaldt, 1975; Atri et al.,
2004; Rasch et al., 2006); whereas cholinesterase inhibition
enhances encoding, but impairs retrieval (Rogers and Kesner,
2003; Gais and Born, 2004). Such state-dependent, bidirectional
cholinergic inﬂuences have been explained in terms of differential
ACh actions on cortical input type (Hasselmo and McGaughy,
2004) – with elevated ACh levels increasing feedforward activity –
that encourages self-association of activated inputs, and therefore
encoding, while decreasing feedback, retrieval-associated activity
in medial temporal cortices. On this account, physostigmine would
be expected to enhance novel stimulus-driven responses at
encoding, but suppress responses to retrieval prompts of the
same stimuli – as found in human hippocampus and amygdala
(Kukolja et al., 2009). The fact that physostigmine-mediated
hippocampal enhancements are only found to subsequently
remembered stimuli (Kukolja et al., 2009; Bentley et al., 2009)
suggest that these modulations are instrumental to any positive
memory effect found with this drug class. This interpretation also
ﬁts with scopolamine generally decreasing hippocampal and
amygdalar activations during encoding (e.g. Sperling et al., 2002;
Craig et al., 2010; Dumas et al., 2010), often while impairing
memory; but causing relative increases in these regions during
retrieval (Antonova et al., 2010).
In the earlier discussion of attention-related cholinergic
modulations (Section 6.3), we noted that pro-cholinergic drugs
may suppress task-related activity, or enhance deactivations, in a
‘resting-state network’ that includes medial temporal regions (e.g.
Furey et al., 2000a; Lawrence et al., 2002; Hahn et al., 2007). In
these paradigms though, memory was not an explicit part of the
task, and/or stimuli were symbolic, rather than rich in detail (e.g.
scenes, faces) – both of which might be expected to engageperirhinal processing less than where pro-cholinergic drugs did
increase activations in these areas (e.g. Schon et al., 2005; Kukolja
et al., 2009). Hence the pattern of cholinergic modulation in medial
temporal regions depends upon task (e.g. whether or not memory
is an explicit aim), phase (e.g. encoding or retrieval) and the
speciﬁc contrasts performed (e.g. whether as a function of
subsequent memory, or task type). Hippocampal responses to
cholinergic challenges may also interact with subject factors, e.g.
age (Dumas et al., 2008, 2010) or estrogen levels (Craig et al., 2010).
Part of the reason for the high variability in cholinergic
neuromodulations seen in functional imaging studies of the
hippocampus may relate to the complex relationship between
septohippocampal cholinergic system, hippocampus and memory.
For example, systemic scopolamine can both increase hippocam-
pal acetylcholine levels, while impairing memory function,
possibly due to differential actions on pre- and postsynaptic
muscarinic receptors, respectively (Mishima et al., 2000). Further-
more, while septohippocampal cholinergic levels correlate with
memory performance, acetylcholine may not be necessary for
hippocampal-dependent memory, with alternative circuits, or
behavioural strategies, available if cholinergic inputs are selec-
tively lesioned (Parent and Baxter, 2004). This may account for
why cholinergic blockade impairs hippocampal activation during
spatial memory encoding, while not affecting memory accuracy,
and at the same time, increases activity within a frontal–
neostriatal network (Antonova et al., 2010).
7.2. Sensory regions
Computational models of memory suggest that cholinergic
facilitation of input-driven associativity within sensory cortices
complement similar modulations within hippocampal–perirhinal
cortices in supporting encoding and retrieval (Hasselmo and
McGaughy, 2004). Functional neuroimaging studies support this
by demonstrating that scopolamine suppresses hippocampal and
fusiform cortex conjointly, speciﬁcally during visual memory-
delay periods (Sperling et al., 2002; Bullmore et al., 2003; Schon
et al., 2005); and impairs long-term fusiform cortex plasticity
(Rosier et al., 1999); in both cases matched by impaired
subsequent recognition (Fig. 3A). Conversely, physostigmine
increases extrastriate visual activations during visual working
memory delay-periods (Furey et al., 2000a), with greater modula-
tion for longer delays (Furey et al., 2008a; Ricciardi et al., 2009),
suggesting a cholinergic interaction with a memory, rather than
merely sensory, process. A similar conclusion was reached by a
study showing that physostigmine-induced increases in fusiform
cortex activations during encoding correlate with subsequent
memory success (Bentley et al., 2009). Presumably, recognised
inﬂuences of ACh on neural processes such as feedforward
associativity, long-term potentiation, and persistent-spiking,
found within sensory as well as perirhinal–entorhinal cortices,
may underlie many of these effects (Gu, 2003; Hasselmo and Stern,
2006).
Accounts of cholinergic inﬂuences on memory processes within
sensory cortices need to dovetail with models of cholinergic
impacts on attentional processing in similar regions (Sarter et al.,
2005). In this regard, modelling has suggested that cholinergic
inﬂuences on sensory cortex circuits – viz. enhancing feedforward
relative to feedback connectivity (Gil et al., 1997) – serve both to
enhance signal detection (and therefore certain aspects of
attentional performance) and formation of novel input associa-
tions, likely to be critical for memory encoding (Hasselmo and
McGaughy, 2004). One prediction then is that cholinergic
modulations of memory will be greater during high- relative to
low-attention conditions. Both psychopharmacological (Warbur-
ton et al., 2001; FitzGerald et al., 2008) and neuroimaging (Bentley
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support this with nicotine or cholinesterase inhibition boosting
memory and fusiform cortex activations selectively for deeply,
relative to superﬁcially, encoded items. In other words, pro-
cholinergic enhancements of sensory cortex activations that occur
selectively during high-attention conditions (see Section 5.1), may
facilitate subsequent recall of encoded stimuli. Additionally,
cholinergic stimulation may enhance connectivity between
sensory, hippocampal–amygdala and frontoparietal cortices (Bent-
ley et al., 2009; Kobiella et al., 2011).
Cholinergic drugs also interact with two well-recognised
functional imaging signatures of implicit memory within sensory
cortices – viz. conditioning-associated sensory remapping, and
repetition priming – often with congruent effects on behaviour
(Table 3C and Fig. 3A). The neural correlates of this disruption
suggest cholinergic inﬂuences on more than one sub-process. For
example, disruption of priming by scopolamine manifests itself
through a diminution of repetition suppression, by virtue of visual
extrastriate cortex activation being increased selectively to old
items under scopolamine (Thiel et al., 2001, 2002a), in contrast to
reduction of activation with repetition under placebo. Given effects
on behaviour are also selective for old items, this suggests that
scopolamine reduces memory storage (i.e. maintenance of a
particular representation), or reactivation, within sensory cortices.
However, the additional ﬁndings of reduced new-item activity in
prefrontal cortex (Thiel et al., 2001), and an absence of drug effect
on priming if given after the item-study phase (Thiel et al., 2002c),
suggests that encoding too may be disrupted, as is more generally
recognised (Hasselmo and McGaughy, 2004).
While repetition suppression recorded electrically among
monkey inferior temporal cortex neurons has not been found to
be cholinergic-dependent (Miller and Desimone, 1993), the
discrepancy with pharmacological-neuroimaging results may
reﬂect restricted neural sampling, or shorter lag times, in the
electrophysiological study. By contrast, the neuroimaging ﬁnding
that scopolamine disrupts remapping of sensory cortex in the
context of an auditory fear-conditioning paradigm (Thiel et al.,
2002a) is remarkable in its accurate mirroring of results following
cholinergic manipulation of similar sensory-learning paradigms in
rodents (Weinberger, 2007).
Inﬂuences of pro-cholinergic drugs on implicit memory-related
activations in sensory cortices appear mixed. On the one hand,
physostigmine increases repetition suppression in higher visual
cortex, speciﬁcally to attended items, with concordant effects on
priming (Bentley et al., 2003a,b). This effect was due to drug-
induced decreases to repeated stimuli (rather than increases to
novel stimuli), and as such mirrors effects of scopolamine on
repeated visual stimuli in a similar occipital region (Thiel et al.,
2001). On the other hand, physostigmine impairs conditioning-
related sensory remapping (Thiel et al., 2002b). However, unlike
scopolamine – that reduces differential sensory responses by
suppressing responses to relevant conditioned stimuli (CS+) (Thiel
et al., 2002a) – physostigmine heightens responses speciﬁcally to
irrelevant non-conditioned stimuli (CS). Once again, both of these
cholinergic-neuroimaging results (Bentley et al., 2003a,b; Thiel
et al., 2002b) indicate that cholinergic modulation of sensory-
based, memory processes interact with attention (Sarter et al.,
2005).
One reason why physostigmine increased neuroimaging
repetition suppression effects but decreased conditioning-associ-
ated sensory remapping may be on account of anatomical factors
(see Section 5.2); with once again, inferior occipital–temporal
regions responding to cholinergic stimulation with a heightening
of attentional effects (typically seen in paradigms using face
stimuli), and vice versa for lateral occipital–temporal regions (e.g.
Bentley et al., 2003a; Furey et al., 2008a,b). Alternatively,physostigmine might impair differential activations in sensory
cortex speciﬁcally during a conditioning paradigm because of the
drug’s tendency to increase ACh levels tonically, rather than
phasically – which might encourage pairing of both CS+ and CS
stimuli with the unconditioned (i.e. noxious) stimulus, in the
presence of high ACh levels (Thiel et al., 2002a).
7.3. Prefrontal regions
Cholinergic modulations of prefrontal activity during working
memory tasks have been discussed earlier in the context of
attentional effects (Sections 6.2 and 6.4), where it was noted that
both cholinergic blockade and stimulation may decrease activity,
albeit with different performance accompaniments (Fig. 3C).
Prefrontal modulations related to long-term memory have also
been observed, although, in an analogous pattern to cholinergic
neuromodulation of medial temporal regions (Kukolja et al., 2009),
effects vary depending on task and phase. Thus scopolamine-
induced suppression of prefrontal cortex is associated with
impaired performance when given prior to encoding (Sperling
et al., 2002; Craig et al., 2009, 2010); but with improved
performance when given afterwards (Bozzali et al., 2006).
Prefrontal modulations may reﬂect both direct actions, e.g. due
to scopolamine disrupting semantic processing of encoded words
(Craig et al., 2009); and/or indirect actions, e.g. secondary to
cholinergic potentiation of sensory or perirhinal cortices (Furey
et al., 2008a).
Scopolamine-induced reductions of memory-related fronto-
parietal (and sensory) cortex activity, as well as of performance,
resemble those induced by benzodiazepines within the same
experimental paradigm (Thiel et al., 2001; Rosier et al., 1999;
Sperling et al., 2002), implying a non-speciﬁc sedation effect.
Arguing against this though is an absence of correlation between
drug-induced modulations of memory-associated activation and
vigilance scores (Thiel et al., 2001; Sperling et al., 2002). Strong
interdependencies between cholinergic and GABAergic neuro-
transmission in many brain regions, including the septohippo-
campal pathway (Parent and Baxter, 2004), may account for such
overlap in neuromodulatory responses between benzodiazepines
and anti-cholinergics. Furthermore, the proﬁle of behavioural and
neural responses in a priming paradigm (Thiel et al., 2001)
suggested a tendency for a greater relative effect of scopolamine on
item storage, as opposed to lorazepam where effects appear to be
on initial item encoding.
8. Inverted-U shaped patterns of cholinergic
neuromodulations
A ﬁnding across the literature as whole is that the pattern of
cholinergic modulation often resembles an inverted U-shaped
function that depends upon the level of regional activation prior to
drug challenge (Fig. 4A). Thus, pro-cholinergic drugs enhance
frontoparietal activity most readily under task conditions where
such activity is relatively low under placebo; but decrease activity
within the same regions, when activations are high to begin with
(Kumari et al., 2003; Bentley et al., 2004; Furey et al., 2008a; Thiel
et al., 2005); or conversely, diminish strong deactivations, while
making weak deactivations more negative (Hahn et al., 2007,
2009). In many cases, low levels of activation (or weakly negative
deactivations) under placebo, that strengthen with cholinergic
stimulation, occur during low-attention conditions, e.g. during a 1-
back working memory task (Kumari et al., 2003); superﬁcial
encoding (Bentley et al., 2008), or with poorly informative cues
(Hahn et al., 2007) or validly cued targets (Thiel et al., 2005).
Conversely, states with high levels of activation (or deactivation),
that lessen with pro-cholinergic drugs, occur when attention is
Fig. 4. Modulations of functional imaging activations by cholinergic drugs often correspond to an inverted-U shaped pattern, depending upon both relative task demands (A)
and subject-speciﬁc factors (B). In many cases, there is also a concordant effect on performance, e.g. in Alzheimer’s disease where physostigmine increases task-related
activations, reaction time and memory, or in healthy subjects where scopolamine decreases the same three parameters.
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encoding, or to highly informative cues, or invalidly cued, or
uncued, targets (corresponding references as above). Similar
inverted-U shaped cholinergic response proﬁles also occur in
sensory (Hahn et al., 2007) and hippocampal (Schon et al., 2005;
Kukolja et al., 2009) regions.
A related effect concerns examples where task-speciﬁc
differential activation observed during unmedicated sessions
decrease following treatment with either a cholinergic antagonist
or cholinergic stimulant. As examples, working memory-associat-
ed prefrontal activity is suppressed by either physostigmine (Furey
et al., 1997, 2000b), or scopolamine (Grasby et al., 1995; Dumas
et al., 2008); while stimulus-evoked activations of primary visual
cortex are suppressed either by donepezil (Silver et al., 2008) or
scopolamine (Mentis et al., 2001). Furthermore, either scopol-
amine or physostigmine can decrease conditioning-associated
sensory cortex remapping (Thiel et al., 2001, 2002c), and decrease
lateral occipital–inferior temporal cortex activations during visual
working memory paradigms (Bullmore et al., 2003; Freo et al.,
2005).
One must consider how methodological issues might relate to
putative inverted-U-shaped phenomena. For example, if a drug
reduces all activations by 10%, then this may be more discernible
for conditions with higher activations to begin with, due to
the proportional effects being larger for those (and vice versa for
drug-induced reductions of deactivations). Conversely, if thehemodynamic response to a particular condition is close to ceiling
in some regions (due either to metabolic-vascular or neural
limitations), then drug-induced increases in neural activity may
only be manifest in other regions, or other conditions, where the
hemodynamic response starts off low. This might explain, for
example, why nicotinic effects in frontoparietal cortex during a
working memory task are most apparent during a relatively easy 1-
back, rather than more difﬁcult, 3-back working memory
conditions (Kumari et al., 2003; Xu et al., 2005); or why the
enhancement of sensory cortex activity by physostigmine is more
pronounced in task-irrelevant than task-relevant conditions
(Bentley et al., 2004, 2008; Section 5.3). Furthermore, one must
always be wary of ‘regression to the mean’ artefacts – arising from
the fact that ﬂoor activations can only get higher, and ceiling
activations only get lower. But such methodological considerations
alone do not appear able to explain the full inverted U-shaped
proﬁle that is typically observed. For instance, while proportional
changes can explain why a more activated region apparently
shows stronger reduction in activation under a drug, this cannot
explain ‘cross-over’ drug x condition interactions, for example,
where the same region shows either an increase, or decrease, in
response to a drug, depending on the starting activation level (e.g.
Hahn et al., 2009). Moreover, concerns about regression to the
mean are less likely in fully counterbalanced crossover designs,
and/or by independent selection of regions of interest for analysis –
techniques used in many of the quoted studies.
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many of the inverted U-like proﬁles of response observed?
According to the ‘attentional effort’ hypothesis (Sarter et al.,
2006), endogenous neocortical cholinergic stimulation may be
instrumental in enhancing anterior and posterior cortical activa-
tions in response to performance challenges. Consequently,
exogenous pro-cholinergic drugs may mimic this modulatory
effect, which can only be appreciated when activations are low to
begin with – i.e. during undemanding conditions. Conversely,
suppression of frontoparietal activity during high-attention
conditions, and decreases in task-driven sensory cortex selectivi-
ty, with pro-cholinergic therapies may correspond to decreases in
top-down or feedback processing, as commented upon earlier
(Sections 2.1 and 2.2), in accord with existing models of
cholinergic function (Hasselmo and McGaughy, 2004; Yu and
Dayan, 2005).
A further type of inverted-U response, seen when comparing
subject types (Fig. 4B), may also have a physiological basis.
According to this proﬁle, pro-cholinergic drugs normalize task-
evoked activation levels in states – such as sleep-deprivation
(Chuah and Chee, 2008), aging (Ricciardi et al., 2009) or disease
(Blin et al., 1997; Jacobsen et al., 2004; Goekoop et al., 2006;
Bentley et al., 2008), or with certain genetic polymorphisms
(Jacobsen et al., 2006) – where such activations start off
abnormally low or high. By contrast, many of these studies also
show either no modulation, or a reverse pattern of modulation, in
the same regions under the same paradigm, when healthy
controls are tested with the same drugs. These contrasting
neuromodulatory signatures for patients and controls are echoed
by equivalent behavioural dissociations, with performance
enhancements by pro-cholinergic drugs selectively in subjects
with abnormal physiological states to begin with, but deteriora-
tions instead for controls (Jacobsen et al., 2004; Bentley et al.,
2008). This ﬁts with data demonstrating that performance
beneﬁts of pro-cholinergic drugs are inversely correlated with
baseline performance (Ernst et al., 2001b; Kukolja et al., 2009;
Newhouse et al., 2004; Thiel et al., 2005; Beglinger et al., 2005).
One explanation is that where drug-induced increases in activity
and/or performance are observed, this reﬂects states in which
there is a relative reduction in tonic ACh release prior to
treatment, e.g. due to genetic variation, disease, sleep-deprivation
or undemanding task conditions.
Responses to nicotine may also diverge depending upon
subjects’ smoking status (e.g. Ernst et al., 2001a; Azizian et al.,
2010; Rose et al., 2010). One of the reasons for this possibly relates
to the fact that some smokers suffer adverse emotions and/or
performance under placebo (i.e. abstinence from smoking),
because of a dependency upon exogenous nicotine for normal
mental well-being and cognitive performance, e.g. to compensate
for chronic nicotinic receptor desensitization. Consequently,
effects of nicotine, relative to placebo, in abstinent smokers
may parallel the situation of cholinergic-deﬁcient subjects, with
pro-cholinergic therapies tending to normalize their usual level of
cholinergic stimulation, and so ameliorate both aberrant neural
responses (whether excessively high or low), and impaired
performance. By contrast, nicotine given to non-smokers pushes
subjects towards a hyper-cholinergic state relative to what they
are accustomed to. This might explain why cholinergic stimulants
increase fronto-parietal activity in smokers (e.g. Hong et al., 2009;
Loughead et al., 2010), but has the opposite effect during similar
tasks in non-smokers (Kumari et al., 2003; Furey et al., 2008a,b).
Conversely, in non-smokers, nicotine increases prefrontal activity
during an easy (1-back) condition (Kumari et al., 2003), whereas in
smokers, it is the withdrawal of nicotine that heightens activity
during this condition (Xu et al., 2005, 2006), possibly reﬂecting
increased effort. Furthermore, the general pattern noted earlier ofnicotine enhancing resting-state network deactivations, while
increasing attention (Ernst et al., 2001a; Hahn et al., 2007), is
sometimes reversed in smokers (Sweet et al., 2010), possibly
because heightened attention is required during drug withdrawal
and craving. Indeed, concentration difﬁculty following nicotine
withdrawal is associated with withdrawal-associated changes in
reciprocal-coupling between resting-state and executive control
networks (Cole et al., 2010).
Inverted-U shaped functions are also seen with dopamine
(Williams and Castner, 2006), and norepinephrine (Introini-
Collison and McGaugh, 1986). For instance, amphetamine
increases performance and prefrontal activation in subjects with
low baseline measures of each, but decreases both in subjects who
begin with high values for each (Mattay et al., 2000). Furthermore,
differences in performance accounted for by genetic polymorph-
isms related to dopaminergic neurotransmission can produce an
inverted-U pattern of response to nicotine (Jacobsen et al., 2006),
providing evidence for cholinergic–dopaminergic interactions
(Dewey et al., 1993). Thus, a common property of neuromodulators
is that their process-optimising capabilities exist within a narrow
concentration range. Two practical implications are that ‘perfor-
mance-enhancing’ drugs may be less likely to beneﬁt high-
performers; and that the effects of such drugs may be predictable
from individuals’ baseline behaviour or brain activity (Giessing
et al., 2007).
9. Conclusion
Physiological consequences of ingesting cholinergic-active
substances have been observed since the Ancient Greek era
(Holzman, 1998), and have been instrumental both for under-
standing the natural cholinergic system, and for developing new
pharmacological applications. Sophisticated experimental tools
are now available that enable precise manipulation and measure-
ment of cholinergic function, including cortical-slice recordings,
the cholinergic-speciﬁc immunotoxin saporin, and choline micro-
electrodes (Hasselmo and Sarter, 2011).
The purpose of this review has been to evaluate the contribu-
tion made by human pharmacological whole-brain functional
neuroimaging in relation to cholinergic physiology. While
functional imaging is limited by its spatiotemporal imprecision
(relative to more invasive methods) and its indirect relationship
with neural activity, it has the notable advantages of being
applicable noninvasively in humans, and of providing whole-brain
coverage. Moreover multiple paradigms now exist where cholin-
ergic pharmacological-neuroimaging ﬁndings closely mirror those
from invasive studies. Notable examples discussed here are:
disruption of auditory cortex remapping (Thiel et al., 2002a),
repetition suppression (Thiel et al., 2001), and perirhinal memory-
delay activity by scopolamine (Schon et al., 2005); as well as
cholinergic stimulation causing a restriction of stimulus-induced
propagation in visual cortex (Silver et al., 2008), and bidirectional
responses in hippocampus and amygdala dependent upon the
phase of memory processing (Kukolja et al., 2009). Importantly, the
directions of such neuroimaging responses to cholinergic chal-
lenges, in the appropriate behavioural contexts, accord with
analogous cholinergic manipulations at the electrophysiological
level, but are now ‘‘scaled up’’ to a neural population level, and
temporally blurred according to the hemodynamic or metabolic
response functions.
Added value from functional imaging arises from its ability to
test hypotheses using approaches more accessible than other
techniques (e.g. by virtue of its whole-brain sampling; sensitivity
to population activity; and use of more naturalistic paradigms
than with non-human designs). For example, while interactions of
ACh with attention have been described in isolated sensory
P. Bentley et al. / Progress in Neurobiology 94 (2011) 360–388 383neurons in vivo (Herrero et al., 2008), or for the effects of ACh on
columnar excitability recorded in cortical slices (Kimura et al.,
1999), functional imaging can complement these by assessing
population activity in vivo, in parietal and sensory regions
simultaneously, while orthogonally manipulating sensory and
attentional variables. As summarised, imaging results also
provide novel insights, while remaining consistent with extant
models. Some of the most important examples here include:
dependency on top-down inﬂuences for cholinergic modulation
of sensory processing (e.g. Bentley et al., 2004); impairment of
top-down, selective-attention effects in sensory cortices by either
too much or too little cholinergic transmission (e.g. Bentley et al.,
2008); the interactions of the above effects with uncertainty (e.g.
probability of valid cuing: Giessing et al., 2006); cholinergic
recruitment or downregulation of frontoparietal activations (e.g.
Furey et al., 2008a,b), along with the possibility that acetylcholine
interacts with the balance between task-related networks and the
default or ‘resting-state’ network (Hahn et al., 2007). Many of
these insights arise from the use of functional neuroimaging to
study population-level, cortically distributed effects, that might
be missed at the ﬁner spatial grain targeted by single-unit or
cortical-slice studies.
Having established that pharmacological-functional neuroim-
aging provides a meaningful tool for probing human neuromodu-
lation, there follow several promising leads that lend themselves to
future enquiry. First, given the likelihood that acetylcholine
inﬂuence anatomically segregated but functionally interconnected
regional processes, e.g. frontoparietal and sensory cortices (Sarter
et al., 2001), it seems likely that many important neuromodulatory
effects will be captured through study of changes in inter-regional
effective connectivity (i.e. functional coupling), rather than
through changes in the strength of regional activation per se.
Analytic techniques for studying interplay between remote but
interconnected regions (e.g. Friston et al., 2003) should ideally be
used in conjunction with traditional contrast-based methods (e.g.
Kobiella et al., 2011). Second, given concern over drug inﬂuences
on the neurovascular relationship, and the possibility that this may
vary anatomically and between patient groups, future pharmaco-
logical fMRI studies could usefully be supplemented by techniques
such as arterial-spin labelling MRI (e.g. Franklin et al., 2011), that
can assess regional blood ﬂow, or techniques immune to vascular
confounds such as magnetoencephalography (MEG). Third, radio-
nuclide imaging techniques sensitive to an increasing array of
cholinergic targets may shed further light on the exact mechanism
of drug action and their localisation. Finally, by translating
neurophysiological techniques from non-human to human sub-
jects, we are in a stronger position to address questions regarding
bridges between cholinergic models and clinical scenarios such as:
how enhancement of task-irrelevant sensory activity by pro-
cholinergic drugs relates to hypercholinergic models of anxiety
and schizophrenia (Sarter et al., 2005); or how behavioural
responses for particular drugs may be predictable by individual
activation proﬁles during appropriate paradigms (Giessing et al.,
2007).
Conﬂict of interest
None declared.
Acknowledgements
PB is supported by a Higher Education Funding Council for
England Award. RJD and JD are supported by the Wellcome Trust.
JD is a Royal Society Anniversary Research Professor. RJD is also
supported by an Award from the Max Planck Society.References
Acquas, E., Wilson, C., Fibiger, H.C., 1996. Conditioned and unconditioned stimuli
increase frontal cortical and hippocampal acetylcholine release: effects of
novelty, habituation, and fear. J. Neurosci. 16 (9), 3089–3096.
Adachi, T., Inanami, O., Ohno, K., Sato, A., 1990. Responses of regional cerebral blood
ﬂow following focal electrical stimulation of the nucleus basalis of Meynert and
the medial septum using the [14C]iodoantipyrine method in rats. Neurosci. Lett.
112 (2–3), 263–268.
Anagnostaras, S.G., Murphy, G.G., Hamilton, S.E., Mitchell, S.L., Rahnama, N.P.,
Nathanson, N.M., Silva, A.J., 2003. Selective cognitive dysfunction in acetylcho-
line M1 muscarinic receptor mutant mice. Nat. Neurosci. 6 (1), 51–58.
Antonova, E., Parslow, D., Brammer, M., Simmons, A., Williams, S., Dawson, G.R.,
Morris, R.G., 2010. Scopolamine disrupts hippocampal activity during allo-
centric spatial memory in humans: an fMRI study using a virtual reality
analogue of the Morris Water Maze. J. Psychopharmacol. September 7 (Epub
ahead of print).
Aoyagi, M., Meyer, J.S., Deshmukh, V.D., Ott, E.O., Tagashira, Y., Kawamura, Y.,
Matsuda, M., Achari, A.N., Chee, A.N., 1975. Central cholinergic control of
cerebral blood ﬂow in the baboon. Effect of cholinesterase inhibition with
neostigmine on autoregulation and CO2 responsiveness. J. Neurosurg. 43 (6),
689–705.
Apparsundaram, S., Martinez, V., Parikh, V., Kozak, R., Sarter, M., 2005. Increased
capacity and density of choline transporters situated in synaptic membranes of
the right medial prefrontal cortex of attentional task-performing rats. J. Neu-
rosci. 25 (15), 3851–3856.
Arneric´, S.P., Honig, M.A., Milner, T.A., Greco, S., Iadecola, C., Reis, D.J., 1988.
Neuronal and endothelial sites of acetylcholine synthesis and release associated
with microvessels in rat cerebral cortex: ultrastructural and neurochemical
studies. Brain Res. 454 (1–2), 11–30.
Arnold, H.M., Burk, J.A., Hodgson, E.M., Sarter, M., Bruno, J.P., 2002. Differential
cortical acetylcholine release in rats performing a sustained attention task
versus behavioral control tasks that do not explicitly tax attention. Neurosci-
ence 114 (2), 451–460.
Atri, A., Sherman, S., Norman, K.A., Kirchhoff, B.A., Nicolas, M.M., Greicius, M.D.,
Cramer, S.C., Breiter, H.C., Hasselmo, M.E., Stern, C.E., 2004. Blockade of central
cholinergic receptors impairs new learning and increases proactive interference
in a word paired-associate memory task. Behav. Neurosci. 118, 223–236.
Azizian, A., Nestor, L.J., Payer, D., Monterosso, J.R., Brody, A.L., London, E.D., 2010.
Smoking reduces conﬂict-related anterior cingulate activity in abstinent ciga-
rette smokers performing a Stroop task. Neuropsychopharmacology 35 (3),
775–782.
Bahro, M., Molchan, S.E., Sunderland, T., Herscovitch, P., Schreurs, B.G., 1999. The
effects of scopolamine on changes in regional cerebral blood ﬂow during
classical conditioning of the human eyeblink response. Neuropsychobiology
39 (4), 187–195.
Bartus, R.T., 2000. On neurodegenerative diseases, models, and treatment strate-
gies: lessons learned and lessons forgotten a generation following the cholin-
ergic hypothesis. Exp. Neurol. 163 (2), 495–529.
Beglinger, L.J., Tangphao-Daniels, O., Kareken, D.A., Zhang, L., Mohs, R., Siemers, E.R.,
2005. Neuropsychological test performance in healthy elderly volunteers be-
fore and after donepezil administration: a randomized, controlled study. J. Clin.
Psychopharmacol. 25 (2), 159–165.
Bentley, P., Driver, J., Dolan, R.J., 2009. Modulation of fusiform cortex activity by
cholinesterase inhibition predicts effects on subsequent memory. Brain 132
(Pt 9), 2356–2371.
Bentley, P., Driver, J., Dolan, R.J., 2008. Cholinesterase inhibition modulates visual and
attentional brain responses in Alzheimer’s disease and health. Brain 131 (Pt 2),
409–424.
Bentley, P., Husain, M., Dolan, R.J., 2004. Effects of cholinergic enhancement on
visual stimulation, spatial attention, and spatial working memory. Neuron 41
(6), 969–982.
Bentley, P., Vuilleumier, P., Thiel, C.M., Driver, J., Dolan, R.J., 2003a. Cholinergic
enhancement modulates neural correlates of selective attention and emotional
processing. Neuroimage 20 (1), 58–70.
Bentley, P., Vuilleumier, P., Thiel, C.M., Driver, J., Dolan, R.J., 2003b. Effects of
attention and emotion on repetition priming and their modulation by cholin-
ergic enhancement. J. Neurophysiol. 90 (2), 1171–1181.
Berntson, G.G., Sarter, M., Cacioppo, J.T., 1998. Anxiety and cardiovascular reactivi-
ty: the basal forebrain cholinergic link. Behav. Brain Res. 94, 225–248.
Berntson, G.G., Shaﬁ, R., Knox, D., Sarter, M., 2003. Blockade of epinephrine priming
of the cerebral auditory evoked response by cortical cholinergic deafferenta-
tion. Neuroscience 116 (1), 179–186.
Biesold, D., Inanami, O., Sato, A., Sato, Y., 1989. Stimulation of the nucleus basalis of
Meynert increasescerebralcorticalbloodﬂowinrats. Neurosci. Lett.98(1),39–44.
Bizzarro, A., Marra, C., Acciarri, A., Valenza, A., Tiziano, F.D., Brahe, C., Masullo, C.,
2005. Apolipoprotein E epsilon4 allele differentiates the clinical response to
donepezil in Alzheimer’s disease. Dement. Geriatr. Cogn. Disord. 20 (4), 254–261.
Blin, J., Ivanoiu, A., Coppens, A., De Volder, A., Labar, D., Michel, C., Laterre, E.C., 1997.
Cholinergic neurotransmission has different effects on cerebral glucose con-
sumption and blood ﬂow in young normals, aged normals, and Alzheimer’s
disease patients. Neuroimage 6 (4), 335–343.
Blin, J., Ray, C.A., Piercey, M.F., Bartko, J.J., Mouradian, M.M., Chase, T.N., 1994.
Comparison of cholinergic drug effects on regional brain glucose consumption
in rats and humans by means of autoradiography and position emission
tomography. Brain Res. 635 (1–2), 196–202.
P. Bentley et al. / Progress in Neurobiology 94 (2011) 360–388384Bond, A., Lader, M., 1974. The use of analogue scales in rating subjective feelings. B J
Med Psychol. 47, 211–218.
Bo¨rgers, C., Epstein, S., Kopell, N.J., 2005. Background gamma rhythmicity and
attention in cortical local circuits: a computational study. Proc. Natl. Acad.
Sci. U. S. A. 102 (19), 7002–7007.
Botly, L.C., De Rosa, E., 2009. Cholinergic deafferentation of the neocortex using 192
IgG-saporin impairs feature binding in rats. J. Neurosci. 29 (13), 4120–4130.
Bozzali, M., MacPherson, S.E., Dolan, R.J., Shallice, T., 2006. Left prefrontal cortex
control of novel occurrences during recollection: a psychopharmacological
study using scopolamine and event-related fMRI. Neuroimage 33 (1), 286–295.
Bro¨cher, S., Artola, A., Singer, W., 1992. Agonists of cholinergic and noradrenergic
receptors facilitate synergistically the induction of long-term potentiation in
slices of rat visual cortex. Brain Res. 573, 27–36.
Brody, A.L., Mandelkern, M.A., London, E.D., Olmstead, R.E., Farahi, J., Scheibal, D.,
Jou, J., Allen, V., Tiongson, E., Chefer, S.I., Koren, A.O., Mukhin, A.G., 2006.
Cigarette smoking saturates brain alpha 4 beta 2 nicotinic acetylcholine recep-
tors. Arch. Gen. Psychiatry 63 (8), 907–915.
Broussard, J.I., Karelina, K., Sarter, M., Givens, B., 2009. Cholinergic optimization of
cue-evoked parietal activity during challenged attentional performance. Eur. J.
Neurosci. 29 (8), 1711–1722.
Brown, G.G., Eyler Zorrilla, L.T., Georgy, B., Kindermann, S.S., Wong, E.C., Buxton,
R.B., 2003. BOLD and perfusion response to ﬁnger-thumb apposition after
acetazolamide administration: differential relationship to global perfusion. J.
Cereb. Blood Flow Metab. 23 (7), 829–837.
Bucci, D.J., Holland, P.C., Gallagher, M., 1998. Removal of cholinergic input to rat
posterior parietal cortex disrupts incremental processing of conditioned sti-
muli. J. Neurosci. 18 (19), 8038–8046.
Bullmore, E., Suckling, J., Zelaya, F., Long, C., Honey, G., Reed, L., Routledge, C., Ng, V.,
Fletcher, P., Brown, J., Williams, S.C., 2003. Practice and difﬁculty evoke an-
atomically and pharmacologically dissociable brain activation dynamics. Cereb.
Cortex 13 (2), 54–144.
Bunce, J.G., Sabolek, H.R., Chrobak, J.J., 2004. Timing of administration mediates the
memory effects of intraseptal carbachol infusion. Neuroscience 127 (3), 593–
600.
Burke, M., Bu¨hrle, Ch., 2006. BOLD response during uncoupling of neuronal activity
and CBF. Neuroimage 32 (1), 1–8.
Bushnell, P.J., Chiba, A.A., Oshiro, W.M., 1998. Effects of unilateral removal of basal
forebrain cholinergic neurons on cued target detection in rats. Behav. Brain Res.
90 (1), 57–71.
Buzsa`ki, G., Gage, F.H., 1989. The cholinergic nucleus basalis: a key structure in
neocortical arousal. EXS 57, 159–171.
Cabrera, S.M., Chavez, C.M., Corley, S.R., Kitto, M.R., Butt, A.E., 2006. Selective lesions
of the nucleus basalis magnocellularis impair cognitive ﬂexibility. Behav.
Neurosci. 120 (2), 298–306.
Che´dotal, A., Umbriaco, D., Descarries, L., Hartman, B.K., Hamel, E., 1994. Light and
electron microscopic immunocytochemical analysis of the neurovascular rela-
tionships of choline acetyltransferase and vasoactive intestical polypeptide
nerve terminals in the rat cerebral cortex. J. Comp. Neurol. 343, 57–71.
Chuah, L.Y., Chee, M.W., 2008. Cholinergic augmentation modulates visual
task performance in sleep-deprived young adults. J. Neurosci. 28 (44),
11369–11377.
Chudasama, Y., Dalley, J.W., Nathwani, F., Bouger, P., Robbins, T.W., 2004. Choliner-
gic modulation of visual attention and working memory: dissociable effects of
basal forebrain 192-IgG saporin lesions and intraprefrontal infusions of scopol-
amine. Learn. Mem. 11 (1), 78–86.
Cohen, E.R., Ugurbil, K., Kim, S.G., 2002. Effect of basal conditions on the magnitude
and dynamics of the blood oxygenation level-dependent fMRI response. J.
Cereb. Blood Flow Metab. 22 (9), 1042–1053.
Cohen, R.M., Gross, M., Semple, W.E., Nordahl, T.E., Sunderland, T., 1994. The
metabolic brain pattern of young subjects given scopolamine. Exp. Brain Res.
100 (1), 133–143.
Cole, D.M., Beckmann, C.F., Long, C.J., Matthews, P.M., Durcan, M.J., Beaver, J.D.,
2010. Nicotine replacement in abstinent smokers improves cognitive with-
drawal symptoms with modulation of resting brain network dynamics. Neuro-
image 52 (2), 590–599.
Conner, J.M., Culberson, A., Packowski, C., Chiba, A.A., Tuszynski, M.H., 2003. Lesions
of the basal forebrain cholinergic system impair task acquisition and abolish
cortical plasticity associated with motor skill learning. Neuron 38 (5), 819–829.
Corbetta, M., Kincade, J.M., Ollinger, J.M., McAvoy, M.P., Shulman, G.L., 2000.
Voluntary orienting is dissociated from target detection in human posterior
parietal cortex. Nat. Neurosci. 3 (3), 292–297.
Courtney, S.M., Ungerleider, L.G., Keil, K., Haxby, J.V., 1997. Transient and sustained
activity in a distributed neural system for human working memory. Nature 386
(6625), 608–611.
Craig, M.C., Brammer, M., Maki, P.M., Fletcher, P.C., Daly, E.M., Rymer, J., Giampietro,
V., Picchioni, M., Stahl, D., Murphy, D.G., 2010. The interactive effect of acute
ovarian suppression and the cholinergic system on visuospatial working mem-
ory in young women. Psychoneuroendocrinology 35 (7), 987–1000.
Craig, M.C., Fletcher, P.C., Daly, E.M., Rymer, J., Brammer, M., Giampietro, V., Stahl,
D., Maki, P.M., Murphy, D.G., 2009. The interactive effect of the cholinergic
system and acute ovarian suppression on the brain: an fMRI study. Horm.
Behav. 55 (1), 41–49.
Dalley, J.W., McGaughy, J., O’Connell, M.T., Cardinal, R.N., Levita, L., Robbins, T.W.,
2001. Distinct changes in cortical acetylcholine and noradrenaline efﬂux during
contingent and noncontingent performance of a visual attentional task. J.
Neurosci. 21 (13), 4908–4914.Davis, S.W., Dennis, N.A., Daselaar, S.M., Fleck, M.S., Cabeza, R., 2008. Que PASA? The
posterior–anterior shift in aging. Cereb. Cortex 18 (5), 1201–1209.
Davis, T.L., Kwong, K.K., Weisskoff, R.M., Rosen, B.R., 1998. Calibrated functional
MRI: mapping the dynamics of oxidative metabolism. Proc. Natl. Acad. Sci. U. S.
A. 95, 1834–1839.
Davidson, M.C., Marrocco, R.T., 2000. Local infusion of scopolamine into intrapar-
ietal cortex slows covert orienting in rhesus monkeys. J. Neurophysiol. 83 (3),
1536–1549.
De Rosa, E., Hasselmo, M.E., Baxter, M.G., 2001. Contribution of the cholinergic basal
forebrain to proactive interference from stored odor memories during associa-
tive learning in rats. Behav. Neurosci. 115 (2), 314–327.
Descarries, L., Gisiger, V., Steriade, M., 1997. Diffuse transmission by acetylcholine
in the CNS. Prog. Neurobiol. 53, 603–625.
Dewey, S.L., Smith, G.S., Logan, J., Brodie, J.D., Simkowitz, P., MacGregor, R.R.,
Fowler, J.S., Volkow, N.D., Wolf, A.P., 1993. Effects of central cholinergic
blockade on striatal dopamine release measured with positron emission
tomography in normal human subjects. Proc. Natl. Acad. Sci. U. S. A. 90
(24), 11816–11820.
DeYoe, E.A., Carman, G.J., Bandettini, P., Glickman, S., Wieser, J., Cox, R., Miller, D.,
Neitz, J., 1996. Mapping striate and extrastriate visual areas in human cerebral
cortex. Proc. Natl. Acad. Sci. U. S. A. 93 (6), 2382–2386.
Dickerson, B.C., 2006. Functional magnetic resonance imaging of cholinergic mod-
ulation in mild cognitive impairment. Curr. Opin. Psychiatry 19 (3), 299–306.
Disney, A.A., Domakonda, K.V., Aoki, C., 2006. Differential expression of muscarinic
acetylcholine receptors across excitatory and inhibitory cells in visual cortical
areas V1 and V2 of the macaque monkey. J. Comp. Neurol. 499 (1), 49–63.
Dringenberg, H.C., Hamze, B., Wilson, A., Speechley, W., Kuo, M.-C., 2007. Hetero-
synaptic facilitation of in vivo thalamocortical long-term potentiation in the
adult rat visual cortex by acetylcholine. Cereb. Cortex 17, 839–848.
Dumas, J.A., Saykin, A.J., McDonald, B.C., McAllister, T.W., Hynes, M.L., Newhouse,
P.A., 2008. Nicotinic versus muscarinic blockade alters verbal working memory-
related brain activity in older women. Am. J. Geriatr. Psychiatry 16 (4), 272–282.
Dumas, J.A., McDonald, B.C., Saykin, A.J., McAllister, T.W., Hynes, M.L., West, J.D.,
Newhouse, P.A., 2010. Cholinergic modulation of hippocampal activity during
episodic memory encoding in postmenopausal women: a pilot study. Meno-
pause 17 (4), 852–859.
Dunnett, S.B., Rogers, D.C., Jones, G.H., 1989. Effects of nucleus basalis magnocel-
lularis lesions in rats on delayed matching and non-matching to position tasks.
Eur. J. Neurosci. 1 (4), 395–406.
Edvinsson, L., MacKenzie, E.T., McCulloch, J., Uddman, R., 1987. Perivascular
innervation and receptor mechanisms in cerebrovascular bed. In: Wood,
J.H. (Ed.), Cerebral Blood Flow. Physiologic and Clinical Aspects. McGraw-
Hill, New York, pp. 145–172.
Egorov, A.V., Hamam, B.N., Franse´n, E., Hasselmo, M.E., Alonso, A.A., 2002. Graded
persistent activity in entorhinal cortex neurons. Nature 420 (6912), 173–178.
Ernst, M., Matochik, J.A., Heishman, S.J., Van Horn, J.D., Jons, P.H., Henningﬁeld, J.E.,
London, E.D., 2001a. Effect of nicotine on brain activation during performance of
a working memory task. Proc. Natl. Acad. Sci. U. S. A. 98 (8), 4728–4733.
Ernst, M., Heishman, S.J., Spurgeon, L., London, E.D., 2001b. Smoking history and
nicotine effects on cognitive performance. Neuropsychopharmacology 25 (3),
313–319.
Erskine, F.F., Ellis, J.R., Ellis, K.A., Stuber, E., Hogan, K., Miller, V., Moore, E., Bartho-
lomeusz, C., Harrison, B.J., Lee, B., Phan, K.L., Liley, D., Nathan, P.J., 2004. Evidence
for synergistic modulation of early information processing by nicotinic and
muscarinic receptors in humans. Hum. Psychopharmacol. 19 (7), 503–509.
Ettinger, U., Williams, S.C., Patel, D., Michel, T.M., Nwaigwe, A., Caceres, A., Mehta,
M.A., Anilkumar, A.P., Kumari, V., 2009. Effects of acute nicotine on brain
function in healthy smokers and non-smokers: estimation of inter-individual
response heterogeneity. Neuroimage 45 (2), 549–561.
Everitt, B.J., Robbins, T.W., 1997. Central cholinergic systems and cognition. Annu.
Rev. Psychol. 48, 649–684.
Eysenck, M.W., Derakshan, N., Santos, R., Calvo, M.G., 2007. Anxiety and cognitive
performance: attentional control theory. Emotion 7 (2), 336–353.
FitzGerald, D.B., Crucian, G.P., Mielke, J.B., Shenal, B.V., Burks, D., Womack, K.B.,
Ghacibeh, G., Drago, V., Foster, P.S., Valenstein, E., Heilman, K.M., 2008. Effects of
donepezil on verbal memory after semantic processing in healthy older adults.
Cogn. Behav. Neurol. 21 (2), 57–64.
Fournier, G.N., Semba, K., Rasmusson, D.D., 2004. Modality- and region-speciﬁc
acetylcholine release in the rat neocortex. Neuroscience 126 (2), 257–262.
Foster, P.S., Drago, V., Webster, D.G., Harrison, D.W., Crucian, G.P., Heilman, K.M.,
2008. Emotional inﬂuences on spatial attention. Neuropsychology 22 (1),
127–135.
Franklin, T., Wang, Z., Suh, J.J., Hazan, R., Cruz, J., Li, Y., Goldman, M., Detre, J.A.,
O’Brien, C.P., Childress, A.R., 2011. Effects of varenicline on smoking cue-
triggered neural and craving responses. Arch. Gen. Psychiatry January 3 (Epub
ahead of print).
Fransen, E., Alonso, A.A., Hasselmo, M.E., 2002. Simulations of the role of the
muscarinic activated calcium-sensitive nonspeciﬁc cation current INCM in
entorhinal neuronal activity during delayed matching tasks. J. Neurosci. 22,
1081–1097.
Freo, U., Ricciardi, E., Pietrini, P., Schapiro, M.B., Rapoport, S.I., Furey, M.L., 2005.
Pharmacological modulation of prefrontal cortical activity during a working
memory task in young and older humans: a PET study with physostigmine. Am.
J. Psychiatry 162 (11), 2061–2070.
Friston, K.J., Harrison, L., Penny, W., 2003. Dynamic causal modelling. Neuroimage
19 (4), 1273–1302.
P. Bentley et al. / Progress in Neurobiology 94 (2011) 360–388 385Frohlich, S., Franco, C.A., 2010. The consciousness circuit – an approach to the hard
problem. Adv. Exp. Med. Biol. 657, 285–301.
Fukuyama, H., Ouchi, Y., Matsuzaki, S., Ogawa, M., Yamauchi, H., Nagahama, Y.,
Kimura, J., Yonekura, Y., Shibasaki, H., Tsukada, H., 1996. Focal cortical blood
ﬂow activation is regulated by intrinsic cortical cholinergic neurons. Neuro-
image 3 (3 Pt 1), 195–201.
Furchgott, R.F., Zawadzki, J.V., 1980. The obligatory role of endothelial cells in the
relaxation of arterial smooth muscle by acetylcholine. Nature 288 (5789),
373–376.
Furey, M.L., Pietrini, P., Haxby, J.V., Alexander, G.E., Lee, H.C., VanMeter, J., Grady,
C.L., Shetty, U., Rapoport, S.I., Schapiro, M.B., Freo, U., 1997. Cholinergic stimu-
lation alters performance and task-speciﬁc regional cerebral blood ﬂow during
working memory. Proc. Natl. Acad. Sci. U. S. A. 94 (12), 6512–6516.
Furey, M.L., Pietrini, P., Haxby, J.V., 2000a. Cholinergic enhancement and increased
selectivity of perceptual processing during working memory. Science 290
(5500), 2315–2319.
Furey, M.L., Pietrini, P., Alexander, G.E., Schapiro, M.B., Horwitz, B., 2000b. Cholin-
ergic enhancement improves performance on working memory by modulating
the functional activity in distinct brain regions: a positron emission tomogra-
phy regional cerebral blood ﬂow study in healthy humans. Brain Res. Bull. 51
(3), 213–218.
Furey, M.L., Pietrini, P., Alexander, G.E., Mentis, M.J., Szczepanik, J., Shetty, U., Greig,
N.H., Holloway, H.W., Schapiro, M.B., Freo, U., 2000c. Time course of pharma-
codynamic and pharmacokinetic effects of physostigmine assessed by func-
tional brain imaging in humans. Pharmacol. Biochem. Behav. 66 (3), 475–481.
Furey, M.L., Ricciardi, E., Schapiro, M.B., Rapoport, S.I., Pietrini, P., 2008a. Cholinergic
enhancement eliminates modulation of neural activity by task difﬁculty in the
prefrontal cortex during working memory. J. Cogn. Neurosci. 20 (7), 1342–1353.
Furey, M.L., Pietrini, P., Haxby, J.V., Drevets, W.C., 2008b. Selective effects of
cholinergic modulation on task performance during selective attention. Neu-
ropsychopharmacology 33 (4), 913–923.
Gais, S., Born, J., 2004. Low acetylcholine during slow-wave sleep is critical
for declarative memory consolidation. Proc. Natl. Acad. Sci. U. S. A. 101 (7),
2140–2144.
Geaney, D.P., Soper, N., Shepstone, B.J., Cowen, P.J., 1990. Effect of central cholinergic
stimulation on regional cerebral blood ﬂow in Alzheimer disease. Lancet 335
(8704), 1484–1487.
Ghatan, P.H., Ingvar, M., Eriksson, L., Stone-Elander, S., Serrander, M., Ekberg, K.,
Wahren, J., 1998. Cerebral effects of nicotine during cognition in smokers and
non-smokers. Psychopharmacology (Berl.) 136 (2), 179–189.
Ghoneim, M.M., Mewaldt, S.P., 1975. Effects of diazepam and scopolamine on
storage, retrieval and organizational processes in memory. Psychopharmaco-
logia 44 (3), 257–262.
Giessing, C., Thiel, C.M., Ro¨sler, F., Fink, G.R., 2006. The modulatory effects of
nicotine on parietal cortex activity in a cued target detection task depend on
cue reliability. Neuroscience 137 (3), 853–864.
Giessing, C., Fink, G.R., Ro¨sler, F., Thiel, C.M., 2007. fMRI data predict individual
differences of behavioral effects of nicotine: a partial least square analysis. J.
Cogn. Neurosci. 19 (4), 658–670.
Gil, Z., Connors, B.W., Amitai, Y., 1997. Differential regulation of neocortical synap-
ses by neuromodulators and activity. Neuron 19 (3), 679–686.
Gill, T.M., Sarter, M., Givens, B., 2000. Sustained visual attention performance-
associated prefrontal neuronal activity: evidence for cholinergic modulation. J.
Neurosci. 20 (12), 4745–4757.
Gitelman, D.R., Prohovnik, I., 1992. Muscarinic and nicotinic contributions to
cognitive function and cortical blood ﬂow. Neurobiol. Aging 13 (2), 313–318.
Goekoop, R., Rombouts, S.A., Jonker, C., Hibbel, A., Knol, D.L., Truyen, L., Barkhof, F.,
Scheltens, P., 2004. Challenging the cholinergic system in mild cognitive
impairment: a pharmacological fMRI study. Neuroimage 23 (4), 1450–1459.
Goekoop, R., Scheltens, P., Barkhof, F., Rombouts, S.A., 2006. Cholinergic challenge in
Alzheimer patients and mild cognitive impairment differentially affects hippo-
campal activation – a pharmacological fMRI study. Brain 129 (Pt 1), 141–157.
Goense, J.B., Logothetis, N.K., 2008. Neurophysiology of the BOLD fMRI signal in
awake monkeys. Curr. Biol. 18 (9), 631–640.
Gollub, R.L., Breiter, H.C., Kantor, H., Kennedy, D., Gastfriend, D., Mathew, R.T.,
Makris, N., Guimaraes, A., Riorden, J., Campbell, T., Foley, M., Hyman, S.E., Rosen,
B., Weisskoff, R., 1998. Cocaine decreases cortical cerebral blood ﬂow but does
not obscure regional activation in functional magnetic resonance imaging in
human subjects. J. Cereb. Blood Flow Metab. 18 (7), 724–734.
Golmayo, L., Nunez, A., Zaborszky, L., 2003. Electrophysiological evidence for the
existence of a posterior cortical–prefrontal–basal forebrain circuitry in modu-
lating sensory responses in visual and somatosensory rat cortical areas. Neu-
roscience 119, 597–609.
Gozzi, A., Jain, A., Giovanelli, A., Bertollini, C., Crestan, V., Schwarz, A.J., Tsetsenis, T.,
Ragozzino, D., Gross, C.T., Bifone, A., 2010. A neural switch for active and passive
fear. Neuron 67 (4), 656–666.
Grady, C.L., Horwitz, B., Pietrini, P., Mentis, M.J., Ungerleider, L.G., Rapoport, S.I.,
Haxby, J.V., 1996. Effect of task difﬁculty on cerebral blood ﬂow during percep-
tual matching of faces. Hum. Brain Mapp. 4, 227–239.
Grady, C.L., McIntosh, A.R., Rajah, M.N., Craik, F.I., 1998. Neural correlates of the
episodic encoding of pictures and words. Proc. Natl. Acad. Sci. U. S. A. 95 (5),
2703–2708.
Grasby, P.M., Frith, C.D., Paulesu, E., Friston, K.J., Frackowiak, R.S., Dolan, R.J., 1995.
The effect of the muscarinic antagonist scopolamine on regional cerebral blood
ﬂow during the performance of a memory task. Exp. Brain Res. 104 (2),
337–348.Greuel, J.M., Luhmann, H.J., Singer, W., 1988. Pharmacological induction of use-
dependent receptive ﬁeld modiﬁcations in the visual cortex. Science 242, 74–77.
Gro¨n, G., Brandenburg, I., Wunderlich, A.P., Riepe, M.W., 2006. Inhibition of hippo-
campal function in mild cognitive impairment: targeting the cholinergic hy-
pothesis. Neurobiol. Aging 27 (1), 78–87.
Gu, Q., 2003. Contribution of acetylcholine to visual cortex plasticity. Neurobiol.
Learn. Mem. 80 (3), 291–301.
Gulledge, A.T., Park, S.B., Kawaguchi, Y., Stuart, G.J., 2007. Heterogeneity of
phasic cholinergic signaling in neocortical neurons. J. Neurophysiol. 97 (3),
2215–2229.
Gustafson, L., Edvinsson, L., Dahlgren, N., Hagberg, B., Risberg, J., Rose´n, I., Ferno¨, H.,
1987. Intravenous physostigmine treatment of Alzheimer’s disease evaluated
by psychometric testing, regional cerebral blood ﬂow (rCBF) measurement, and
EEG. Psychopharmacology (Berl.) 93 (1), 31–35.
Hahn, B., Ross, T.J., Wolkenberg, F.A., Shakleya, D.M., Huestis, M.A., Stein, E.A., 2009.
Performance effects of nicotine during selective attention, divided attention,
and simple stimulus detection: an fMRI study. Cereb. Cortex 19 (9), 1990–2000.
Hahn, B., Ross, T.J., Yang, Y., Kim, I., Huestis, M.A., Stein, E.A., 2007. Nicotine
enhances visuospatial attention by deactivating areas of the resting brain
default network. J. Neurosci. 27 (13), 3477–3489.
Hallstrom, A., Sato, A., Sato, Y., Ungerstedt, U., 1990. Effect of stimulation of the
nucleus basalis of Meynert on blood ﬂow and extracellular lactate in the
cerebral cortex with special reference to the effect of noxious stimulation of
skin and hypoxia. Neurosci. Lett. 116, 227–232.
Hasenfratz, M., Ba¨ttig, K., 1992. Action proﬁles of smoking and caffeine: Stroop
effect. EEG, and peripheral physiology. Pharmacol. Biochem. Behav. 42 (1),
155–161.
Hasselmo, M.E., 1995. Neuromodulation and cortical function: modeling the phys-
iological basis of behavior. Behav. Brain Res. 67, 1–27.
Hasselmo, M.E., 1999. Neuromodulation: acetylcholine and memory consolidation.
Trends Cogn. Sci. 3 (9), 351–359.
Hasselmo, M.E., Bodelo´n, C., Wyble, B.P., 2002. A proposed function for hippocampal
theta rhythm: separate phases of encoding and retrieval enhance reversal of
prior learning. Neural Comput. 14 (4), 793–817.
Hasselmo, M.E., Cekic, M., 1996. Suppression of synaptic transmission may allow
combination of associative feedback and self-organizing feedforward connec-
tions in the neocortex. Behav. Brain Res. 79 (1–2), 153–161.
Hasselmo, M.E., McGaughy, J., 2004. High acetylcholine levels set circuit dynamics
for attention and encoding and low acetylcholine levels set dynamics for
consolidation. Prog. Brain Res. 145, 207–231.
Hasselmo, M.E., Sarter, M., 2011. Modes and models of forebrain cholinergic
neuromodulation of cognition. Neuropsychopharmacology 36 (1), 52–73.
Hasselmo, M.E., Stern, C.E., 2006. Mechanisms underlying working memory for
novel information. Trends Cogn. Sci. 10, 487–493.
Hasselmo, M.E., Wyble, B.P., 1997. Free recall and recognition in a network model of
the hippocampus: simulating effects of scopolamine on human memory func-
tion. Behav. Brain Res. 89, 1–34.
Henson, R.N., Rugg, M.D., 2003. Neural response suppression, haemodynamic
repetition effects, and behavioural priming. Neuropsychologia 41 (3), 263–270.
Herath, P., Young, J., Roland, P., 2002. Two mechanisms of protracted reaction times
mediated by dissociable cortical networks. Eur J Neurosci. 16 (3), 529–539.
Herrero, J.L., Roberts, M.J., Delicato, L.S., Gieselmann, M.A., Dayan, P., Thiele, A., 2008.
Acetylcholine contributes through muscarinic receptors to attentional modu-
lation in V1. Nature 454 (7208), 1110–1114.
Himmelheber, A.M., Sarter, M., Bruno, J.P., 2000. Increases in cortical acetylcholine
release during sustained attention performance in rats. Brain Res. Cogn. Brain
Res. 9 (3), 313–325.
Himmelheber, A.M., Sarter, M., Bruno, J.P., 2001. The effects of manipulations of
attentional demand on cortical acetylcholine release. Brain Res. Cogn. Brain Res.
12 (3), 353–370.
Holland, P.C., Gallagher, M., 2006. Different roles for amygdala central nucleus and
substantia innominata in the surprise-induced enhancement of learning. J.
Neurosci. 26 (14), 3791–3797.
Holley, L.A., Turchi, J., Apple, C., Sarter, M., 1995. Dissociation between the atten-
tional effects of infusions of a benzodiazepine receptor agonist and an inverse
agonist into the basal forebrain. Psychopharmacology (Berl) 120 (1), 99–108.
Holzman, R.S., 1998. The legacy of Atropos, the fate who cut the thread of life.
Anesthesiology 89 (1), 241–249.
Honer, W.G., Prohovnik, I., Smith, G., Lucas, L.R., 1988. Scopolamine reduces frontal
cortex perfusion. J. Cereb. Blood Flow Metab. 8 (5), 635–641.
Hong, L.E., Schroeder, M., Ross, T.J., Buchholz, B., Salmeron, B.J., Wonodi, I., Thaker,
G.K., Stein, E.A., 2009. Nicotine enhances but does not normalize visual sus-
tained attention and the associated brain network in schizophrenia. Schizophr.
Bull. August 27 (Epub ahead of print).
Hopﬁnger, J.B., Buonocore, M.H., Mangun, G.R., 2000. The neural mechanisms of top-
down attentional control. Nat. Neurosci. 3 (3), 284–291.
Hoss, W., Messer Jr., W.S., Monsma Jr., F.J., Miller, M.D., Ellerbrock, B.R., Scranton, T.,
Ghodsi-Hovsepian, S., Price, M.A., Balan, S., Mazloum, Z., et al., 1990. Biochem-
ical and behavioral evidence for muscarinic autoreceptors in the CNS. Brain Res.
517 (1–2), 195–201.
Hsieh, C.Y., Cruikshank, S.J., Metherate, R., 2000. Differential modulation of auditory
thalamocortical and intracortical synaptic transmission by cholinergic agonist.
Brain Res. 880, 51–64.
Huerta, P.T., Lisman, J.E., 1993. Heightened synaptic plasticity of hippocampal CA1
neurons during a cholinergically induced rhythmic state. Nature 364 (6439),
723–725.
P. Bentley et al. / Progress in Neurobiology 94 (2011) 360–388386Iannetti, G.D., Wise, R.G., 2007. BOLD functional MRI in disease and pharmacological
studies: room for improvement? Magn. Reson. Imaging 25 (6), 978–988.
Introini-Collison, I.B., McGaugh, J.L., 1986. Epinephrine modulates long term reten-
tion of an aversively motivated discrimination. Behav. Neural Biol. 45, 358–365.
Jacobsen, L.K., Gore, J.C., Skudlarski, P., Lacadie, C.M., Jatlow, P., Krystal, J.H., 2002.
Impact of intravenous nicotine on BOLD signal response to photic stimulation.
Magn. Reson. Imaging 20 (2), 141–145.
Jacobsen, L.K., D’Souza, D.C., Mencl, W.E., Pugh, K.R., Skudlarski, P., Krystal, J.H.,
2004. Nicotine effects on brain function and functional connectivity in schizo-
phrenia. Biol. Psychiatry 55 (8), 850–858.
Jacobsen, L.K., Pugh, K.R., Mencl, W.E., Gelernter, J., 2006. C957T polymorphism of
the dopamine D2 receptor gene modulates the effect of nicotine on working
memory performance and cortical processing efﬁciency. Psychopharmacology
(Berl.) 188 (4), 530–540.
Kamboj, S.K., Curran, H.V., 2006. Scopolamine induces impairments in the recogni-
tion of human facial expressions of anger and disgust. Psychopharmacology
(Berl.) 185 (4), 529–535.
Kanwisher, N., McDermott, J., Chun, M.M., 1997. The fusiform face area: a module in
human extrastriate cortex specialized for face perception. J. Neurosci. 17 (11),
4302–4311.
Kilgard, M.P., Merzenich, M.M., 1998. Cortical map reorganization enabled by
nucleus basalis activity. Science 279 (5357), 1714–1718.
Kim, E.J., Jeong, D.U., 1999. Transdermal scopolamine alters phasic REM activity in
normal young adults. Sleep 22 (4), 515–520.
Kimura, A., Sato, A., Takano, Y., 1990. Stimulation of the nucleus basalis of Meynert
does not inﬂuence glucose utilization of the cerebral cortex in anesthetized rats.
Neurosci. Lett. 119 (1), 101–104.
Kimura, F., Fukuda, M., Tsumoto, T., 1999. Acetylcholine suppresses the spread of
excitation in the visual cortex revealed by optical recording: possible differen-
tial effect depending on the source of input. Eur. J. Neurosci. 11, 3597–3609.
Klink, R., Alonso, A., 1997. Muscarinic modulation of the oscillatory and repetitive
ﬁring properties of entorhinal cortex layer II neurons. J. Neurophysiol. 77,
1813–1828.
Kobiella, A., Ulsho¨fer, D.E., Vollmert, C., Vollsta¨dt-Klein, S., Bu¨hler, M., Esslinger, C.,
Smolka, M.N., 2011. Nicotine increases neural response to unpleasant stimuli
and anxiety in non-smokers. Addict. Biol. 16 (2), 285–295.
Koene, R.A., Gorchetchnikov, A., Cannon, R.C., Hasselmo, M.E., 2003. Modeling goal-
directed spatial navigation in the rat based on physiological data from the
hippocampal formation. Neural Netw. 16, 577–584.
Kopelman, M.D., 1986. The cholinergic neurotransmitter system in human memory
and dementia: a review. Q. J. Exp. Psychol. A 38, 535–573.
Kozak, R., Bruno, J.P., Sarter, M., 2006. Augmented prefrontal acetylcholine release
during challenged attentional performance. Cereb. Cortex 16 (1), 9–17.
Krnjevic´, K., Phillis, J.W., 1963. Acetylcholine-sensitive cells in the cerebral cortex. J.
Physiol. 166, 296–327.
Krnjevic´, K., Pumain, R., Renaud, L., 1971. The mechanism of excitation by acetyl-
choline in the cerebral cortex. J. Physiol. 215 (1), 247–268.
Kukolja, J., Thiel, C.M., Fink, G.R., 2009. Cholinergic stimulation enhances neural
activity associated with encoding but reduces neural activity associated with
retrieval in humans. J. Neurosci. 29 (25), 8119–8128.
Kumari, V., Gray, J.A., ffytche, D.H., Mitterschiffthaler, M.T., Das, M., Zachariah, E.,
Vythelingum, G.N., Williams, S.C., Simmons, A., Sharma, T., 2003. Cognitive
effects of nicotine in humans: an fMRI study. Neuroimage 19 (3), 1002–
1013.
Kumari, V., Aasen, I., ffytche, D., Williams, S.C., Sharma, T., 2006. Neural correlates of
adjunctive rivastigmine treatment to antipsychotics in schizophrenia: a ran-
domized, placebo-controlled, double-blind fMRI study. Neuroimage 29 (2),
545–556.
Kuo, M.C., Rasmusson, D.D., Dringenberg, H.C., 2009. Input-selective potentiation
and rebalancing of primary sensory cortex afferents by endogenous acetylcho-
line. Neuroscience 163 (1), 430–441.
Lacombe, P., Sercombe, R., Verrecchia, C., Philipson, V., MacKenzie, E.T., Seylaz, J.,
1989. Cortical blood ﬂow increases induced by stimulation of the substantia
innominata in the unanesthetized rat. Brain Res. 491, 1–14.
Lambe, E.K., Picciotto, M.R., Aghajanian, G.K., 2003. Nicotine induces glutamate
release from thalamocortical terminals in prefrontal cortex. Neuropsychophar-
macology 28, 216–225.
Laplante, F., Morin, Y., Quirion, R., Vaucher, E., 2005. Acetylcholine release is elicited
in the visual cortex, but not in the prefrontal cortex, by patterned visual
stimulation: a dual in vivo microdialysis study with functional correlates in
the rat brain. Neuroscience 132 (2), 501–510.
Lawrence, N.S., Ross, T.J., Stein, E.A., 2002. Cognitive mechanisms of nicotine on
visual attention. Neuron 36 (3), 539–548.
Leithner, C., Royl, G., Offenhauser, N., Fu¨chtemeier, M., Kohl-Bareis, M., Villringer, A.,
Dirnagl, U., Lindauer, U., 2009. Pharmacological uncoupling of activation in-
duced increases in CBF and CMRO(2). J. Cereb. Blood Flow Metab. September 30
(Epub ahead of print).
Lewandowski, M.H., Mu¨ller, C.M., Singer, W., 1993. Reticular facilitation of cat visual
cortical responses is mediated by nicotinic and muscarinic cholinergic mecha-
nisms. Exp. Brain Res. 96, 1–7.
Lidow, M.S., Gallager, D.W., Rakic, P., Goldman-Rakic, P.S., 1989. Regional differ-
ences in the distribution of muscarinic cholinergic receptors in the macaque
cerebral cortex. J. Comp. Neurol. 289 (2), 247–259.
Linville, D.G., Williams, S., Raszkiewicz, J.L., Arneric, S.P., 1993. Nicotinic agonists
modulate basal forebrain control of cortical cerebral blood ﬂow in anesthetized
rats. J. Pharmacol. Exp. Ther. 267 (1), 440–448.Logothetis, N.K., 2002. The neural basis of the blood-oxygen-level-dependent
functional magnetic resonance imaging signal. Philos. Trans. R. Soc. Lond. B:
Biol. Sci. 357 (1424), 1003–1037.
Lo¨rincz, M.L., Crunelli, V., Hughes, S.W., 2008. Cellular dynamics of cholinergically
induced alpha (8–13 Hz) rhythms in sensory thalamic nuclei in vitro. J. Neu-
rosci. 28 (3), 660–671.
Loughead, J., Wileyto, E.P., Valdez, J.N., Sanborn, P., Tang, K., Strasser, A.A., Ruparel,
K., Ray, R., Gur, R.C., Lerman, C., 2009. Effect of abstinence challenge on brain
function and cognition in smokers differs by COMT genotype. Mol. Psychiatry
14 (8), 820–826.
Loughead, J., Ray, R., Wileyto, E.P., Ruparel, K., Sanborn, P., Siegel, S., Gur, R.C.,
Lerman, C., 2010. Effects of the alpha4beta2 partial agonist varenicline on brain
activity and working memory in abstinent smokers. Biol. Psychiatry 67 (8),
715–721.
Loughead, J., Ray, R., Wileyto, E.P., Ruparel, K., O’Donnell, G.P., Senecal, N., Siegel, S.,
Gur, R.C., Lerman, C., 2011. Brain activity and emotional processing in smokers
treated with varenicline. Addict. Biol., doi:10.1111/j.1369-1600.2011.00324.x.
Martinez, A., DiRusso, F., Anllo-Vento, L., Sereno, M.I., Buxton, R.B., Hillyard, S.A.,
2001. Putting spatial attention on the map: timing and localization of stimulus
selection processes in striate and extrastriate visual areas. Vision Res. 41,
1437–1457.
Matsuda, M., Meyer, J.S., Deshmukh, V.D., Tagashira, Y., 1976. Effect of acetylcholine
on cerebral circulation. J. Neurosurg. 45 (4), 423–431.
Mattay, V.S., Callicott, J.H., Bertolino, A., Heaton, I., Frank, J.A., Coppola, R., Berman,
K.F., Goldberg, T.E., Weinberger, D.R., 2000. Effects of dextroamphetamine on
cognitive performance and cortical activation. Neuroimage 12 (3), 268–275.
McCormick, D.A., 1992. Cellular mechanisms underlying cholinergic and noradren-
ergic modulation of neuronal ﬁring mode in the cat and guinea pig dorsal lateral
geniculate nucleus. J. Neurosci. 12 (1), 278–289.
McCormick, D.A., Prince, D.A., 1986. Mechanisms of action of acetylcholine in the
guinea-pig cerebral cortex in vitro. J. Physiol. 375, 169–194.
McGaughy, J., Dalley, J.W., Morrison, C.H., Everitt, B.J., Robbins, T.W., 2002. Selective
behavioral and neurochemical effects of cholinergic lesions produced by intra-
basalis infusions of 192 IgG-saporin on attentional performance in a ﬁve-choice
serial reaction time task. J. Neurosci. 22 (5), 1905–1913.
McGaughy, J., Koene, R.A., Eichenbaum, H., Hasselmo, M.E., 2005. Cholinergic
deafferentation of the entorhinal cortex in rats impairs encoding of novel
but not familiar stimuli in a delayed nonmatch-to-sample task. J. Neurosci.
25 (44), 10273–10281.
McNamara, D., Larson, D.M., Rapoport, S.I., Soncrant, T.T., 1990. Preferential meta-
bolic activation of subcortical brain areas by acute administration of nicotine to
rats. J. Cereb. Blood Flow Metab. 10 (1), 48–56.
Mentis, M.J., Sunderland, T., Lai, J., Connolly, C., Krasuski, J., Levine, B., Friz, J., Sobti,
S., Schapiro, M., Rapoport, S.I., 2001. Muscarinic versus nicotinic modulation of a
visual task: a pet study using drug probes. Neuropsychopharmacology 25 (4),
555–564.
Mesulam, M.M., Volicer, L., Marquis, J.K., Mufson, E.J., Green, R.C., 1986. Systematic
regional differences in the cholinergic innervation of the primate cerebral
cortex: distribution of enzyme activities and some behavioural implications.
Ann. Neurol. 19 (2), 144–151.
Mesulam, M.M., Geula, C., 1991. Acetylcholinesterase-rich neurons of the human
cerebral cortex: cytoarchitectonic and ontogenetic patterns of distribution. J.
Comp. Neurol. 306 (2), 193–220.
Miller, E.K., Desimone, R., 1993. Scopolamine affects short-term memory but not
inferior temporal neurons. Neuroreport 4 (1), 81–84.
Mishima, K., Iwasaki, K., Tsukikawa, H., Matsumoto, Y.T., Egashira, N., Abe, K.,
Egawa, T., Fujiwara, M., 2000. The scopolamine-induced impairment of spatial
cognition parallels the acetylcholine release in the ventral hippocampus in rats.
Jpn. J. Pharmacol. 84 (2), 163–173.
Moore, H., Sarter, M., Bruno, J.P., 1995. Bidirectional modulation of cortical acetyl-
choline efﬂux by infusion of benzodiazepine receptor ligands into the basal
forebrain. Neurosci. Lett. 189, 31–34.
Morris, J.S., Friston, K.J., Dolan, R.J., 1998. Experience-dependent modulation of
tonotopic neural responses in human auditory cortex. Proc. R. Soc. Lond. B: Biol.
Sci. 265, 649–657.
Muir, J.L., Everitt, B.J., Robbins, T.W., 1994. AMPA-induced excitotoxic lesions of the
basal forebrain: a signiﬁcant role for the cortical cholinergic system in atten-
tional function. J. Neurosci. 14 (4), 2313–2326.
Murphy, P.C., Sillito, P.C., 1991. Cholinergic enhancement of direction selectivity in
the visual cortex of the cat. Neuroscience 40 (1), 13–20.
Nakahata, K., Kinoshita, H., Hama-Tomioka, K., Ishida, Y., Matsuda, N., Hatakeyama,
N., Haba, M., Kondo, T., Hatano, Y., 2008. Cholinesterase inhibitor donepezil
dilates cerebral parenchymal arterioles via the activation of neuronal nitric
oxide synthase. Anesthesiology 109 (1), 124–129.
Nelson, C.L., Sarter, M., Bruno, J.P., 2005. Prefrontal cortical modulation of acetyl-
choline release in posterior parietal cortex. Neuroscience 132 (2), 347–359.
Newhouse, P.A., Potter, A., Singh, A., 2004. Effects of nicotinic stimulation on
cognitive performance. Curr. Opin. Pharmacol. 4, 36–46.
Nordberg, A., 2004. Functional studies of cholinergic activity in normal and Alz-
heimer disease states by imaging technique. Prog. Brain Res. 145, 301–310.
Ogawa, M., Fukuyama, H., Ouchi, Y., Yamauchi, H., Matsuzaki, S., Kimura, J., Tsukada,
H., 1996. Uncoupling between cortical glucose metabolism and blood ﬂow after
ibotenate lesion of the rat basal forebrain: a PET study. Neurosci. Lett. 204 (3),
193–196.
Ogawa, M., Magata, Y., Ouchi, Y., Fukuyama, H., Yamauchi, H., Kimura, J., Yonekura,
Y., Konishi, J., 1994. Scopolamine abolishes cerebral blood ﬂow response to
P. Bentley et al. / Progress in Neurobiology 94 (2011) 360–388 387somatosensory stimulation in anesthetized cats: PET study. Brain Res. 650 (2),
249–252.
Ouchi, Y., Fukuyama, H., Ogawa, M., Yamauchi, H., Kimura, J., Magata, Y., Yonekura,
Y., Konishi, J., 1996. Cholinergic projection from the basal forebrain and cerebral
glucose metabolism in rats: a dynamic PET study. J. Cereb. Blood Flow Metab. 16
(1), 34–41.
Parent, M.B., Baxter, M.G., 2004. Septohippocampal acetylcholine: involved in but
not necessary for learning and memory? Learn. Mem. 11 (1), 9–20.
Parikh, V., Man, K., Decker, M.W., Sarter, M., 2008. Glutamatergic contributions to
nicotinic acetylcholine receptor agonist-evoked cholinergic transients in the
prefrontal cortex. J. Neurosci. 28 (14), 3769–3780.
Parnavelas, J.G., Kelly, W., Burnstock, G., 1985. Ultrastructural localization of choline
acetyltransferase in vascular endothelial cells in rat brain. Nature 316 (6030),
724–725.
Passetti, F., Dalley, J.W., O’Connell, M.T., Everitt, B.J., Robbins, T.W., 2000. Increased
acetylcholine release in the rat medial prefrontal cortex during performance of
a visual attentional task. Eur. J. Neurosci. 12 (8), 3051–3058.
Paterson, D., Nordberg, A., 2000. Neuronal nicotinic receptors in the human brain.
Prog. Neurobiol. 61 (1), 75–111.
Phillips, J.M., McAlonan, K., Robb, W.G., Brown, V.J., 2000. Cholinergic neurotrans-
mission inﬂuences covert orientation of visuospatial attention in the rat.
Psychopharmacology (Berl.) 150 (1), 112–116.
Phillis, J.W., Chong, G.C., 1965. Acetylcholine release from the cerebral and cere-
bellar cortices: its role in cortical arousal. Nature 207 (5003), 1253–1255.
Polli, F.E., Barton, J.J., Cain, M.S., Thakkar, K.N., Rauch, S.L., Manoach, D.S., 2005. Rostral
and dorsal anterior cingulate cortex make dissociable contributions during
antisaccade error commission. Proc. Natl. Acad. Sci. U. S. A. 102, 15700–15705.
Potkin, S.G., Anand, R., Fleming, K., Alva, G., Keator, D., Carreon, D., Messina, J., Wu,
J.C., Hartman, R., Fallon, J.H., 2001. Brain metabolic and clinical effects of
rivastigmine in Alzheimer’s disease. Int. J. Neuropsychopharmacol. 4 (3),
223–230.
Postma, P., Gray, J.A., Sharma, T., Geyer, M., Mehrotra, R., Das, M., Zachariah, E.,
Hines, M., Williams, S.C., Kumari, V., 2006. A behavioural and functional
neuroimaging investigation into the effects of nicotine on sensorimotor gating
in healthy subjects and persons with schizophrenia. Psychopharmacology
(Berl) 184 (3–4) 589–599.
Power, A.E., 2004. Muscarinic cholinergic contribution to memory consolidation:
with attention to involvement of the basolateral amygdala. Curr. Med. Chem. 11
(8), 987–996.
Quigley, K.S., Sarter, M.F., Hart, S.L., Berntson, G.G., 1994. Cardiovascular effects of
the benzodiazepine receptor partial inverse agonist FG 7142 in rats. Behav.
Brain Res. 62, 11–20.
Raichle, M.E., Snyder, A.Z., 2007. A default mode of brain function: a brief history of
an evolving idea. Neuroimage; 37 (4) 1083–1090.
Rasch, B.H., Born, J., Gais, S., 2006. Combined blockade of cholinergic receptors shifts
the brain from stimulus encoding to memory consolidation. J. Cogn. Neurosci.
18, 793–802.
Rauch, A., Rainer, G., Logothetis, N.K., 2008. The effect of a serotonin-induced
dissociation between spiking and perisynaptic activity on BOLD functional
MRI. Proc. Natl. Acad. Sci. U. S. A. 105 (18), 6759–6764.
Ricciardi, E., Pietrini, P., Schapiro, M.B., Rapoport, S.I., Furey, M.L., 2009. Cholinergic
modulation of visual working memory during aging: a parametric PET study.
Brain Res. Bull. 79 (5), 322–332.
Richardson, R.T., DeLong, M.R., 1990. Context-dependent responses of primate
nucleus basalis neurons in a go/no-go task. J. Neurosci. 10 (8), 2528–2540.
Ridley, R.M., Baker, H.F., Leow-Dyke, A., Cummings, R.M., 2005. Further analysis of
the effects of immunotoxic lesions of the basal nucleus of Meynert reveals
substantial impairment on visual discrimination learning in monkeys. Brain
Res. Bull. 65 (5), 433–442.
Robbins, T.W., Everitt, B.J., Marston, H.M., Wilkinson, J., Jones, G.H., Page, K.J., 1989.
Comparative effects of ibotenic acid- and quisqualic acid-induced lesions of the
substantia innominata on attentional function in the rat: further implications
for the role of the cholinergic neurons of the nucleus basalis in cognitive
processes. Behav. Brain Res. 35 (3), 221–240.
Roberts, M.J., Zinke, W., Guo, K., Robertson, R., McDonald, J.S., Thiele, A., 2005.
Acetylcholine dynamically controls spatial integration in marmoset primary
visual cortex. J. Neurophysiol. 93 (4), 2062–2072.
Rodriguez, R., Kallenbach, U., Singer, W., Munk, M.H., 2004. Short- and long-term
effects of cholinergic modulation on gamma oscillations and response synchro-
nization in the visual cortex. J. Neurosci. 24 (46), 10369–10378.
Rogers, J.L., Kesner, R.P., 2003. Cholinergic modulation of the hippocampus during
encoding and retrieval. Neurobiol. Learn. Mem. 80 (3), 332–342.
Rombouts, S.A., Goekoop, R., Stam, C.J., Barkhof, F., Scheltens, P., 2005. Delayed
rather than decreased BOLD response as a marker for early Alzheimer’s disease.
Neuroimage 26 (4), 1078–1085.
Rose, E.J., Ross, T.J., Kurup, P.K., Stein, E.A., 2010. Nicotine modulation of information
processing is not limited to input (attention) but extends to output (intention).
Psychopharmacology (Berl.) 209 (4), 291–302.
Rosier, A.M., Cornette, L., Dupont, P., Bormans, G., Mortelmans, L., Orban, G.A., 1999.
Regional brain activity during shape recognition impaired by a scopolamine
challenge to encoding. Eur. J. Neurosci. 11 (10), 3701–3714.
Rycroft, N., Rusted, J.M., Hutton, S.B., 2005. Acute effects of nicotine on visual search
tasks in young adult smokers. Psychopharmacology (Berl.) 181, 160–169.
Rypma, B., Berger, J.S., Prabhakaran, V., Bly, B.M., Kimberg, D.Y., Biswal, B.B.,
D’Esposito, M., 2006. Neural correlates of cognitive efﬁciency. Neuroimage
33 (3), 969–979.Sarter, M., Hasselmo, M.E., Bruno, J.P., Givens, B., 2005. Unraveling the attentional
functions of cortical cholinergic inputs: interactions between signal-driven and
cognitive modulation of signal detection. Brain Res. Brain Res. Rev. 48, 98–111.
Sarter, M., Gehring, W.J., Kozak, R., 2006. More attention must be paid: the
neurobiology of attentional effort. Brain Res. Rev. 51 (2), 145–160.
Sarter, M., Givens, B., Bruno, J.P., 2001. The cognitive neuroscience of sustained
attention: where top-down meets bottom-up. Brain Res. Brain Res. Rev. 35 (2),
146–160.
Sarter, M., Parikh, V., Howe, W.M., 2009. Phasic acetylcholine release and the
volume transmission hypothesis: time to move on. Nat. Rev. Neurosci. 10
(5), 383–390.
Sato, H., Hata, Y., Hagihara, K., Tsumoto, T., 1987a. Effects of cholinergic depletion on
neuron activities in the cat visual cortex. J. Neurophysiol. 58 (4), 781–794.
Sato, H., Hata, Y., Masui, H., Tsumoto, T., 1987b. A functional role of cholinergic
innervation to neurons in the cat visual cortex. J. Neurophysiol. 58 (4),
765–780.
Sato, A., Sato, Y., Uchida, S., 2004. Activation of the intracerebral cholinergic nerve
ﬁbers originating in the basal forebrain increases regional cerebral blood ﬂow in
the rat’s cortex and hippocampus. Neurosci. Lett. 361 (1–3), 90–93.
Schon, K., Atri, A., Hasselmo, M.E., Tricarico, M.D., LoPresti, M.L., Stern, C.E., 2005.
Scopolamine reduces persistent activity related to long-term encoding in the
parahippocampal gyrus during delayed matching in humans. J. Neurosci. 25
(40), 9112–9123.
Scremin, O.U., Rovere, A.A., Raynald, A.C., Giardini, A., 1973. Cholinergic control of
blood ﬂow in the cerebral cortex of the rat. Stroke 4 (2), 233–239.
Scremin, O.U., Sonnenschein, R.R., Rubinstein, E.H., 1982. Cholinergic cerebral
vasodilatation in the rabbit: absence of concomitant metabolic activation. J.
Cereb. Blood Flow Metab. 2 (2), 241–247.
Scremin, O.U., Torres, C., Scremin, A.M., O’Neal, M., Heuser, D., Blisard, K.S., 1991.
Role of nucleus basalis in cholinergic control of cortical blood ﬂow. J. Neurosci.
Res. 28 (3), 382–390.
Selden, N.R., Gitelman, D.R., Salamon-Murayama, N., Parrish, T.B., Mesulam, M.M.,
1998. Trajectories of cholinergic pathways within the cerebral hemispheres of
the human brain. Brain 121 (12), 2249–2257.
Sillito, A.M., Kemp, J.A., 1983. Cholinergic modulation of the functional organization
of the cat visual cortex. Brain Res. 289 (1–2), 143–155.
Silver, M.A., Shenhav, A., D’Esposito, M., 2008. Cholinergic enhancement reduces
spatial spread of visual responses in human early visual cortex. Neuron 60 (5),
904–914.
Smiley, J.F., Morrell, F., Mesulam, M.M., 1997. Cholinergic synapses in human
cerebral cortex: an ultrastructural study in serial sections. Exp. Neurol. 144
(2), 361–368.
Sperling, R., Greve, D., Dale, A., Killiany, R., Holmes, J., Rosas, H.D., Cocchiarella, A.,
Firth, P., Rosen, B., Lake, S., Lange, N., Routledge, C., Albert, M., 2002. Functional
MRI detection of pharmacologically induced memory impairment. Proc. Natl.
Acad. Sci. U. S. A. 99 (1), 455–460.
Stein, E.A., Pankiewicz, J., Harsch, H.H., Cho, J.K., Fuller, S.A., Hoffmann, R.G.,
Hawkins, M., Rao, S.M., Bandettini, P.A., Bloom, A.S., 1998. Nicotine-induced
limbic cortical activation in the human brain: a functional MRI study. Am. J.
Psychiatry 155 (8), 1009–1015.
Suckling, J., Wink, A.M., Bernard, F.A., Barnes, A., Bullmore, E., 2008. Endogenous
multifractal brain dynamics are modulated by age, cholinergic blockade and
cognitive performance. J. Neurosci. Methods 174 (2), 292–300.
Sutherland, M.T., Ross, T.J., Shakleya, D.M., Huestis, M.A., Stein, E.A., 2011. Chronic
smoking, but not acute nicotine administration, modulates neural correlates of
working memory. Psychopharmacology (Berl.) 213 (1), 29–42.
Sweet, L.H., Mulligan, R.C., Finnerty, C.E., Jerskey, B.A., David, S.P., Cohen, R.A.,
Niaura, R.S., 2010. Effects of nicotine withdrawal on verbal working memory
and associated brain response. Psychiatry Res. 183 (1), 69–74.
Tang, Y., Mishkin, M., Aigner, T.G., 1997. Effects of muscarinic blockade in perirhinal
cortex during visual recognition. Proc. Natl. Acad. Sci. U. S. A. 94 (23), 12667–
12669.
Teipel, S.J., Drzezga, A., Bartenstein, P., Mo¨ller, H.J., Schwaiger, M., Hampel, H., 2006.
Effects of donepezil on cortical metabolic response to activation during
(18)FDG-PET in Alzheimer’s disease: a double-blind cross-over trial. Psycho-
pharmacology (Berl.) 187 (1), 86–94.
Thiel, C.M., Henson, R.N., Morris, J.S., Friston, K.J., Dolan, R.J., 2001. Pharmacological
modulation of behavioral and neuronal correlates of repetition priming. J.
Neurosci. 21 (17), 6846–6852.
Thiel, C.M., Bentley, P., Dolan, R.J., 2002b. Effects of cholinergic enhancement on
conditioning-related responses in human auditory cortex. Eur. J. Neurosci. 16
(11), 2199–2206.
Thiel, C.M., Friston, K.J., Dolan, R.J., 2002a. Cholinergic modulation of experience-
dependent plasticity in human auditory cortex. Neuron 35 (3), 567–574.
Thiel, C.M., Henson, R.N., Dolan, R.J., 2002c. Scopolamine but not lorazepam
modulates face repetition priming: a psychopharmacological fMRI study. Neu-
ropsychopharmacology 27 (2), 282–292.
Thiel, C.M., Zilles, K., Fink, G.R., 2005. Nicotine modulates reorienting of visuospatial
attention and neural activity in human parietal cortex. Neuropsychopharma-
cology 30 (4), 810–820.
Thiel, C.M., Fink, G.R., 2007. Visual and auditory alertness: modality-speciﬁc and
supramodal neural mechanisms and their modulation by nicotine. J. Neuro-
physiol. 97 (4), 2758–2768.
Thiel, C.M., Fink, G.R., 2008. Effects of the cholinergic agonist nicotine on reorienting
of visual spatial attention and top-down attentional control. Neuroscience 152
(2), 381–390.
P. Bentley et al. / Progress in Neurobiology 94 (2011) 360–388388Thienel, R., Kellermann, T., Schall, U., Voss, B., Reske, M., Halfter, S., Sheldrick, A.J.,
Radenbach, K., Habel, U., Shah, N.J., Kircher, T., 2009b. Muscarinic antagonist
effects on executive control of attention. Int. J. Neuropsychopharmacol. 12 (10),
1307–1317.
Thienel, R., Voss, B., Kellermann, T., Reske, M., Halfter, S., Sheldrick, A.J., Radenbach, K.,
Habel, U., Shah, N.J., Schall, U., Kircher T, 2009a. Nicotinic antagonist effects
on functional attention networks. Int. J. Neuropsychopharmacol. 12 (10),
1295–1305.
Tsukada, H., Kakiuchi, T., Ando, I., Shizuno, H., Nakanishi, S., Ouchi, Y., 1997.
Regulation of cerebral blood ﬂow response to somatosensory stimulation
through the cholinergic system: a positron emission tomography study in
unanesthetized monkeys. Brain Res. 749 (1), 10–17.
Tsukada, H., Sato, K., Kakiuchi, T., Nishiyama, S., 2000. Age-related impairment of
coupling mechanism between neuronal activation and functional cerebral
blood ﬂow response was restored by cholinesterase inhibition: PET study with
microdialysis in the awake monkey brain. Brain Res. 857 (1–2), 158–164.
Tsukada, H., Nishiyama, S., Fukumoto, D., Ohba, H., Sato, K., Kakiuchi, T., 2004.
Effects of acute acetylcholinesterase inhibition on the cerebral cholinergic
neuronal system and cognitive function: functional imaging of the conscious
monkey brain using animal PET in combination with microdialysis. Synapse 52
(1), 1–10.
Uchida, S., Hotta, H., 2009. Cerebral cortical vasodilatation mediated by nicotinic
cholinergic receptors: effects of old age and of chronic nicotine exposure. Biol.
Pharm. Bull. 32 (3), 341–344.
Uchida, S., Kagitani, F., Nakayama, H., Sato, A., 1997. Effect of stimulation of nicotinic
cholinergic receptors on cortical cerebral blood ﬂow and changes in the effect
during aging in anesthetized rats. Neurosci. Lett. 228 (3), 203–206.
van Eijsden, P., Hyder, F., Rothman, D.L., Shulman, R.G., 2009. Neurophysiology of
functional imaging. Neuroimage 45 (4), 1047–1054.
van Turennout, M., Bielamowicz, L., Martin, A., 2003. Modulation of neural activity
during object naming: effects of time and practice. Cereb. Cortex 13 (4), 381–391.
Vaucher, E., Borredon, J., Bonvento, G., Seylaz, J., Lacombe, P., 1997. Autoradiographic
evidence for ﬂow-metabolism uncoupling during stimulation of the nucleus
basalis of Meynert in the conscious rat. J. Cereb. Blood Flow Metab. 17 (6),
686–694.
Vidal, C., Changeux, J.P., 1993. Nicotinic and muscarinic modulations of excitatory
synaptic transmission in the rat prefrontal cortex in vitro. Neuroscience 56 (1),
23–32.
Vinberg, J., Grill-Spector, K., 2008. Representation of shapes, edges, and surfaces across
multiple cues in the human visual cortex. J. Neurophysiol. 99 (3), 1380–1393.
von Engelhardt, J., Eliava, M., Meyer, A.H., Rozov, A., Monyer, H., 2007. Functional
characterization of intrinsic cholinergic interneurons in the cortex. J. Neurosci.
27 (21), 5633–5642.
Vossel, S., Thiel, C.M., Fink, G.R., 2006. Cue validity modulates the neural correlates
of covert endogenous orienting of attention in parietal and frontal cortex.
Neuroimage 32 (3), 1257–1264.
Vossel, S., Thiel, C.M., Fink, G.R., 2008. Behavioral and neural effects of nicotine on
visuospatial attentional reorienting in non-smoking subjects. Neuropsycho-
pharmacology 33 (4), 731–738.
Wagner, A.D., Koutstaal, W., Schacter, D.L., 1999. When encoding yields remember-
ing: insights from event-related neuroimaging. Philos. Trans. R. Soc. Lond. B:
Biol. Sci. 354 (1387), 1307–1324.
Warburton, D.M., Skinner, A., Martin, C.D., 2001. Improved incidental memory with
nicotine after semantic processing, but not after phonological processing.
Psychopharmacology (Berl.) 153 (2), 258–263.Weinberger, N.M., 2007. Associative representational plasticity in the auditory
cortex: a synthesis of two disciplines. Learn. Mem. 14 (1–2), 1–16.
Wesnes, K., Warburton, D.M., 1984. Effects of scopolamine and nicotine on
human rapid information processing performance. Psychopharmacology
82, 147–150.
Williams, G.V., Castner, S.A., 2006. Under the curve: critical issues for elucidating D1
receptor function in working memory. Neuroscience 139 (1), 263–276.
Wilson, F.A., Rolls, E.T., 1990. Neuronal responses related to the novelty and
familiarity of visual stimuli in the substantia innominata, diagonal band of
Broca and periventricular region of the primate basal forebrain. Exp. Brain Res.
80 (1), 104–120.
Wink, A.M., Bernard, F., Salvador, R., Bullmore, E., Suckling, J., 2006. Age and
cholinergic effects on hemodynamics and functional coherence of human
hippocampus. Neurobiol. Aging 27 (10), 1395–1404.
Witte, E.A., Davidson, M.C., Marrocco, R.T., 1997. Effects of altering brain cholinergic
activity on covert orienting of attention: comparison of monkey and human
performance. Psychopharmacology (Berl.) 132 (4), 324–334.
Womelsdorf, T., Fries, P., Mitra, P.P., Desimone, R., 2006. Gamma-band synchroni-
zation in visual cortex predicts speed of change detection. Nature 439 (7077),
733–736.
Wonnacott, S., Barik, J., Dickinson, J., Jones, I.W., 2006. Nicotinic receptors modulate
transmitter cross talk in the CNS: nicotinic modulation of transmitters. J. Mol.
Neurosci. 30, 137–140.
Xiang, Z., Huguenard, J.R., Prince, D.A., 1998. Cholinergic switching within neocor-
tical inhibitory networks. Science 281 (5379), 985–988.
Xu, J., Mendrek, A., Cohen, M.S., Monterosso, J., Rodriguez, P., Simon, S.L., Brody, A.,
Jarvik, M., Domier, C.P., Olmstead, R., Ernst, M., London, E.D., 2005. Brain activity
in cigarette smokers performing a working memory task: effect of smoking
abstinence. Biol. Psychiatry 58 (2), 143–150.
Xu, J., Mendrek, A., Cohen, M.S., Monterosso, J., Simon, S., Brody, A.L., Jarvik, M.,
Rodriguez, P., Ernst, M., London, E.D., 2006. Effects of acute smoking on brain
activity vary with abstinence in smokers performing the N-Back task: a pre-
liminary study. Psychiatry Res. 148 (2–3), 103–109.
Xu, J., Mendrek, A., Cohen, M.S., Monterosso, J., Simon, S., Jarvik, M., Olmstead, R.,
Brody, A.L., Ernst, M., London, E.D., 2007. Effect of cigarette smoking on
prefrontal cortical function in nondeprived smokers performing the Stroop
Task. Neuropsychopharmacology 32 (6), 1421–1428.
Yantis, S., Schwarzbach, J., Serences, J.T., Carlson, R.L., Steinmetz, M.A., Pekar, J.J.,
Courtney, S.M., 2002. Transient neural activity in human parietal cortex during
spatial attention shifts. Nat. Neurosci. 5 (10), 995–1002.
Young, B.J., Otto, T., Fox, G.D., Eichenbaum, H., 1997. Memory representation within
the parahippocampal region. J. Neurosci. 17 (13), 5183–5195.
Yu, A.J., Dayan, P., 2005. Uncertainty neuromodulation, and attention. Neuron 46
(4), 681–692.
Zilles, K., Palomero-Gallagher, N., Grefkes, C., Scheperjans, F., Boy, C., Amunts, K.,
Schleicher, A., 2002. Architectonics of the human cerebral cortex and transmit-
ter receptor ﬁngerprints: reconciling functional neuroanatomy and neuro-
chemistry. Eur. Neuropsychopharmacol. 12 (6), 587–599.
Zilles, K., Wree, A., 1990. Dausch N-D Anatomy of the neocortex: neurochemical
organization. In: Kolb, B., Tees, R.C. (Eds.), The Cerebral Cortex of the Rat. MIT
Press, Cambridge, MA, pp. 113–150.
Zinke, W., Roberts, M.J., Guo, K., McDonald, J.S., Robertson, R., Thiele, A., 2006.
Cholinergic modulation of response properties and orientation tuning of neu-
rons in primary visual cortex of anaesthetized Marmoset monkeys. Eur. J.
Neurosci. 24 (1), 314–328.
